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Background People with diabetes are at an increased risk of developing 
vascular disease, which is the leading cause of morbidity and mortality in this 
population. The retina is one of the few places in the body that offers non-
invasive visualisation of the vascular system and thus provides a rich 
platform to evaluate local and systemic vascular disease. Recent 
advancements in retinal image analysis tools allow us to evaluate the retinal 
microvasculature in a more efficient and unbiased way compared to manual 
methods. Local retinal changes may provide insight into vascular disease 
prior to overt pathological changes.  
Aim The aim of this thesis was to explore and evaluate retinal vessel traits in 
relation to various manifestations of vascular disease, specifically diabetic 
retinopathy and cognitive decline, using prospectively collected data. In 
addition to undertaking this research, this PhD project also aimed to 
contribute to the collection of primary data from in ongoing longitudinal cohort 
in order to provide data not only for this project, but for many other future and 
ongoing projects.  
Methods Edinburgh Type 2 Diabetes Study is a cohort of 1,066 adults aged 
60-75 years with type 2 diabetes living in the Lothian region of Scotland. Data 
were collected through research clinics as well as record linkage. Diabetic 
retinopathy status was obtained from the national screening programme and 
to evaluate cognitive decline, dementia diagnosis was obtained from a 
combination of medical records, death records and self-report. Cognitive 
decline was also evaluated using cognitive status derived from a battery of 
cognitive tests administered at baseline and then again after 10 years. 
Retinal images were analysed using VAMPIRE software for central retinal 
arteriolar equivalent (CRAE), central retinal venular equivalent (CRVE), 
arteriolar and venular tortuosity, fractal dimension and density.  
Results A total of 83 participants (11.6%) developed retinopathy over 10 
years. After controlling for a wide number of cardiometabolic, diabetic and 
vascular risk factors, there was evidence of an association between 
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increased venular tortuosity and incident retinopathy (odds ratio (OR) 1.51, 
95% confidence interval (CI) 1.15 to 1.98, p = 0.003), as well as decreased 
standardised fractal dimension and incident retinopathy (OR 0.75, 0.58 to 
0.96, p = 0.025).  
Of the total 1066, 106 (9.9%) were determined to have a dementia diagnosis 
after 10 years of follow-up. Cognitive decline, as measured by cognitive 
testing after 10 years, controlling for baseline cognitive status, was measured 
in the 581 returning participants. There were no independent associations 
between the retinal vessel traits and cognitive decline, using either dementia 
or the general intelligence factor, after controlling for various covariates. 
There was, however, evidence of age-related decreases in fractal dimension 
and density over the course of the study. 
Conclusions This thesis has provided evidence from the ET2DS that 
venular tortuosity and fractal dimension are independently associated with 
diabetic retinopathy. The independent associations were modest and need to 
be contextualised within the heterogeneity that exists within the supporting 
literature as well as replicated in other studies, but they provide exciting 
support for the use of the retinal vessel traits in future risk prediction 
modelling for diabetic retinopathy. There was no evidence of an association 
between the reported retinal vessel traits and cognitive decline. Novel 
findings regarding age-related decreases in fractal dimension and density are 
important as more information is coming to light regarding the vessel traits 







People with diabetes are at a higher risk of damage to the blood vessels, 
which is the leading cause of death and disease in people with diabetes. The 
retina, which is the layer of tissue in the very back of the eye, is one of the 
few places in the body that blood vessels can be richly visualised using non-
invasive methods, so it offers a unique platform to evaluate the health of the 
blood vessels in the eye as well as providing a surrogate for health of blood 
vessels throughout the body. Recent advancements in image analysis tools 
for the retina allows for more efficient and detailed evaluation of these tiny 
blood vessels. It is the hope that small changes in the blood vessels of the 
eye provide insight into damage throughout the body as an early marker 
before major disease is established.  
The aim of this thesis was to explore and evaluate retinal blood vessel 
measurements in relation to various manifestations of vessel damage, 
specifically diabetic retinopathy (vessel disease in the eye) and cognitive 
decline. Measurements evaluated in this thesis include blood vessel widths, 
how curved and twisted the vessels are, called tortuosity, and how complex 
the vessel system is in the image, called fractal dimension. Another important 
aim of this PhD project was to contribute to the data collection for the 
ongoing study that this project was a part of, in order to contribute a 
substantial amount of data for not only this project but many others.  
Data from the Edinburgh Type 2 Diabetes Study were used, which includes 
1,066 adults aged 60-75 years with type 2 diabetes living in the Lothian 
region of Scotland. Data were collected at baseline and after 10 years 
through research clinics as well as linking with medical and other records. 
Diabetic retinopathy status was obtained from the national screening 
programme records and to evaluate cognitive decline, dementia diagnosis 
was obtained from a combination of medical records, death records and self-
report. Cognitive decline was also evaluated using cognitive status derived 
from cognitive tests administered at baseline and then again after 10 years.  
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A total of 83 participants developed retinopathy over 10 years. After taking in 
to account a wide number of other risk factors, there was evidence that 
increased tortuosity of the retinal veins was associated with a participant 
developing retinopathy after 10 years. Also, decreased fractal dimension was 
associated with developing retinopathy. The analysis suggested tortuosity 
may be a good candidate marker to help predict those who will develop 
retinopathy. 
Of the total 1066, 106 were determined to have a dementia diagnosis after 
10 years. Cognitive decline, as measured by cognitive testing was measured 
in the 581 returning participants. There were no withstanding associations 
between the retinal blood vessel measurements and cognitive decline. There 
was, however, evidence of age-related decreases in vessel network 
complexity over the course of the study. 
The findings from this thesis provide evidence that in this population with type 
2 diabetes, tortuosity of the retinal veins and fractal dimension are associated 
with developing diabetic retinopathy, above and beyond other known risk 
factors. These findings are promising for the role of retinal vessel traits in the 
development of risk prediction and stratification for diabetic retinopathy, but 
require further validation in other similar studies as well as contextualisation 
within the field regarding heterogeneity of the methods and findings. There 







Diabetes mellitus is a metabolic condition of multiple aetiologies 
characterised by chronic hyperglycaemia (American Diabetes Association, 
2014). Hyperglycaemia is caused by a reduced ability of the pancreas to 
produce insulin, impaired insulin action, or a combination of both. Sustained 
hyperglycaemia can cause damage to the vascular system of the body and is 
associated with increased risk of heart disease, stroke, kidney disease and 
death (Fowler, 2011). 
Insulin is a hormone secreted by the pancreas which is a key factor in the 
uptake of blood glucose into the cells of the body. 𝛽-cells of the pancreas are 
able to detect nutrient levels in the body through changes in glycolysis, a 
metabolic pathway responsible for converting glucose into usable energy, 
and respond by altering the secretion of insulin. In other cells of the body the 
end product of glycolysis, pyruvate, is mainly converted to lactate, but due to 
low expression of lactic acid dehydrogenase in the 𝛽-cells, pyruvate will enter 
the higher energy yield metabolic processes in the mitochondria. This rapid 
increase in cellular energy initiates insulin secretion from the 𝛽-cells (Chen, 
Cruzat and Newsholme, 2016).  
𝛽-cell dysfunction is a leading factor in the onset of diabetes, both type 1 and 
type 2. Type 1 diabetes is caused by an autoimmune attack on the 𝛽-cells, 
resulting in their reduced ability to produce insulin. Onset of type 2 diabetes 
is more complex and can begin with decreased insulin action (insulin 
resistance) due to obesity and physical inactivity, leading to hyperglycaemia 
and an up regulation of insulin production (Stumvoll, Goldstein and Haeften, 
2005). Hyperinsulinaemia is a result of, and contributing factor to, insulin 
resistance in target tissues and a build-up of glucose in the blood, which also 
increases insulin resistance. Hyperglycaemia will cause the 𝛽-cells to 
produce even more insulin and can lead to their dysfunction and death, which 
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can occur relatively early in the disease process (Reaven, 1988; Weyer et al., 
1999). 
Symptoms associated with diabetes include polyuria and polydipsia 
(increased urination and thirst), as well as blurred vision and unexplained 
weight loss. Diagnosis can be confirmed by several types of glucose tests. 
These include (1) a non-fasting plasma glucose concentration ≥ 11.1 mmol/l, 
(2) a fasting plasma glucose concentration of ≥ 7.0 mmol/l, or (3) a plasma 
glucose concentration ≥ 11.1 mmol/l two hours after commencing an oral 
glucose tolerance test where the patient would be fasting and then consume 
a glucose drink (World Health Organization, 2006). Another method of 
measuring glucose levels is by glycated haemoglobin (HbA1c) which is an 
indicator of glucose levels over the previous 10 to 12 weeks, but this method 
is relied on less and is not recommended for certain patients (World Health 
Organization, 2011). An HbA1c of > 6.5% is used to indicate the presence of 
diabetes. Any one of the glucose tests can confirm a diagnosis of diabetes if 
the patient is also presenting with polyuria and polydipsia, but if these 
symptoms are not present then repeat glucose measures should be taken for 
confirmation. 
Classifications of diabetes falls mainly into two types: type 1 and type 2, 
although there are other forms including gestational diabetes, and 
monogenetic causes such as in maturity onset diabetes of the young 
(MODY). Type 1 diabetes is associated with genetic susceptibility as well as 
environmental triggers of an autoimmune response and is often associated 
with a younger age of onset. The aetiology of type 2 diabetes is complicated 
and involves common factors such as obesity, age, and lifestyle, but also 
includes genetic causes, which is thought to contribute to the wide variations 
in incidence based on geographical and ethnic differences (Adeghate et al., 
2006). Type 2, the more prevalent type, has historically been associated with 
an older age of onset but has been increasingly diagnosed in children 
(Dabelea et al., 2014).  
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Treatment for type 1 diabetes includes regular subcutaneous insulin 
injections and monitoring. Type 2 can be treated with a continuum of 
interventions that include dietary restrictions, weight reduction, exercise, oral 
glucose lowering agents, as well as insulin injections (American Diabetes 
Association, 2018). Medication choices for treatment of type 2 diabetes 
depends on the specific HbA1c target, comorbidities and contraindications of 
the individual. Metformin remains the most widely preferred anti-
hyperglycaemic medication, and can be intensified with dual or triple 
treatment with other medications such as sulphonylurea, dipeptidyl 
peptidase-4 inhibitors (DPP-4), thiazolidinedione and sodium-glucose 
cotransporter 2 (SGLT2) inhibitor (National Institute for Health and Care 
Excellence, 2015; American Diabetes Association, 2018). There are newer 
non-insulin injectables, such as glucagon-like peptide-1 (GLP-1) receptor 
agonists, used to treat type 2 diabetes for patients that are struggling to 
control their glucose levels with oral agents alone (Meier, 2012). Insulin is 
initiated in type 2 diabetes if oral agents or non-insulin injectables are 
contraindicated or not controlling blood glucose levels sufficiently.  
While there are effective treatments for diabetes, there are still many barriers 
to people with the disease living healthy lives. One such barrier is perceived 
stigma, which can be social or even from healthcare providers (Browne et al., 
2013). It is a common misperception that diabetes, especially type 2, is the 
fault of the patient and the disease comes solely from a person’s own poor 
eating and exercise habits. A high proportion of people with both type 1 and 
type 2 diabetes report feeling this type of stigma (N. F. Liu et al., 2017). 
Stigma can create a barrier to seeking medical treatment and to proper self-
management, which are both necessary in managing the primary disease as 
well as the associated complications.  
1.1.1 Burden of disease 
The most recent report by the World Health Organization (WHO) estimated 
the prevalence of diabetes at 422 million worldwide in 2014, and in 2017, the 
International Diabetes Federation (IDF) estimated 451 million to have 
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diabetes, half of whom remain undiagnosed (Roglic, 2016; Cho et al., 2018). 
In the United Kingdom, 3.8 million people have been diagnosed with diabetes 
and roughly another million have diabetes that is undiagnosed (Diabetes UK, 
2018, 2019). The WHO estimates that the incidence of diabetes has 
quadrupled since 1980, largely due to increased rates of type 2 diabetes, and 
the age standardised prevalence in adults has increased from 4.7% to 8.5% 
in the same time period (Roglic, 2016). In an analysis in the US, with data 
from 2000-2011, it is estimated that the population from age 20 has an 
increased lifetime risk of diabetes that has gone up 20% for men and 13% for 
women when compared with data from 1985-1989 (Gregg et al., 2014).  
Roughly 90% of cases of diabetes are attributed to type 2 diabetes, 8% type 
1 diabetes and the remaining 2% are more rare types (Diabetes UK, 2019). 
Diabetes constitutes a large burden on human health as well as the health 
care system, and currently costs the National Health Service (NHS) £10 
billion annually, or about 10% of the budget, with 80% of that cost due to 
complications and comorbidities (Hex et al., 2012). Obesity is increasing 
worldwide as unhealthy eating patterns combined with reduced physical 
activity are rapidly rising, putting a strain on health care globally (Zheng, Ley 
and Hu, 2018). If past trends continue, the global economic burden is set to 
increase from $1.3 trillion (US dollars) in 2015 to $2.5 trillion in 2030, or as 
much as 2.2% of the global gross domestic product (GDP) (Bommer et al., 
2018). 
1.1.2 Morbidity and mortality 
Diabetes carries an increased risk of morbidity and mortality so much so that 
it is estimated a 50-year-old person with diabetes will die an average of six 
years earlier than a person without diabetes of the same age (Roger et al., 
2012). People with diabetes have an increased risk of vascular damage, 
which is the main cause of morbidity and mortality. Sustained 
hyperglycaemia promotes vascular damage through increased inflammatory 
mechanisms, oxidative stress, formation of advanced glycation end products 
(AGEs), which are the product of glycation of plasma proteins in the 
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presence of sugar, endothelial dysfunction and other modes, and the 
vasculature’s counteractive measures to these damaging effects are 
suppressed (Rask-madsen and King, 2013; Singh et al., 2014; Carol Yimlui 
Cheung et al., 2015).  
This combination of increased damage and reduced ability of the cells to 
repair themselves leads to vascular complications that are broadly 
categorized as macrovascular and microvascular complications. 
Macrovascular disease, often used interchangeably with cardiovascular 
disease, refers to the larger blood vessels in the body and manifests as 
coronary artery disease, such as myocardial infarction, cerebrovascular 
disease, which includes stroke, as well as peripheral vascular disease 
(Fowler, 2011). Microvascular disease refers to damage in the small vessels 
and in people with diabetes usually refers to retinopathy, nephropathy and 
neuropathy. It has been estimated that as many as 50% of people with 
diabetes have evidence of microvascular disease and roughly a quarter have 
macrovascular disease (Litwak et al., 2013). 
Complications from macrovascular disease account for the largest burden of 
disease and largest economic burden in people with diabetes. Heart disease 
and stroke are the leading cause of morbidity and mortality among people 
with type 2 diabetes (Fowler, 2011). Death from cardiovascular disease is 
two to four times more likely in adults with diabetes compared to adults 
without (CDC and USD HHS, 2012). Diabetic retinopathy, a significant 
manifestation of microvascular disease in the eyes, is the leading cause of 
blindness in adults under 75 years (Fong et al., 2004), and diabetes is the 
leading cause of kidney failure (Atkins, 2005; Levey and Coresh, 2012).  
Diabetes is not just related to the incidence of vascular disease, but recent 
studies have found an increased risk of death from cancer, although it’s not 
fully understood what the mechanism for the increased risk is (Emerging Risk 
Factors Collaboration et al., 2011). Also, type 2 diabetes is related to 
increased risk of cognitive impairment and dementia (Biessels et al., 2014; 
Biessels and Despa, 2018). Again, the mechanism for the role of diabetes in 
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dementia is not yet clear, and some evidence suggests that lower early age 
cognition predicts type 2 diabetes (Altschul, Starr and Deary, 2018). As 
people with diabetes are living to more advanced ages this relationship is 
becoming more apparent and the importance for understanding their 
interrelatedness and possibility for intervention is growing. Cognitive decline 
and the association with the retina in diabetes is a central focus of this thesis 
and the relationship will be discussed further in this chapter.  
 Diabetic Retinopathy 
Diabetic retinopathy (DR) is a common microvascular complication in people 
who have diabetes. A study from 2010 estimated the prevalence of DR to be 
28.5%, and vision threatening retinopathy to be 4.4% of US adults with 
diabetes (Zhang et al., 2010). However, this estimate is conservative, with 
some studies estimating prevalence of DR as high as 55% in their population 
and vision threatening retinopathy as high as 7.1% (Cheung, Mitchell and 
Wong, 2010; Ting, Cheung and Wong, 2016). Diabetic retinopathy is the 
leading cause of vision loss in middle-aged people, throughout the world, and 
from 1990 to 2015, all other common causes of blindness and vision 
impairment saw a reduced prevalence, except for diabetic retinopathy, which 
increased during this time (Klein, 2007; Flaxman et al., 2017).  
 
Figure 1. Cartoon graphic of retina with different features of diabetic 




1.2.1 Clinical features of progression of diabetic 
retinopathy and pathophysiology 
Diabetic retinopathy, is categorised into different severity stages, which may 
differ depending on the specific scale you are using, but the main feature 
being a difference between non-proliferative (NPDR) and proliferative DR 
(PDR). Early forms of the disease are often asymptomatic, with vision 
impairment not being present until late stages in the disease, after significant 
tissue damage. 
 In general, very mild non-proliferative DR is characterised as the presence of 
microaneurysms only, progressing to mild NPDR with the addition of hard 
exudates, cotton-wool spots and mild retinal haemorrhages (Meyerle, Chew 
and Ferris III, 2008; Tarr et al., 2012). As the disease progresses from 
moderate to severe NPDR, these features will be found more widespread 
throughout the retina, the haemorrhages becoming more severe, and the 
additional presence of venous beading. The most severe stage of the 
disease is the onset of PDR, which is defined by the presence of newly 
formed, finely looping, blood vessels, termed neovascularisation (Danis and 
Davis, 2008). Some of these features can be seen in Figure 1. 
Diabetic maculopathy is a category of DR, related both to NPDR and PDR, 
and is the most common cause of vision loss in people with type 2 diabetes 
(Ciulla et al. 2003). Maculopathy is the result of macular oedema, 
characterised by retinal thickening in the area of the macula from fluid and 
plasma constituents that accumulate as a result of vascular damage leading 
to increased permeability and leaky vessels (Meyerle, Chew and Ferris III, 
2008). This increased permeability causes a breakdown in the inner blood-
retinal barrier, which serves to protect the outer neural retinal tissues from 
the harmful molecules in the circulatory system of the inner retinal vessels 
(Klaassen, Van Noorden and Schlingemann, 2013) This fluid accumulation 
results in hard exudates and can lead to vision impairment and loss. 
The retina is one of the earliest tissues in the body to show diabetic damage 
as the capillary endothelial cells in the retina are particularly susceptible to 
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the negative effects of the various cascades that occur due to the presence 
of hyperglycaemia (Brownlee, 2005; Cheung, Mitchell and Wong, 2010). 
Changes in the retinal endothelium in the presence of hyperglycaemia begin 
to cause damage to capillaries in the forms described in the previous 
paragraph, namely microaneurysm, cotton wool spots and hard exudates, 
which lead to the loss of capillaries. This results in areas of low and non-
perfusion. Overtime, with the accumulation of vascular damage, can lead to 
retinal ischaemia and hypoxia and increased vascular permeability. There is 
also evidence that inflammatory mechanisms contribute to retinal vascular 
damage (Meyerle, Chew and Ferris III, 2008). Hypoxia stimulates a release 
(VEGF), leading to proliferation of new vessels, neovascularization which is 
the marker of advanced PDR. These new, delicate vessels can leak and 
rupture easily, leading to fluid build-up behind the retina which can cause 
vitreous detachment, haemorrhage and loss of sight (Tarr et al., 2012).  
1.2.2 Treatment of diabetic retinopathy 
Diabetic retinopathy often begins asymptomatically but can progress to 
blurred vision, reduced visual acuity and eventual blindness. The current 
treatment mainstay for DR is controlling hyperglycaemia and blood pressure, 
which are part of the direct cause of retinal vascular damage in order to 
prevent progression of the disease (Mohamed, Gillies and Wong, 2007). 
More advanced retinopathy can be treated with laser photocoagulation, 
however, this does not treat the underlying cause of DR and can damage 
vision, leading to night blindness, and so new treatments are currently being 
sought. Anti-VEGF intraocular injections are currently being introduced, as 
VEGF plays an important role in new vessel formation when stimulated by 
hypoxia (Do et al., 2008). Other novel treatments being investigated include 
protein kinase C inhibitors, steroid injections and somatostatin receptor 
agonists (Duh, 2008). Other pathways and molecules of interest as possible 
treatment targets include erythropoietin as a suppressor of retinal 
neovascularisation and carbonic anhydrase to reduce vascular permeability 
(Cheung, Mitchell and Wong, 2010). 
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1.2.3 Diabetic retinopathy screening and grading 
Retinopathy is the most common complication in diabetes, and roughly all 
people with type 2 diabetes will show evidence within 20 years of diagnosis 
(Fowler, 2008). More than 60% of all people with type 2 diabetes will have 
some form of retinopathy (Fong et al., 2004). High prevalence of DR has led 
to many health systems adopting regular diabetic screening programs to help 
diagnose and monitor the disease to reduce to the risk of progression. The 
Scottish Diabetic Retinal Screening Collaborative (Scottish DRS) is one such 
programme that exists to promote equitable care to all people in Scotland 
with diabetes (Zachariah, Wykes and Yorston, 2015). The Scottish DRS 
aspires to monitor all its patients on a yearly basis by taking retinal images, 
where possible, and screen for retinopathy and maculopathy to help advise 
appropriate care and treatment. The Scottish DRS scheme uses their own 
retinopathy grading criteria which goes from R0 (no observable retinopathy) 
to R4, which is used when there is evidence of PDR.  
There are other grading scales used for diabetic retinopathy and the most 
commonly used is the Early Treatment of Diabetic Retinopathy Study 
(ETDRS) grading system, often referred to as the modified Airlie House 
classification system, referring to the scale from which it was developed 
(Early Treatment Diabetic Retinopathy Study Research Group, 1991). The 
ETDRS scale has been used as the gold standard of retinopathy diagnosis 
for some time and uses 7-field stereoscopic images for review. The 
classifications span 13 categories from 10, indicating no retinopathy, up to 
85, indicating severe vitreous haemorrhage or retinal detachment. The 
ETDRS scale is commonly used in research settings but is less commonly 
used clinically due its complexities and image requirements. 
1.2.4 Diabetic retinopathy risk factors 
Risk factors for DR reported by epidemiological studies in people with type 2 
diabetes vary widely, but the most commonly reported are lifestyle and 
cardiometabolic factors including systolic blood pressure, cholesterol, 
obesity, diabetes factors including hyperglycaemia and duration of diabetes 
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(Stratton et al., 2001; Tam et al., 2009; Romero-Aroca et al., 2010, 2011; 
Zhang et al., 2010; Pugliese et al., 2012; Bertelsen et al., 2013; Salinero-Fort 
et al., 2013; Xu et al., 2014; Y. Liu et al., 2017). Risk of vascular disease, 
including heart disease and stroke are increased in people with DR (Cheung, 
Rogers, et al., 2007; Cheung, Wang, et al., 2007). Ethnicity has been shown 
to be an important risk factor for retinopathy, with higher incidences in South 
Asian and African American populations (Wong et al., 2006; Raymond et al., 
2008). However, as the ET2DS population is made of up 98% ethnically 
white participants, differences in ethnicity are not evaluated in this thesis. 
Demographic, lifestyle and cardiometabolic risk factors 
Age has been linked with diabetic retinopathy, but the association has been 
shown to be complicated. In the United Kingdom Prospective Diabetes Study 
(UKPDS) there was an association between older age and progression of 
established retinopathy but not retinopathy incidence (Stratton et al., 2001). 
Participants with DR in the US based National Health and Nutrition 
Examination Survey (NHANES) 2005-2006 were slightly older than those 
without retinopathy (Zhang et al., 2010). A cohort in England showed that 
people with NPDR were slightly older than those with no retinopathy, but 
participants with PDR were younger than those with NPDR (Jones et al., 
2012). In two cross-sectional studies, younger age was associated with 
increased risk of any retinopathy and more advanced retinopathy (Pugliese 
et al., 2012; Y. Liu et al., 2017). Although these findings are contrary to other 
studies, it is not wholly unexpected as earlier-onset diabetes, before the age 
of 40, confers a higher risk of advanced retinopathy (Song and Gray, 2011). 
Gender has been found to be a risk factor in several studies, such as the 
cross-sectional NHANES study, which found evidence that male sex was 
independently associated with prevalent DR (Zhang et al., 2010). However, 
another study, which collected data prospectively, found a possible increased 
risk of incident retinopathy in women, after four years (Salinero-Fort et al., 
2013), but the vast majority of epidemiological studies have not found 
evidence of sex as an independent risk factor. 
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Increased blood pressure is thought to be an important modifiable risk factor 
for diabetic retinopathy as the mechanical stretching and damage of the 
endothelium from increased blood flow can lead to the release of VEGF 
(Cheung, Mitchell and Wong, 2010). Historically, epidemiological studies 
often did not find an association between systolic blood pressure and DR, but 
clinical trials of strict glycaemic control noted systolic blood pressure as a 
modifiable risk factor (Stratton et al., 2001; Mohamed, Gillies and Wong, 
2007). More recent epidemiological studies have found an association 
between elevated systolic blood pressure or presence of hypertension and 
DR, indicating it is a strongly related risk factor (Romero-Aroca et al., 2010; 
Zhang et al., 2010; Jones et al., 2012; Xu et al., 2014; Y. Liu et al., 2017).  
Obesity has been established as a consistent risk factor for vascular disease, 
with the increase of fatty acids activating adipocytokines, such as 
proinflammatory markers and procoagulant factors, that can act unfavourably 
on other organs and lead to cardiovascular dysfunction (Calabro et al., 2013). 
Obesity is generally considered as a body mass index (BMI) over 30, but this 
definition can differ depending on the population. In relation to DR, there 
have been a plethora of epidemiological studies showing a relationship with 
obesity (usually defined using BMI, but also with waist-to-hip ratio (WHR)), 
but the findings are inconsistent and often not strong enough to indicate a 
direct causal association (van Leiden et al., 2002; Cheung and Wong, 2007). 
Currently there is a lack of clarity of the role obesity plays in the development 
of DR, but it is still an important factor to consider because it has a clear 
impact on the vascular system. 
In general, smoking is a risk factor for vascular damage due to its negative 
effect on vascular endothelial cells as well as increasing damaging 
inflammatory cascades and instigating oxidative stress to the vasculature, all 
of which are factors in the development of DR (Powell, 1998; Tsiara, Elisaf 
and Mikhailidis, 2003). However, few studies have identified smoking as an 
independent risk factor of DR. Conversely, two studies have reported an 
inverse relationship between smoking and retinopathy (Stratton et al., 2001; 
Pugliese et al., 2012). In both cases, study authors were unable to determine 
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an exact reason for this surprising result but commented the findings could 
be limited by not knowing the number of cigarettes that were smoked, 
publication bias and the confounding nature of smokers possibly being less 
likely to adhere to strict medical treatment. 
The association between blood lipids and DR varies between studies. Total 
cholesterol was associated with minimal NPDR in a Dutch study, but not 
more advanced retinopathy (van Leiden et al., 2002). In a study of type 1 
diabetes, retinopathy was associated with low density lipoprotein (LDL) and 
inversely associated with high density lipoprotein (HDL) concentrations, in 
men (Lyons et al., 2004). Two other studies also identified increased LDL 
cholesterol as a risk factor for retinopathy (Salinero-Fort et al., 2013; Y. Liu et 
al., 2017). In another study, total cholesterol to HDL ratio was associated with 
diabetic macular oedema (Romero-Aroca et al., 2010). This variance in 
association may indicate a role of dyslipidaemia in retinopathy, but probably 
not a causal pathway.  
Diabetes related risk factors 
Sustained hyperglycaemia is believed to be one of the initiating causes of the 
many factors contributing to vascular endothelial dysfunction and vascular 
permeability that are a part of establishing DR, which include inflammation, 
oxidative stress, formation of AGEs and protein kinase C (Cheung, Mitchell 
and Wong, 2010; Singh et al., 2014). Therefore, it is unsurprising that many 
epidemiological studies have identified increased and uncontrolled HbA1c as 
the most common risk factor for diabetic retinopathy (Stratton et al., 2001; 
Tam et al., 2009; Romero-Aroca et al., 2010; Zhang et al., 2010; Jones et al., 
2012; Pugliese et al., 2012; Salinero-Fort et al., 2013; Xu et al., 2014; Y. Liu 
et al., 2017).  
In many studies, a longer duration of diabetes has been found to be 
associated with increased risk of diabetic retinopathy and is often used 
clinically as an important risk factor (Romero-Aroca et al., 2010; Zhang et al., 
2010; Jones et al., 2012; Pugliese et al., 2012; Salinero-Fort et al., 2013; Xu 
et al., 2014; Y. Liu et al., 2017). The longer a person’s vascular system is 
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exposed to sustained or intermittent hyperglycaemia, the more damage will 
be inflicted. This is also related to the association between treatment of 
diabetes and risk or progression of DR, specifically those that take insulin for 
type 2 diabetes, as well as some studies showing taking oral treatments 
versus no medications being at an increased risk (Stratton et al., 2001; 
Romero-Aroca et al., 2010; Zhang et al., 2010; Jones et al., 2012; Pugliese 
et al., 2012; Y. Liu et al., 2017). There is a common need to increase 
intensity of medication dosage and type the longer a person has diabetes in 
order to control hyperglycaemia. 
Diabetic retinopathy and other forms of vascular disease 
Data from the Framingham Study suggested a link between DR and 
cardiovascular disease and in a paper from 2012 Pugliese et al also showed 
evidence of a cross-sectional association (Hiller et al., 1988; Pugliese et al., 
2012). One study found diabetic retinopathy to be a risk factor for 
cardiovascular mortality, specifically in women (Juutilainen et al., 2007). 
Prospective data from the Atherosclerosis Risk in Communities study (ARIC) 
demonstrated that diabetic retinopathy is a risk factor for incident ischaemic 
stroke during the nearly eight year follow-up (Wong et al., 2002; Cheung, 
Rogers, et al., 2007). There is a debate between whether this association is 
due to microvascular damage of the retina simply being a precursor to more 
overt damage of the larger vessels, or if there is a specific mechanistic link 
between retinopathy and macrovascular disease.  
Diabetic retinopathy is itself a type of microvascular disease, so it is often 
considered to be associated with other forms of microvascular disease, such 
as nephropathy. Microalbuminuria indicates that there are small amounts of 
protein entering the urine due to pathologically increased permeability of the 
kidneys and is an early marker of nephropathy. The optimal diagnosis of 
microalbuminuria is with a timed urinary excretion, but often this is not 
feasible, so an untimed albumin-creatinine ratio (ACR) is used, with >3 
mg/mmol indicating presence of microalbuminuria, although different ranges 
are cited especially regarding variations within sex and age (Kidney Disease 
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Improving Global Outcomes, 2013). There is strong evidence of an 
association between microalbuminuria and DR, as evidenced in many 
studies (Romero-Aroca et al., 2010; Pugliese et al., 2012; Xu et al., 2012; 
Bertelsen et al., 2013). One study, that used a cut-off of >3.4 mg/mmol ACR 
to indicated microalbuminuria, demonstrated an association between 
increased risk of retinopathy and levels of microalbuminuria currently less 
than the standard cut-off, indicating that a lower threshold, as low as 1.16 
mg/mmol, may be clinically relevant (Bertelsen et al., 2013).  
Genetic risk factors of diabetic retinopathy 
The largest know GWAS study evaluating DR, to date, that also incorporated 
duration of diabetes and glycaemic control, did not identify any withstanding 
genetic variants in the total, multi-ethnic study population, but did find a 
network of genes in the African American subgroup related to PDR (Pollack 
et al., 2019). Previous replication studies have also been unable to replicate 
findings regarding DR related genetic variants (Grassi et al., 2012; Hosseini 
et al., 2015). There may indeed be a heritability to diabetic retinopathy, but it 
is likely to be modest and significantly outweighed by non-genetic risk 
factors. This thesis does not evaluate the genetics of DR as GWAS was not 
performed in the utilised cohort, so this is just a cursory description of the 
subject.  
 Cognitive Decline 
1.3.1 Cognitive ageing and impairment 
The study of cognitive ageing and impairment is an area of research 
interested in how the function of memory changes throughout a person’s life, 
and specifically, mechanisms of decline in later years. Encompassed in the 
normal, non-pathological process of ageing, it is believed that various 
memory functions will naturally decrease with age, including working 
memory, spatial memory and memory for faces (Schaie, 2015). Other 
cognitive deficits are in relation to verbal abilities and include word-recall and 
language production, which may manifest as hesitation and repetitions when 
speaking (Schaie, 2015). Cognitive ageing greatly depends on different 
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factors including cognitive ability in younger years, education level, socio-
economic status and health and physical fitness (Smith, 2016).  
When cognitive ability is below what is normally expected for a person’s age 
and education this is termed ‘cognitive impairment’, and the term ‘cognitive 
decline’ describes accelerated cognitive aging, which can span from mild to 
severely debilitating (Harada, Natelson Love and Triebel, 2013). Mild 
cognitive impairment (MCI) is a syndrome used to describe people that 
exhibit reduced cognitive ability for what would be expected, but the 
impairment does not overtly interfere with daily life (Gauthier et al., 2006). 
When cognitive impairment is present to a degree at which daily functioning, 
mood and behaviour of the person are affected, a dementia diagnosis may 
be considered (Ritchie and Lovestone, 2002). However, not all people that 
exhibit symptoms of cognitive impairment will progress to develop frank 
dementia.  
Mild cognitive impairment 
Mild cognitive impairment is present in 10%-20% of people over 65 years and 
is often thought of as an intermediate step between normal cognition and 
dementia as between 11% and 33% of people with MCI will develop 
dementia within two years, most commonly Alzheimer’s disease, and many 
of the diagnostic criteria for MCI overlap with dementia (Gauthier et al., 2006; 
Petersen, 2011; Petersen et al., 2014). However, the progression is 
heterogeneous, and a proportion of people with MCI will return to a normal 
cognitive range, although with increased risk of later cognitive impairment 
(Koepsell and Monsell, 2012; Sachdev et al., 2013). This is because MCI can 
be caused by a varied number of stimuli, such as depression, anxiety, drug 
use or other comorbidities and when these are appropriately treated a person 
may regain cognitive function (Petersen et al., 2014). If a person is 
diagnosed with MCI the most promising course of treatment may be to 
reduce risk factors for dementia which include controlling systolic 




Dementia is prevalent in about 5% of the population over 60 years and as the 
population is becoming older the absolute numbers are growing rapidly 
worldwide (Prince et al., 2015). Dementia is not a singular disease but has 
various aetiologies and may present and progress in a variety of ways. 
Primary dementias include, Alzheimer’s dementia, vascular dementia, 
dementia with Lewy bodies and frontotemporal dementia, to name a few 
(Ritchie and Lovestone, 2002).  
Alzheimer’s dementia is a neurogenerative disease and is the most common 
type of dementia. There are two types of diagnostic lesions in the brain 
associated with Alzheimer’s which are neuritic plaques resulting from amyloid 
β-protein deposits building up to pathological levels, and neurofibrillary 
tangles composed of hyperphosphorylated tau proteins (Selkoe, 2001). The 
build-up of these plaques and tangles lead to a cascade which includes 
inflammatory responses and oxidative stress that results in progressive 
cellular dysfunction in the brain and ultimately dementia. 
Vascular dementia, the second most common cause of age-related 
dementia, is defined by evidence of cognitive impairment across multiple 
domains that is associated with clinical evidence of cerebrovascular disease 
(often using imaging such as MRI and computed tomography scanning 
and/or patient history of vascular disease such as stroke) (Gorelick et al., 
2011). The energy requirements for the brain to function optimally are vast. 
Any alterations in the cerebral vascular system that supplies vital nutrients 
and maintains necessary conditions for normal functioning, such as those 
seen with cerebrovascular disease, can have an important impact the brain, 
resulting in cognitive impairment, although this is not fully understand at this 
time (Iadecola, 2013).  
These two types of dementia, vascular and Alzheimer’s, do not always exist 
independently and it is not uncommon to find a mixed aetiology of dementia 
with signs of cerebrovascular disease in persons that also have 
neurodegenerative pathology reflecting Alzheimer’s dementia (Knopman et 
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al., 2003; Gorelick et al., 2011; Iadecola, 2013; Toledo et al., 2013). There is 
still a lot unknown about the exact causes and progression of dementia and 
how the burden of different pathologies, independently and together, drive 
cognitive impairment, but it is most likely a combination of many complex 
factors that can differ person-to-person. 
It is important to understand the underlying cause of dementia in a person, as 
best as possible, in order to take appropriate action aimed at reducing 
progression and preventing associated co-morbidities. There is no cure for 
dementia and treatment is limited but often involves treatment of vascular risk 
factors such as hypertension, hypercholesterolemia and smoking, as well as 
symptoms of depression (O’Brien and Thomas, 2015). Also, if a person has 
diabetes, it may be important to target insulin resistance, such as through 
diet, exercise and medication (Cholerton et al., 2016).  
Certain classes of drugs can be used to help reduce the progression of 
Alzheimer’s dementia such as acetylcholinesterase inhibitors and memantine 
hydrochloride, but there is no effective treatment in reversing the effects of 
dementia (Qaseem et al., 2008). There are currently no medications used to 
treat vascular dementia, however, it has been suggested that there may be 
some benefit of treating patients with a vascular dementia diagnosis in the 
same manner as Alzheimer’s, not least because Alzheimer’s disease cannot 
reliably be ruled out in elderly patients with cognitive decline (Knopman, 
2006).  
1.3.2 Diabetes and cognitive decline 
There is an increasingly well-established association between diabetes and 
cognitive impairment, with diabetes acting as a risk factor for accelerated 
cognitive decline (Luchsinger and Mayeux, 2004; Tilvis et al., 2004; Biessels 
et al., 2014; Zhang et al., 2017; Biessels and Despa, 2018). Cognitive 
impairment in diabetes has a variety of phenotypes and is likely to be 
multi[factorial in aetiology (Biessels and Despa, 2018). While the precise 
pathophysiological mechanisms underlying the links are unknown, proposed 
theories rooted in evidence suggest the role of peripheral metabolic 
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alterations due to insulin resistance. The latter may indirectly cause damage 
in the brain, vascular injury as a consequence of hyperglycaemia and 
disruption of insulin to perform its normal functions in the brain (Cholerton et 
al., 2016). However, it is most likely a combination as there are multiple risk 
factors mediating the relationship between diabetes and cognitive decline 
(Feinkohl et al., 2015). 
Insulin is known to be an important factor in the brain for memory and 
cognitive processes. Peripheral insulin is transported across the blood-brain 
barrier to the central nervous system, which is rich with insulin receptors 
(Banks, Jaspan and Kastin, 1997). Insulin has a neuroprotective effect in the 
brain, working against cell death, oxidative stress, neurotoxic effects of 
amyloid β-protein build-up and ischemia, which all help support learning and 
memory functions (Gasparini et al., 2001; Ghasemi et al., 2013). However, 
prolonged elevated circulating insulin, combined with insulin insensitivity, as 
seen in diabetes, can have an opposing effect (Cholerton et al., 2016). 
Underscoring this important link between insulin and cognition, a recent 
population based study in Finland found insulin resistance to be an 
independent predictor of cognitive decline (Ekblad et al., 2017). In a Chinese 
population, researchers found that high fasting glucose concentrations, yet 
not in the range for a diabetes diagnosis, was associated with dementia 
independently of vascular risk factors and magnetic resonance imaging 
findings on vascular damage (Mortimer et al., 2010). This indicates that blood 
glucose and insulin resistance, independently of other risk factors, may play 
a causal role in increased incidence of poor cognition in diabetes. 
In addition to links with accelerated cognitive decline, a recent meta-analysis 
has shown that diabetes is associated with an increased risk of any type of 
dementia, but in particular with vascular dementia (127% increased risk) and 
also a 56% increased risk of Alzheimer’s dementia (Gudala et al., 2013). 
Studies have identified reductions in brain volume alongside cognitive 
impairments in people with type 2 diabetes, in comparison to no diabetes, 
which do not correspond with vascular lesions, leading to the conclusion that 
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the association is not mediated only through vascular damage from diabetes 
(Moran et al., 2013, 2016; Brundel, Kappelle and Biessels, 2014).  
Insulin deficiency and insulin resistance have been identified as important 
links to the neurodegeneration that is seen in Alzheimer’s dementia. Raised 
peripheral insulin levels, as a result of diabetes, leads to lower brain insulin 
levels and dysfunction of insulin receptors in the brain, and reduced 
clearance of amyloid β-protein and increased hyperphosphorylation of tau 
proteins (Ahmed, Mahmood and Zahid, 2015). There is also evidence that 
diabetes is associated with Alzheimer’s neurodegeneration independently of 
amyloid β and tau proteins, as oxidative stress caused by hyperglycaemia 
increases programmed cell death in the central nervous system (Vincent, 
Brownlee and Russell, 2002). It is possible that vascular risk factors 
associated with both diabetes and Alzheimer’s disease have a direct effect 
on Alzheimer’s disease not mediated directly through infarcts related to 
vascular dementia, but through concomitant cerebrovascular disease 
(Knopman, 2006). This helps to support a view that dementia (Alzheimer’s, 
vascular and mixed aetiology) can be considered forms of vascular disease 
in people with diabetes. Also, that defining and diagnosing each separately is 
highly complicated.  
1.3.3 Risk factors for cognitive decline 
With the increased prevalence of dementia in people with diabetes it is 
important to understand the other risk factors for dementia to evaluate if there 
are modifiable means of reducing the disease before it is established. 
Despite many epidemiological studies demonstrating associations between 
various risk factors and dementia, there is still very little evidence of any 
strongly predictive risk factors, aside from age. Because dementia is 
somewhat of a rare outcome, as opposed to something like diabetic 
retinopathy, and the ethical concerns with including people with dementia in a 
study, the study of dementia and its risk factors is often underpowered. Also, 
much of this type of research has been performed in the general population, 
so may not be wholly applicable to people with diabetes.  
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A longitudinal study with 20 years follow-up aimed to develop a risk 
prediction tool for late-life dementia risk in a middle-aged population. This 
study found that older age, higher blood pressure, higher total cholesterol 
and obesity to be greatly associated with incident dementia (Kivipelto et al., 
2006). Another prospective study with a long follow-up of 27 years, also 
found middle age obesity to be an independent risk factor for dementia 
(Whitmer, Gunderson, et al., 2005). A very large analysis that combined four 
prospective studies from several European countries, with 528 incident cases 
of dementia, identified age, female sex and smoking to be associated with 
increased risk of dementia (Launer et al., 1999). Due to the relationship 
between dementia and cardiovascular disease, a retrospective study that 
included 8845 participants investigated markers of cardiovascular health in 
midlife and their associations with later development of dementia and 
identified high blood pressure, high cholesterol, smoking and diabetes at 
midlife to be associated with dementia, individually and as a composite score 
(Whitmer, Selby, et al., 2005). 
Cerebrovascular disease is an accepted risk factor for dementia, especially 
vascular dementia. Ischaemic stroke is known to be largely associated with 
dementia, and both have similar risk factors (Gorelick, 1997). In the 
Framingham study there was an estimated doubling in risk of dementia after 
stroke (Ivan et al., 2004). Another prospective study interested in dementia 
and stroke found an association between the two, as well as other markers of 
small vessel disease, which included white matter hyperintensities, 
ventricular atrophy and cerebral infarcts (Kuller et al., 2005). Currently, 
research into white matter hyperintensities, which can be seen using 
magnetic resonance imaging, is very intriguing as a possible biomarker for 
dementia and stroke as their presence greatly increases the risk of both 
diseases (Wardlaw, Valdés Hernández and Muñoz-Maniega, 2015).  
Epidemiological studies have had mixed findings regarding the association 
between myocardial infarction (MI) and dementia, but findings from the 
Rotterdam study identified unrecognised MI, diagnosed by electrocardiogram 
but not self-reported or identified in medical notes, to be associated with 
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dementia in men, but not associated with recognised MI (Ikram et al., 2008). 
The prospective Cardiovascular Health Cognition Study found that 
participants that went on to develop dementia after the nearly 6 years of 
follow-up were more likely to have previously been diagnosed with coronary 
artery disease and had a bypass, after adjustments for age and sex (Kuller et 
al., 2005). 
Along with age, hypertension is probably the most consistently cited risk 
factor for dementia and because it is modifiable through medication and 
lifestyle, poses a possibility for risk reduction. A 15 year longitudinal study 
found higher blood pressure at age 70 to be associated with development of 
dementia at age 79-85, although they also found blood pressure to have a 
greater decrease in people with dementia closer to the time of diagnosis 
(Skoog et al., 1996). Studying the causal relationship of hypertension on 
dementia using observational data in elderly people, especially in a 
population with diabetes, is exceedingly difficult as many would be receiving 
treatment for hypertension, confounding the association.  
With consistent findings that blood pressure is associated with dementia, 
research groups have set out to determine if the use of antihypertensives 
could reduce the risk of dementia. The findings of such studies have been 
mixed. An observational study which found a modest reduction in dementia 
and cognitive decline in men that received antihypertensive treatment 
compared with those that had evidence of hypertension but did not receive 
treatment, and this risk reduction increased with length of time on the 
antihypertensive medication (Peila et al., 2006). However, in a randomised 
controlled trial in elderly people given an antihypertensive or placebo, there 
was no reduction in incident dementia, but this study was ended early due to 
a reduced risk of mortality, stroke and heart failure in the treatment group 
(Peters et al., 2008). In a more recent promising randomised controlled trial, 
researchers evaluated the effects of risk factor reduction through diet, 
exercise and cognitive training on cognitive decline in a slightly at-risk elderly 
population, and found, when compared to participants that received normal 
risk factor reduction information, a modest reduction in cognitive decline 
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(Ngandu et al., 2015), indicating that there is possibly more benefit in 
reducing the underlying causes of hypertension and other risk factors. 
Excessive alcohol consumption can have a detrimental effect on the brain 
and cognition (Joyce, 1994). However, current epidemiological evidence 
suggests that moderate alcohol intake may be beneficial for dementia risk 
most likely due to alcohol’s effect on reduced platelet adhesion, increasing 
HDL cholesterol and improving endothelial function (Ruitenberg et al., 2002; 
Mukamal et al., 2003; Anstey, Mack and Cherbuin, 2009). But not all alcohol 
intake is beneficial as high intake of alcohol is generally believed to increase 
risk of dementia (Luchsinger and Mayeux, 2004). So, while alcohol intake is 
associated with dementia risk, the amount of alcohol matters to whether that 
association is positive or negative. 
Severe hypoglycaemic episodes are characterised by low blood glucose 
concentrations that require assistance for recovery and are generally a 
consequence of insulin treatment of diabetes. Cellular metabolism in the 
brain is nearly exclusively dependent on glucose to function normally, so it 
has been hypothesized that these acute episodes of low blood glucose can 
cause dysfunction in the brain, that can accumulate to cognitive impairment. 
This was shown in a study from 1991, where recurrent episodes of severe 
hypoglycaemia were associated with cognitive impairment in people treated 
with insulin (Langan et al., 1991). Similar findings were identified in the 
Edinburgh Type 2 Diabetes Study (ET2DS), which demonstrated an 
association between a history of hypoglycaemia and lower cognitive ability 
after four years and a steeper cognitive decline, as well as incident 
hypoglycaemic episodes associated with increased cognitive decline 
(Feinkohl et al., 2014). Similar findings were reported from the ARIC cohort 
study, which demonstrated a prospective association between a history of 
hypoglycaemia and incident dementia (Lee et al., 2018). There is, however, 
an uncertainty if hypoglycaemia is the cause of the cognitive decline or if 
reduced cognitive function, and ability to perceive oncoming hypoglycaemia, 
is a risk factor for hypoglycaemic episodes (Bruce et al., 2009; Feinkohl et 
al., 2014). Understanding this relationship more thoroughly, especially if 
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hypoglycaemia is a risk factor for cognitive decline, could offer an opportunity 
to identify modifiable risk factors for cognitive decline (Biessels et al., 2014) 
Apolipoprotein E (APOE) is a plasma protein that is involved in cholesterol 
transport and the presence of the e4 variant, as opposed to alleles e2 and 
e3, to be largely increased in those with Alzheimer’s dementia (Farrer et al., 
1997; Slooter et al., 2004). Due to its role in lipid transport, the APOE e4 
genetic variant has also been investigated and found to be associated with 
cardiovascular disease mortality (Rosvall et al., 2009).  
1.3.4 Measuring cognitive decline 
The term cognitive ability simply refers to the skills and competencies a 
person has in order to complete mental based activities and includes areas 
such as memory, language, motor skills, and visual-spatial processing. 
Cognitive impairment is a pathologic reduction in these abilities based on 
some criteria, often in research this is based on a single or multitude of tests, 
or a portion of the population somewhere below the average. Cognitive 
decline is a reduction in cognitive ability over time at a greater trajectory than 
what is expected for the age and education level of the person. In research, 
cognitive decline often requires measuring cognitive ability at more than one 
time point and comparing between them. Alternatively, many studies of 
cognitive decline use a dementia diagnosis as a binary outcome of cognitive 
decline, indicating the person’s cognitive ability has declined so much it has 
reached a pathological state.  
While dementia is a good marker of cognitive decline, diagnosis of dementia 
is not infallible, and dementia does not manifest the same in all people. A 
dementia diagnosis requires a robust diagnostic process and is only common 
in the elderly. There are many people with probable dementia that are not 
diagnosed or do not meet the exact criteria and there are people with a 




Cognitive decline is a complex health condition that cannot be easily 
measured. The research field of cognitive epidemiology provides a method to 
test cognitive ability, separate from a dementia diagnosis, as a risk factor and 
outcome for health and lifestyle parameters and generally is undertaken 
using a battery of validated cognitive tests (Deary and Batty, 2007). It is a 
difficult task to measure and describe cognitive ability and decline using 
clinical based tests that often need to be undertaken relatively quickly and 
with simple instructions. Different tests and combinations of tests have been 
created over the years and include the well-known Wechsler Adult 
Intelligence Scale (WAIS) and Stanford-Binet test (Thorndike, Hagen and 
Sattler, 1986; Wechsler, 1997). The general intelligence factor, g, is now 
commonly used in cognitive epidemiology, which was first described by 
Spearman in 1904. Spearman believed that people possess a general 
intelligence that underpins cognitive abilities and that performance in one 
cognitive domain is related to performance in other domains. Therefore, g is 
a measure that correlates with and explains a large portion of variance 
between different cognitive tests and represents cognitive ability over a range 
of domains.  
In order to measure and report general intelligence, measurement of different 
cognitive domains needs to be undertaken using specifically designed and 
validated cognitive subtests, like what are available in the WAIS and 
Stanford-Binet tests. Domains that need to be considered include nonverbal 
reasoning, memory (verbal memory, nonverbal memory and working 
memory), executive function and processing speed. Scores of tests that 
measure these various domains are combined using reductive statistical 
methods such as principle components analysis or factor analysis that 
provide a single value that incorporates the values for the various tests.  
There are many limitations in the study of cognitive ageing and change, 
including the fact that many participants in studies on ageing tend to be more 
intelligent and healthier than the general population, making it difficult to 
extrapolate the findings. Another problem is that if one is studying ageing in 
an older population there is an expectation of increased mortality and 
25 
 
morbidity related dropouts, so how should these samples be analysed in 
order to avoid severe survival bias? Rabbitt et al. investigated a longitudinal 
cohort that had significant dropout and death rates over the course of their 
20-year study and determined that those that dropped out and died would 
have contributed significantly to the results and by excluding them the effects 
of ageing were underestimated (Rabbitt, Lunn and Wong, 2008). By 
excluding those that have dropped out or died you will be left with a healthier 
or more mildly unhealthy population which will inevitably alter your findings. 
How missing data is handled, as well as statistical models chosen for 
analysis are important in managing these issues.  
It should also be taken in to consideration, when undertaking the 
measurement of cognition with measures such as g, that the historical 
context of such measures is rooted deeply in the eugenics movement of the 
early 20th century (Pilgrim, 2008). Specifically, the belief that intelligence was 
a heritable trait was of interest to the field of eugenics and how its 
measurement could be applied to the movement. Spearman was widely 
praised by popular eugenicists for his work on the discovery of general 
intelligence (McDougall, 1914). However, current psychological research 
aims to use measures of intelligence to study cognitive status and investigate 






involves injecting fluorescent dye and imaging the retina guided by the dye 
and OCT-A involves repeated, rapid imaging that can be knitted together to 
show dynamic flow and is arguably superior to the older FA method (Spaide, 
Klancnik and Cooney, 2015).  
Retinal vasculature formation and maturation, including patterning, is guided 
by VEGF, various axon guidance molecules, as well as the transforming 
growth factor beta (TGFβ), and blood flow (Fruttiger, 2007). The pattern of 
the retinal vasculature seeks to optimise the efficiency of blood flow and any 
changes in the efficiency can lead to alterations in the geometric 
characteristics and these deviations may lead to impaired microcirculatory 
transport (MacGillivray et al., 2014). In diabetes, the vascular alterations and 
damage caused by the disease increase sheer stress of the vasculature and 
decrease efficiency of blood flow (Tooke, 1995). Understanding the 
differences and changes within the retina and their relationship to disease 
manifestation and progression as a possible mechanism to stratify risk, is key 
in using the retina as a source of biomarkers for local and systemic vascular 
disease. 
The retina offers a unique platform for research on the vascular system as it 
is one of the only locations in the body to easily visualise the vascular system 
non-invasively. Within the past decade, retinal-imaging and analysis 
technology has improved. A limiting factor of digital retinal images used to be 
a lack of reliable software to conduct efficient analysis; generally, analysis 
would have to be carried out on a manual basis, reducing the number of 
images that could be included within a study to a manageable level of only 
several hundred. This subsequently led to the development of several 
software packages that are currently being used by research groups around 
the world. As the analysis of retinal images is becoming ever more 
automated, the potential for quick and easy, non-invasive, testing for pre-
symptomatic stages of cardiovascular and microvascular disease is rapidly 
becoming a focus for researchers and clinicians. In diabetes, the retina, as a 
very early marker for vascular disease is especially important as it is altered 
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very early on in the disease, due to hyperglycaemia, inflammation and 
endothelial dysfunction (Carol Yimlui Cheung et al., 2015).  
Retinal traits that can be analysed using this software commonly include 
vessel widths, bifurcation angles and coefficients, fractal dimensions and 
vessel tortuosity, although numerous novel measurements are sometimes 
reported. Vessel widths, as measured by a summary index reflecting true 
vessel widths, can be broken down into three different measurements: 
central retinal artery equivalent (CRAE), central retinal vein equivalent 
(CRVE) and the ratio of the two, arteriovenous ratio (ARV). Vessel widths are 
currently the most researched retinal trait. Vessel tortuosity describes the 
degree of curvature of a vessel, and bifurcation angles describes the angles 
of the branching vessels. Fractal dimension (FD) describes how a pattern fills 
a two-dimensional space, and in the application of retinal imaging, measures 
the branching complexity of the retinal vasculature (Perez-Rovira et al., 
2011). 
1.4.3 VAMPIRE Software 
Vascular Assessment and Measurement Platform for Images of the Retina 
(VAMPIRE) software offers researchers the ability to quantitatively analyse 
retinal images on a semi-automatic basis (Perez-Rovira et al., 2011). This 
state-of-the-art software, developed in an international collaboration based at 
the Universities of Edinburgh and Dundee, has a wide range of applications, 
and is expected to be a useful tool in identifying biomarkers for the diagnosis 
and progression of chronic disease (MacGillivray et al. 2014; Patton & 
Constable 2006). In 2018, the online VAMPIRE version was launched and 
includes an improved user-interface compared with the previous desktop 
versions.  
For vessel detection, the software utilises a two-dimensional Gabor wavelet 
algorithm as a pre-processing step to segment the retinal vessels within 
fundus camera images (Soares et al., 2006; Perez-Rovira et al., 2011). The 
basis of VAMPIRE image processing is to identify which pixels in the image 
are vessels and which are not. This relies on the retinal vessels being linear 
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in shape, they generally take on a Gaussian profile to their cross-sectional 
intensity distribution, and all originate from a single focal region, the optic disc 
(Patton and Constable, 2006). All algorithms in VAMPIRE were implemented 
in MATLAB (r2017a, Mathworks, USA) . 
When using VAMPIRE, the user uploads an image, upon which the software 
detects the boundary of the optic disc and the position of the fovea. The user 
can adjust these features as necessary. The software then generates a map 
of the vasculature and attempts to classify vessels as arterioles or venules, 
which can be edited by the user if necessary. A final analysis step is 
undertaken to generate the various quantitative traits. After a user is trained, 
VAMPIRE software is easy to use in order to generate a vast amount of 
retinal feature data that are reproducible and easily accessible.  
There are other software platforms that offer similar capabilities such as the 
Singapore “I” Vessel Assessment (SIVA) software, which was developed in 
collaboration with National University of Singapore and Singapore Eye 
Research Institute (Singapore Eye Research Institute, 2011), open source 
Interactive Vessel ANalaysis (IVAN) software produced by the University of 
Wisconsin, and Quantitative Analysis of Retinal Vessel Topology and siZe 
(QUARTZ) (Fraz et al., 2015), to name a few. While there are many 
similarities between the software types, there are also differences in 
algorithm implementation, automaticity and interface options. 
1.4.4 Retinal vessel trait associations 
Early changes in the microvasculature of the retina are theorised to be a 
response to, and product of, the accumulation of damage caused by vascular 
risk factors, such as hypertension (MacGillivray et al., 2014). It is believed 
that insult caused by high blood pressure, inflammation and other 
mechanisms, would affect changes in the smallest and most delicate vessels 
of the microvasculature and local alterations reflect widespread 
microvascular disease. These changes include widening or narrowing of the 
vessels, changes in the twisted nature, reflected as tortuosity and the overall 
complexity of the vascular network, or fractal dimension, to name a few.  
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In recent years, there have been many studies that have investigated these 
retinal trait changes and their association with chronic disease, especially 
diseases and outcomes involving the macro- and microvasculature. A study 
which utilised VAMPIRE software investigated fractal measures of retinal 
vasculature and their association with cognitive ageing (Taylor et al., 2015). 
This study from the Lothian Birth Cohort evaluated a single retinal image in 
later life compared with intelligence quotient (IQ) measured at a young age 
and found no association between fractal measures of the retina and 
cognitive ageing. Researchers have investigated retinal microvascular 
changes as an indicator of diabetic nephropathy, as well as stroke risk, 
although not all studies found evidence of an association (Ding et al., 2012; 
Kawasaki et al., 2012; McKay et al., 2018). A population based cohort study 
from China found an association between retinal vascular widths and 
markers of chronic kidney disease, especially in people with diabetes (Bao et 
al., 2015). 
In the review produced by Sun et al. (2009), the authors discuss retinal 
vascular structure and the links that have been researched with risk factors 
such as cardiovascular health, stroke, blood pressure and diabetes, as well 
as many others. There is substantial evidence suggesting that smaller 
arteriolar and venular width is associated with higher current blood pressure 
and older age, while larger vascular width is associated with diabetes and/or 
higher blood glucose and cigarette smoking. Obesity is associated with 
smaller arterioles and larger venules. Mechanistic theories for 
pathophysiological changes in retinal vasculature include sustained 
hypertension, ageing, atherosclerosis, inflammation and endothelial 
dysfunction, as well as blood flow parameters, including oxygenation and 
shear stress (Sun et al., 2009). Specifically in people with diabetes, the 
hypothesis is that arteriolar and venular dilation may reflect hyperperfusion 
resulting from hyperglycaemia and lactic acidosis from retinal hypoxia 
(Grunwald, DuPont and Riva, 1996; Sun et al., 2009). 
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Retinal vascular measurements and diabetic retinopathy 
Diabetic Retinopathy is one of the earliest complications of diabetes which is 
reflected in the high prevalence and can lead to visual impairment and vision 
loss, but with early detection, the disease can be treated and slowed 
reducing the burden on the patients and health care system. Clinical 
evidence of retinopathy may actually be a late indicator of microvascular 
damage to the retina and the blood-retinal barrier and being able to stratify 
people by their risk of developing retinopathy before these overt pathological 
pathways have begun is important (Carol Yimlui Cheung et al., 2015). 
Utilising regularly obtained retinal images together with automated or semi-
automated analysis software is of great interest in the medical field to reduce 
burden of disease.  
Recent studies have provided some evidence for the usefulness of new 
software in helping to predict and detect diabetic retinopathy before serious 
pathology occurs, although substantial heterogeneity in such studies makes 
firm interpretations difficult. There has also been evidence of retinal vascular 
traits providing information on other forms of retinopathy, for example, a 
study evaluating retinopathy of prematurity found increased tortuosity in eyes 
effected by the disease when compared with healthy eyes (Wilson et al., 
2012). This association in retinopathy of prematurity may provide an analogy 
between retinal tortuosity and the development of diabetic retinopathy. 
Chapter 2 (page 37) of this thesis is a systematic literature review that 
explores the current evidence around the association between retinal vessel 
traits and diabetic retinopathy.  
Retinal vascular measurements and cognition 
As the retina functions to process light and colour for sight and relay these 
messages to the brain the retina is considered an extension of the brain and 
nervous system. During early embryological development, the retina is 
derived from the ectoderm, which is derived from the neural tube, also known 
as the neuroectoderm (Snell and Lemp, 2013). The ectoderm also gives rise 
to the optic nerve and other structures that connect the eye to the brain. It is 
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hypothesised that these structural and developmental connections persist 
and are reflected in co-development of disease. In a population-based study 
in Iceland, researchers found evidence of the co-existence of microvascular 
lesions in both the retina and brain, especially in those with diabetes (Qiu et 
al. 2008). These findings indicated an interrelatedness between the 
pathology of the retina and brain, although it should be noted this analysis 
was not conducted prospectively, so any temporal relationship cannot be 
determined.  
Utilising the retinal vasculature as an indicator of the role of small vessel 
health in the brain in relation to cognitive state and decline is gaining a great 
deal of research interest (Patton et al., 2005; Umemura, Kawamura and 
Hotta, 2017; McGrory, Ballerini, Doubal, et al., 2019). It has the potential to 
illuminate subclinical small vessel changes before overt pathology and allow 
for early detection and treatment of cognitive impairment and dementia, 
which are experiencing rapidly increasing incidence with aging populations 
around the world. The large Atherosclerosis Risk in Communities (ARIC) 
study found, in a cross-sectional analysis, that retinal microvascular 
abnormalities, which included focal narrowing, haemorrhages and 
microaneurysms were associated with subclinical cerebral infarcts, 
independently of stroke risk factors (Cooper et al., 2006). Chapter 3 (page 
79) of this thesis is a systematic literature review exploring the relationship 
between retinal vessel traits and cognitive decline. All current research 
pertaining to that association was compiled and evaluated in order to provide 
context for the findings of this thesis.  
There have been other systematic reviews similar to that conducted in 
Chapter 3, including a recent one on the use of fundus photography to 
research retinal changes in dementia, which found some evidence for the 
use of measures including vessel widths and fractal dimension (McGrory et 
al. 2017). While offering hope for the use of retinal biomarkers in diagnosis 
and prognosis of patients, the review called for further prospective studies 
that utilise standardised protocols for retinal imaging and analysis, as well as 
combination with other clinical biomarkers such as cerebrospinal fluid 
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sampling and neuroimaging and paying attention to differences in dementia 
type. 
Another systematic review also found evidence that retinal vascular 
abnormalities may be associated with markers of cognitive decline and 
dementia, although the associations were tenuous, and more robust in cross-
sectional studies compared with longitudinal studies (Heringa et al. 2013). In 
this review, the authors evaluated any dementia, and not by specific type, 
specifically Alzheimer’s, vascular dementia or mixed, so we cannot determine 
distinct differences by aetiology. These systematic reviews reflect the wide-
ranging findings of recent studies that have evaluated retinal vascular 
markers in relation to cognition and that further research is required to 
determine true associations and what subgroups of patients on the spectrum 
of cognitive decline would benefit from novel biomarkers derived from retinal 
imaging. The review conducted in this thesis was compared with these other 
recent reviews for methodological similarities and differences, as well as 
results.  
1.4.5 Limitations in measuring retinal vessel traits 
Although moving from manual measurement methods to semi-automated 
software has enabled more objective measurements of retinal vascular 
parameters to be obtained, there are limitations. One such issue is 
standardising optic disc size to counteract camera magnification and obtain 
reliable measurements across image sets. It is now widely accepted that the 
vertical optic disc varies between people but is on average around 1,800 
microns in diameter so this is the size generally utilised for standardisation, 
but this is still debated (Quigley et al., 1990; McGrory et al., 2018). 
Racial differences have also been shown to have an effect on retinal vascular 
parameters, making relationships with risk factors more difficult to parse (Li et 
al., 2013). One factor is iris pigment colour variability, as a surrogate for 
retinal pigmentation. This can be linked with ethnicity and might contribute to 
errors in measurements or could account for some genetic differences 
between study populations due to differences in contrast and pixel density of 
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retinal images that were both stronger in Caucasian, blue-eyed children, 
compared with brown-eyed East Asian children (Rochtchina et al., 2008). 
Further research is needed to fully understand how these factors affect the 
ability to measure and track changes in the retinal vasculature and compare 
people with different ethnic and genetic backgrounds. 
Poor retinal image quality, due to either technical or anatomical issues, can 
hamper a study causing some participant data to be unusable if the software 
cannot accurately identify key features such as the vessels or optic disc 
boundary. Other problems might be inappropriate comparison of 
measurements from different software or measures produced by different 
graders (McGrory et al., 2018).  
Retinal vascular widths are the most commonly evaluated parameter, but 
these measures suffer from certain issues. The most common descriptors for 
vessel widths are the summary indices CRAE and CRVE, which reflect outer 
vessel width. These measures are not able to capture the internal luminal 
widths, which may show greater changes from vascular damage (Carol 
Yimlui Cheung et al., 2015). Also, there is a confounding effect of associated 
venular and arteriolar sizes, but simply controlling for the other, which is the 
standard statistical approach, can create concerns of multicollinearity. Also, 
the utilisation of AVR, which is calculated as a ratio of CRAE and CRVE, may 
mask important differences in the two vascular measures.  
Another concern is the symmetry of retinal vascular changes between the 
right and left eye, or rather the asymmetry. While there are many symmetrical 
properties observed in the retinal vasculature there is evidence of pathology 
affecting the retina asymmetrically, which complicates the theory that the 
changes in the retinal vasculature is a representation of the wider micro- and 
macrovascular system of the body. Choosing to analyse a single eye or both 
eyes and average the results requires consideration so as not to mask a true 
association or to select a significant finding that is only present in a single 
eye (Cameron et al., 2017). 
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 Chapter Summary 
People with diabetes are at an increased risk of developing vascular related 
complications such as diabetic retinopathy and increased cognitive decline. 
There is currently very limited ability to accurately predict those that will go on 
to develop these quality of life-limiting conditions. The retina, being one of the 
few places in the body where the vasculature can be visualised non-
invasively, offers a unique place to study local and systemic vascular 
disease, and possibly add novel predictive capability to already established 
vascular risk factors. Using recently developed semi-automated software, the 




2 Association between retinal vessel traits and 
retinopathy: a systematic literature review 
 Introduction 
Diabetic Retinopathy has a high prevalence amongst people with diabetes 
and can lead to visual impairment and vision loss, but with early detection the 
disease can be treated and progression slowed, reducing the burden on the 
patient’s quality of life as well as the health care system (Fendrick, Javitt and 
Chiang, 1992; Mazhar et al., 2011). Utilising regularly obtained retinal images 
together with automated or semi-automated analysis software to measure 
retinal traits for the prediction of diabetic retinopathy is of great interest in the 
medical field to reduce burden of disease.  
Recent studies indicate that there is evidence of the usefulness of new 
software in determining an association between retinal vessel traits and 
retinopathy, possibly before serious pathology (S.L. Rogers et al., 2008; Roy, 
Klein and Janal, 2011; Klein et al., 2018). The purpose of this systematic 
literature review was to provide comprehensive, evidence-based, information 
on the current epidemiological research that has been conducted to better 
understand the association between retinal vessel traits and diabetic 
retinopathy. I aimed to include all relevant studies and have presented their 
findings, as well as the details of how the studies were conducted, including 
population characteristics, measures of the exposure and outcomes, and 
discussed their methodological quality. This review serves to support the 
study design and considerations for this thesis, as well as provide a platform 
of analysis and comparison for the findings.  
 Objectives 
The objective of this systematic review was to identify and collate all studies 
that have evaluated the association between retinal vessel traits (RVTs) and 
diabetic retinopathy (DR) in people with diabetes, using fundus images and a 




2.3.1 Types of studies 
I included non-randomised observational epidemiological design studies (i.e. 
cross-sectional, case-control, cohort). Experimental studies, such as 
randomised controlled trials, were considered if the population fit the 
inclusion criteria and the intervention did not confound the results and make 
the inclusion inappropriate. An example of this could be a randomised 
controlled trial evaluating an intervention used for something other than 
treating diabetic retinopathy that may also include retinal vessel trait 
measurements, for the entire study or a subset, and diabetic retinopathy as 
an outcome.  
2.3.2 Types of participants 
People with diabetes mellitus (type 1 or type 2) or general population studies 
with a subset of people with diabetes that stratified outcomes by diabetes 
status that could be analysed separate from those without diabetes were 
included.   
2.3.3 Types of retinal vessel traits 
I included studies that evaluated any RVT identified using fundus imaging 
and assisted by automated or semi-automated computer software designed 
for measuring retinal features. Studies were excluded if they used manual 
methods of measuring RVTs, even if digitally assisted. I also excluded 
studies if they were using the traits to diagnose existing diabetic retinopathy. 
2.3.4 Types of outcome measures 
Outcomes of interest were limited to any measure of DR. I included studies if 
they considered DR as a dichotomous outcome or if they classified DR 
according to severity measure, such as mild, moderate and proliferative.  
2.3.5 Search methods for identification of studies 
Using the OVID® platform, I searched the MEDLINE and EMBASE 
databases for all relevant studies, using a sensitive search strategy. The full 
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search strategy can be found in Appendix 1. I also undertook hand-
searching of the references of relevant studies and reviews. The electronic 
search was limited to English language studies conducted in humans. The 
search was undertaken on February 14th, 2019 and included the time period 
from 1997 to the search date.  
2.3.6 Data collection 
Any studies were considered for inclusion if they met the inclusion criteria for 
study type, participant type as well as outcome and vessel analysis. Studies 
were excluded if they included less than 100 participants, due to low power to 
detect an association. Also, studies that only had data published in abstracts 
or conference proceedings, and not a fully peer-reviewed published 
reference, were excluded due to a paucity of information being provided in 
such abbreviated texts. Studies were excluded if their methodology was 
wholly different from the other studies, so much so that comparison would be 
inappropriate.  
A data extraction form was prepared to identify key information and findings 
from the included studies. Data extracted included the type of study, study 
aim, location, follow-up time frame, number of participants included, type and 
duration of diabetes, age and gender of participants, RVTs and how they 
were analysed, DR grading scheme used, outcomes, statistical models used 
and covariates controlled for. I collected the outcome data for any analyses 
evaluating the association between RVTs and DR. If a study reported data on 
other outcomes, such as other retinal pathology, this type of data was not 
collected as it was out with the scope of this review.  
2.3.7 Assessment of study quality 
Using a modified version of the Critical Appraisal Skills Programme (CASP) 
appraisal tool I evaluated the quality of each study (CASP UK, 2018). The 
CASP tool includes separate but similar tools for case-control studies and 
cohort studies, making easy comparison of quality between the study types. 
CASP is designed as a check-list style resource to help organise and 
evaluate the quality of studies using an evidence-based approach. I 
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evaluated and reported on eight domains of quality for each study: (1) Did the 
study address a clearly focused issue? (2) Was the study recruited in an 
acceptable way; in case-control studies, were cases and controls recruited 
appropriately? (3) Was the exposure and outcome accurately measured to 
minimise bias? (4) Have the authors identified all important confounding 
factors and included them in the analysis? (5) Was the follow up of the 
subjects complete enough and long enough? (6) How precise are the results 
and do you believe the results? (7) Do the results fit with other available 
evidence? (8) Are sources of funding and/or conflicts of interest reported? 
See Appendix 2 for further details on the criteria I was looking for to fulfil 
each domain.  
To present the findings of the quality assessment I generated tables with a 
row for each study and a column for each domain. I either reported the 
methods of the study or in some cases stated ‘Yes’ if the criteria were met or 
the specific reasons the requirements were not fully met. I added a colour to 
each cell to help give a quick visual assessment: green indicates that all 
criteria were met; yellow indicates that there are some concerns with the 
study in relation to that domain or that not all the criteria were met; red 
indicates serious concerns with the domain.  
2.3.8 Measures of effect 
I planned to undertake meta-analysis using fixed-effects methods if the data 
extracted from the included studies was deemed to be satisfactorily 
homogenous in terms of exposures, outcomes and modelling methods. 
However, after inclusion and extraction, it was clear that the studies and their 
data varied too greatly for meta-analysis. I therefore undertook thorough 
descriptions of the included studies’ methods and results, using tables and 
figures to present the results of the individual studies. 
 Results  
2.4.1 Results of the search 
A total of 8087 references were identified in the EMBASE and MEDLINE 
database search and after de-duplication 6131 references remained. An 
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additional 43 duplicates were identified during the title and abstract review. 
After titles and abstracts were reviewed, full articles were retrieved for 76 
references. After full references were reviewed, a total of 36 references from 
14 studies were included in this systematic literature review. See Appendix 3 
for the full study selection PRISMA flow diagram. 
Twelve references were excluded because of low sample size (<100 
participants) (Kristinsson, Gottfredsdottir and Stefansson, 1997; Kunicki et 
al., 2009; Bucca et al., 2012; Crosby-Nwaobi and Heng, 2012; Talu, 2013; 
Habib et al., 2014, 2016; Muraoka et al., 2014; Leontidis et al., 2015; 
Leontidis, Al-Diri and Wigdahl, 2015; Popovic et al., 2018; Kostic et al., 
2018). Three references were excluded because the relevant analyses were 
only presented in conference abstracts (Sandoval et al., 2016; Forster et al., 
2018; Li et al., 2018). The study by Lim et al. was excluded due to serious 
inconsistencies between the methods and results as well as statistical 
modelling concerns (Lim et al., 2017). A further study was excluded due to 
methods of analysis being inconsistent with the remainder of the included 
studies, and the  aim of the study was to compare different methods of fractal 
dimension analysis for optimal predictive ability for proliferative diabetic 
retinopathy (PDR) (Orlando et al., 2017).  
2.4.2 Included Studies 
See Table 1, Table 2 and Table 3 (on pages 51, 52 and 53, respectively) 
for general characteristics of included studies by study type. For this chapter, 
as well as Chapters 3, 5-7, all tables and figures are at the end of their 
respective chapter. This was done for clarity as many of the tables and 
figures are long and impede the ability to read the text and it was difficult to 
place them near the relevant text.  
Fourteen studies were included in this review. They include, in alphabetical 
order, the Australian Diabetes, Obesity and Lifestyle Study (AusDiab) 
(Tikellis et al., 2007), the Blue Mountains Eye Study (Kifley et al., 2007), 
Danish Cohort of Pediatric Diabetes 1987 (DCPD1987) (Broe et al. 2014), 
Desheng Diabetic Eye Study (Yang et al., 2016), Darwin Region Urban 
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Indigenous Diabetes Study (DRUID) (Dirani et al., 2010), Grauslund 2010 
(Grauslund et al., 2010), Inter99 Eye Study (Drobnjak et al., 2017), New 
Jersey 725 Study (Roy, Klein and Janal, 2011), Multi-Ethnic Study of 
Atherosclerosis (MESA) (Nguyen et al., 2008), Sasongko 2011 (Sasongko 
et al., 2011), Singapore Indian Eye Study (SINDI) (Tsai et al., 2011), 
Singapore Malay Eye Study (SiMES) (Cheung et al., 2012), Sydney 
Paediatric Diabetes Study (Alibrahim et al., 2006) and the Wisconsin 
Epidemiologic Study of Diabetic Retinopathy (WESDR) (Klein et al., 
2012). Many of the included studies include multiple references so I have 
included the main reference in text and in the references section for this 
literature review I included the other references under the study heading. 
Supporting references and excluded studies for this chapter that are not 
specifically an included study are in the general reference section of the 
thesis. 
Eight of the included studies performed cross-sectional analyses of the data 
(Blue Mountains Eye Study, Desheng Diabetic Eye Study, DRUID, Grauslund 
2010, Inter99 Eye Study, MESA, Sasongko 2011 and SINDI). Four studies 
reported both cross-sectional and longitudinal data (AusDiab, DCPD1987, 
SiMES and Sydney Paediatric Diabetes Eye Study). Two studies included 
only longitudinal data (New Jersey 725 and WESDR).  
The number of participants ranged from 110 up to 2366. In the longitudinal 
studies the follow-up times ranged from 2.5 years to 16 years. Three studies 
were undertaken in participants with only type 2 diabetes, four studies in 
participants with type 1 diabetes and seven studies that included mixed 
aetiology, although most of the mixed studies had a far larger proportion of 
those with type 2 diabetes. Five studies were conducted in Australia, three in 
Denmark, three in the United States, two in Singapore and one in China. 
Twelve of the included studies reported on vessel widths, five reported on 
tortuosity and five reported on fractal dimension (FD). Other vessel 
measurements that were reported included length-distance ratio (LDR), 
branching angles, branching coefficients between parent and daughter 
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vessels, amongst several other branching geometry measures. For this 
review I chose to only report data on widths (central retinal arteriolar 
equivalent (CRAE) and central retinal venular equivalent (CRVE), tortuosity 
and FD, as these are the traits described in the primary analysis of this 
thesis. For the diagnosis and classification of DR, thirteen studies reported 
using the Early Treatment of Diabetic Retinopathy Study (ETDRS) 
classification system or another modified Airlie House Classification of DR 
system. One study reported DR using a simplified version of the Wisconsin 
grading system (AusDiab). See Table 4 (on page 54) for information on DR 
and RVTs for the individual studies. Appendix 4 contains further information 
on the retinal images used in each study.  
2.4.3 Findings of included studies 
Due to the heterogeneity of retinal vessel analysis, outcome reporting, 
statistical modelling and other factors, meta-analysis was not considered an 
appropriate method for comparing the included studies. I therefore have 
undertaken a descriptive approach of the findings of the individual studies 
using visual association figures that indicate if the study found evidence of an 
association using their specific statistical modelling methods. There was no 
pooling of raw data to create the figures using methods such as meta-
analysis. For studies that did not find a statistically significant association 
between the RVT and DR, an arrow was used to indicate the direction of the 
point estimate, see Figure 4 (page 62) as an example. In meta-analysis, the 
logic is to combine results of several, usually small, studies, which 
themselves may have not had power to reach statistical significance, but 
when combined, the evidence may be statistically significant, indicating a 
possible true effect. Therefore, using arrows to indicate direction of a non-
significant association allows readers to see any trends that are  important, 
and possibly would have shown statistical significance if meta-analysis was 
employed. For the figures I reported on the outcome ‘any DR’, where 
available, if not available I included the study reported comparison such as 
PDR or varying severity levels of DR and specified this within the plot.  
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Appendix 5 contains further information on the statistical models used and 
covariates controlled for. Table 5 (page 56) contains the extracted results 
from the individual studies and is located at the end of this chapter. Some of 
the included studies had multiple reports of the same RVTs in different 
references with different results, with it not always being clear why there were 
differences. I chose to include results from the reports with the greatest 
number of participants and/or the longest follow-up, where possible.  
Central Retinal Arterial Equivalent (CRAE) 
Twelve studies reported on CRAE, but two studies reported both cross-
sectional and longitudinal data, so these two studies are included twice on 
the association plot. Of the eight studies reporting cross-sectional data, only 
one found a statistically significant association between wider CRAE and any 
DR. For the seven studies that did not find a statistically significant 
association, there was a mixture of point estimates favouring both increased 
and decreased CRAE.  In the six studies that reported longitudinal data, four 
studies found an association between wider CRAE and DR, three of which 
were reporting any DR and one on PDR. The other two studies with no 
statistically significant association both favoured wider CRAE, with one study 
reporting on progression to PDR and the other on any DR. See Figure 4 
(page 62). 
It should be noted that for several of the studies that did not show a 
statistically significant association within their population, MESA, SINDI and 
Desheng, there was a pattern of wider CRAE for minimal and/or mild DR, but 
then narrower CRAE for moderate or severe DR.  
Central Retinal Venular Equivalent (CRVE) 
As with CRAE, 12 studies reported on CRVE, and two reported both cross-
sectional and longitudinal data so they appear twice on the plot. For the 
cross-sectional data, seven of the eight studies reported a positive 
association between wider CRVE and DR and the one study with a non-
significant association also favoured wider CRVE. Four of those studies 
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reported on any DR, and three reported varying levels of DR severity 
compared with no DR.  
For the longitudinal data, four of the six studies reported evidence that wider 
CRVE is associated with incident DR or progression of DR. Two of these 
studies reported on any DR compared with no DR, and the other two 
reported specifically on PDR. For the remaining two studies, one reported an 
association between narrower CRVE, and DR and one study reported no 
association, but the point estimate also favoured narrower CRVE(Figure 5, 
page 63). 
Arterial tortuosity 
Five studies reported on arterial tortuosity, four of which reported cross-
sectional data, of which one also reported longitudinal data, and one that only 
reported longitudinal data. Of the cross-sectional reports, two of the four 
found evidence of a positive association between increased arterial tortuosity 
and DR. Of the two showing an association, one compared mild or moderate 
DR to no DR and one compared any DR to no DR. For both longitudinal 
reports, there was evidence of an association between increased arterial 
tortuosity and any DR. The two studies that did not find a statistically 
significant association reported point estimates also favouring increased 
arterial tortuosity and any DR. See Figure 6 (page 63).  
Venular tortuosity 
The same five studies that reported on arterial tortuosity also reported on 
venular tortuosity, with four studies reporting cross-sectional data, and two 
reporting longitudinal data. Only a single study, reporting longitudinal data, 
demonstrated a statistically significant association between increased 
venular tortuosity and any DR, but the remaining four studies, although not 
statistically significant, also had point estimates supporting this association. 
See Figure 7 (page 64). 
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Fractal Dimension (FD) 
Fractal dimension was reported as an outcome in five studies, two of which 
provided both cross-sectional and longitudinal data, one that reported cross-
sectional data only and two that reported longitudinal data only. Of the three 
studies reporting cross-sectional data one showed an association between 
decreased FD and PDR, one showed no association, but had a point 
estimate favouring increased FD and any DR, and one demonstrated a 
positive association between increased FD and any DR. For the longitudinal 
data, three reported no association, two of which had point estimates 
favouring decreased FD, the third did not provide the numeric data. One 
longitudinal report showed evidence of decreased FD being associated with 
PDR. See Figure 8 (page 64). 
2.4.4 Quality assessment of included studies 
See Table 6 (page 65) at the end of this chapter for full details on quality 
assessment for the individual studies. The first, seventh and eighth domains 
have been omitted from the table as all studies met the requirements and 
there was limited space for the table.  
Did the study address a clearly focused issue? 
All the included studies set out to address clearly focused research 
questions, with no major concerns.  
Was the study recruited in an acceptable way? 
Seven of the fourteen studies were deemed to have recruited their study 
populations in an acceptable way to reduce bias (Blue Mountains Eye Study, 
Grauslund 2010, Desheng Diabetic Eye study, DCPD1987, SiMES, AusDiab 
and New Jersey 725 Study).  
The following six studies utilised mostly sufficient methods to reduce bias, but 
there were some concerns regarding recruitment. The DRUID study 
experienced difficulties in recruiting participants due to practical and 
sensitivity issues in recruiting indigenous people in Australia. They used 
several methods to try to identify and recruit participants, but they still 
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encountered issues in recruiting sufficient participants. The Inter99 study is a 
large Danish population-based study and for the smaller eye study, a portion 
of the larger cohort were invited. Standard World Health Organisation (WHO) 
definitions of diabetes were utilised to select participants, but the 
investigators also allowed for self-reported cases of diabetes, which could 
lead to bias. The Sasongko 2011 study recruited consecutively from two 
separate eye clinics, but they provided no information on the non-attenders 
or how generalizable their study population is. The MESA study was not fully 
powered to evaluate people with diabetes which reduces their applicability to 
this analysis. The SINDI study used robust methods of identifying participants 
that included age-stratified, random sampling from computer-generated lists 
provided by the Singapore Ministry of Home Affairs, but there was evidence 
that those excluded were at a higher risk of poor health as they were older 
and had higher blood pressure and HbA1c. However, those excluded from 
the SINDI study were also more likely to be female and non-smokers. The 
WESDR study is at possible risk of misclassification bias of their participants 
with diabetes as they used the age of onset to categorise type 1 and type 2 
diabetes, which can be unreliable.  
I noted strong concerns regarding the recruitment of the Sydney Paediatric 
Diabetes Study. I identified multiple references that fit the inclusion criteria for 
the review that all used this study population for different analyses but there 
is no continuity between the studies regarding how they chose their study 
populations from the larger cohort. It is concerning that there is no mention 
that the individual studies are using the same population as another similar 
analysis. Also, there is no information provided in any of the studies 
regarding the non-participating invitees. I have chosen to include the 
references as one study, so I do not include the same participants multiple 
times in the review. 
Was the exposure and outcome accurately measured to minimise bias? 
Aside from the Desheng Eye Study, which met all the criteria, each of the 
included studies were missing some level of description of how the exposure 
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and outcomes were measured that would minimise bias. For most studies, 
they did not describe who, and if they were trained or blinded, was measuring 
the retinal vessels or grading for DR. Also, several studies did not provide 
information on if intra/intergrader reliability measures were undertaken. In 
one case, the name of the software used for analysis was not provided.  
Have the authors identified all important confounding factors and included 
them in the analysis? 
All of the included studies controlled for certain participant characteristics in 
their analysis. Five of the included studies controlled for all the characteristics 
identified as being important. The remaining 12 studies were missing one or 
more characteristics in their analyses, most notably, several studies that 
evaluated vessel widths did not control for venular width when analysing 
arterial width, or vice versa. This is important as the two are highly correlated, 
but also controversial due to concerns with multicollinearity. Also, several 
studies did not control for duration of diabetes, which is an important factor 
for development of diabetic retinopathy.  
Was the follow-up of subjects complete enough and long enough? 
For seven of the studies, this field was not relevant as they only conducted 
cross-sectional analyses. For the remaining six studies that did provide 
follow-up data, four were deemed to have sufficient numbers of participants 
and follow-up was appropriately long (DCPD1987, SiMES New Jersey 725, 
WESDR). For the AusDiab study, the follow-up was only five years, which 
may be too short for the outcome and also there was no clear description of 
attrition. There were major concerns with the follow-up data presented for the 
Sydney Paediatric Diabetes Study as follow-up was only on average 2.9 
years, which is considered too short for diabetic retinopathy.  
How precise are the results? Do you believe the results? 
Most of the included studies were not well powered towards participants with 
diabetes as they generally made up a smaller subset of a larger cohort. Also, 
quite a few studies did not include confidence intervals or other measures 
that help to understand the magnitude of the effect, making it difficult to 
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interpret the results. However, even with underpowered studies, several were 
still able to detect statistically significantly differences. The Sydney Paediatric 
Diabetes Study used the same base population for several different 
analyses, and at times with different conclusions. Because limited information 
was provided on how these analyses, and the population they were based 
on, differed or were the same, there is doubt from opposing findings from the 
same population. 
Do the results fit with other available evidence? 
Overall, the findings from each study were determined to fit within the wider 
literature. Currently there is a paucity of evidence regarding the association 
between retinal vessel traits and diabetic retinopathy.  
Are sources of funding and/or conflicts of interest reported? 
All included studies provided sources of funding and financial support.  
 Discussion 
2.5.1 Summary of the main results 
Fourteen studies were included in this review. Due to major differences in 
study design, analysis methods and reporting of results, meta-analysis was 
not possible as a method for combining data from the individual studies. 
Several of the longitudinal analyses suggest there may be an association 
between wider CRAE and risk of diabetic retinopathy, but this association is 
not as evident in cross-sectional studies. Many of the included studies that 
evaluated CRVE demonstrated an association between wider CRVE and risk 
of diabetic retinopathy, in both cross-section and longitudinal studies. Only 
five studies evaluated tortuosity, and there is some evidence that increased 
arterial tortuosity may be associated with risk of diabetic retinopathy. 
Although the majority of the studies that evaluated venular tortuosity did not 
find any statistically significant associations, all had point estimates that 
favoured increased venular tortuosity and an association with retinopathy, 
which, if meta-analysis was performed, may have provided evidence of an 
association. The results of the five studies that looked at the relationship 
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between fractal dimension and risk of diabetic retinopathy were mixed, but 
with a possibility that lower fractal dimension is associated with retinopathy. 
Further discussion of these findings, put in the context of this thesis, will be 
continued in the general discussion chapter.  
2.5.2 Quality and completeness of data 
Overall, the quality of the included studies was moderate, with only minor 
concerns that were often unavoidable, or due to insufficient description within 
the report. There were some concerns with how participants were selected 
from large study populations, and measurement of the RVTs and DR was not 
always made clear. Most of the included studies had low numbers of people 
with diabetes, which reduces the power, making findings difficult to interpret. I 
only had major concerns with the findings from one study, the Sydney 
Paediatric Diabetes Study, as the same population was used in multiple 
analyses, but there was no explanation of how the individual analyses chose 
the participants they used, and the inclusion numbers, and at times the 
conclusions varied between each report. This same study also had a limited 
follow-up.   
2.5.3 Conclusions 
There is evidence to suggest that certain retinal vessel traits are associated 
with diabetic retinopathy. These associations need to be further explored in 
large, longitudinal cohorts that have sufficient numbers of people with 
diabetes to conduct well-powered analyses. Determining if there is a 
prospective relationship between vessel traits and retinopathy, above and 
beyond current known risk factors, will help to establish if retinal vessel traits 































Figure 6. Arterial tortuosity and risk of diabetic retinopathy 
 










Figure 7. Venular tortuosity and risk of diabetic retinopathy 
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3 Association between retinal vessel traits and 
cognitive decline: a systematic literature 
review 
 Introduction 
The retina is considered an extension of the cerebrovascular system, both of 
which share developmental and physiologic characteristics, as well as 
pathological markers (Cooper et al., 2006; Snell and Lemp, 2013). These 
links make the retina a plausible candidate for early detection of pathology in 
the cerebrovasculature, including dementia and cognitive decline. In recent 
years, there have been many studies that have investigated retinal traits and 
their association with chronic disease including cognitive impairment and 
decline, this is due to the fact that the retina is a such an easily visualised 
part of the vascular system.  
As previously described in Section 1.4, a study from the Lothian Birth 
Cohort, which utilised VAMPIRE software, investigated fractal measures of 
retinal vasculature and their association with cognitive ageing by evaluating a 
single retinal image in later life compared with IQ measured at a young age 
and found now association (Taylor et al., 2015). The large Multi-Ethnic Study 
of Atherosclerosis (MESA) study observed larger arteriolar width measures 
over 8 years of follow-up that were associated with decreased cognitive 
measures in their large, prospective longitudinal cohort (Hughes et al. 2016). 
There have been several other studies evaluating these traits that used 
different methods of describing cognitive decline and measuring retinal traits, 
with varying results. 
The purpose of this systematic literature review was to provide 
comprehensive, evidence-based information on the current epidemiological 
research that has been conducted to better understand the association 
between retinal vessel traits and cognition. I aimed to include all relevant 
studies and present their findings, as well as the details of how the studies 
were conducted, including population characteristics, measures of the 
exposure and outcomes, and to discuss their methodological quality. The 
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review serves to support the study design and considerations for this thesis, 
as well as provide a platform of analysis and comparison of the primary 
results. The methods in this chapter are very similar to those in Chapter 2, 
but methodological descriptions are included so that if a person is reading 
this chapter out of order still receives the full contextualisation.  
 Objectives 
The objective of this systematic review was to identify and collate all studies 
that have evaluated the association between retinal vessel traits (RVTs) and 
cognitive ability or cognitive decline, using fundus images and a digital 
platform for semi-automatic or automatic analysis. 
 Methods 
3.3.1 Types of studies 
I included non-randomised, observational epidemiological study designs (i.e. 
cross-sectional, case-control, cohort). Experimental studies, such as 
randomised controlled trials, were considered if the population fit the 
inclusion criteria and the intervention did not confound the results and make 
the inclusion inappropriate. For instance, if a randomised controlled trial was 
evaluating an intervention for something other than the treatment of cognitive 
decline, and had measured retinal vessel traits for the study, or a subset of 
the study, and also had cognitive decline or dementia as an outcome, the 
study may be considered for inclusion. 
3.3.2 Types of participants 
There were no restrictions to the type of participant considered for inclusion, 
based on features such as age or comorbidities.  
3.3.3 Types of RVTs 
I included studies that evaluated any RVT identified using fundus imaging 
and assisted by automated or semi-automated computer software designed 
for measuring retinal features. Studies were excluded if they used manual 
methods of measuring RVTs, even if digitally assisted. The most common 
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RVTs to be studied included widths (central retinal arteriolar equivalent 
(CRAE) and central retinal venular equivalent (CRVE), tortuosity and fractal 
dimension (FD).  
3.3.4 Types of outcome measures 
Outcome measures were limited to any measure of cognitive ability or 
change, such as tests or a battery of tests, specifically designed to measure 
a single or multiple cognitive domain. I also included studies with participants 
based on a cognitive diagnosis, such as dementia or cognitive impairment. 
Studies were excluded if they did not specify how cognitive status was 
measured. 
3.3.5 Search methods for identification of studies 
Using the OVID® platform, I searched the MEDLINE, EMBASE and 
PsychINFO databases for all relevant studies, using a sensitive search 
strategy. The full search strategy can be found in Appendix 6. I also 
undertook hand-searching of the references of relevant studies and reviews.  
The electronic search was limited to English language studies conducted in 
humans. The search date was undertaken on February 14th, 2019 and 
included the time period from 2007 to the present date. The year 2007 was 
chosen as a previous PhD student conducted a similar systematic review for 
their thesis project, which the search strategy of this review was based on, 
and was subsequently published (Ding et al., 2008).   
3.3.6 Data collection 
Any study that met the inclusion criteria for study type, participant type as 
well as outcome and vessel analysis, were considered for inclusion. Studies 
were excluded if they included less than 100 participants, due to low power to 
detect an association. Also, studies that only had data published in abstracts 
or conference proceedings, and not a fully peer-reviewed published 
reference, were excluded due to a paucity of information being provided in 
such abbreviated texts. 
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A data extraction spreadsheet was prepared to identify key information and 
findings from the included studies. Data extracted included the type of study, 
location, follow-up time frame, number of participants included, age and 
gender of participants, retinal vessel measurements and how they were 
analysed, how cognitive status or decline was measured, including criteria for 
pathophysiological diagnosis, outcomes, statistical models used and 
covariates controlled for. I collected the outcome data for any analyses 
evaluating the association between RVTs and cognition. If a study reported 
data on other outcomes, such as brain volume or imaging, this type of data 
was not collected as it was out with the scope of the review.  
3.3.7 Assessment of study quality 
Using a modified version of the Critical Appraisal Skills Programme (CASP) 
quality appraisal tool I evaluated the quality of each study (CASP UK, 2018). 
The CASP tool includes separate but similar tools for case-control studies 
and cohort studies, making easy comparison of quality between the different 
study types. CASP is designed as a check-list style resource to help organise 
and evaluate the quality of studies using an evidence-based approach. This 
tool does not generate a single value or score, but rather provides a narrative 
for each of the included domains. I evaluated and reported on eight areas of 
quality for each study: (1) Did the study address a clearly focused issue? (2) 
Was the study recruited in an acceptable way; in case-control studies, were 
cases and controls recruited appropriately? (3) Was the exposure and 
outcome accurately measured to minimise bias? (4) Have the authors 
identified all important confounding factors and included them in the 
analysis? (5) Was the follow up of the subjects complete enough and long 
enough? (6) How precise are the results? Do you believe the results? (7) Do 
the results fit with other available evidence? (8) Are sources of funding 
reported? See Appendix 2 for further information I used to evaluate each 
domain. 
To present the findings of the quality assessment I generated a table with a 
row for each study and column for each domain. I either reported the 
methods of the study or in some cases stated ‘Yes’ if the criteria were met, or 
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the specific reasons the requirements were not fully met. I added a colour to 
each cell to help give a quick visual assessment: green indicates that all 
criteria were satisfactorily met; yellow indicates that there were some 
concerns with the study in relation to that domain; red indicates serious 
concerns with the domain.  
3.3.8 Measures of effect 
I planned to undertake meta-analysis using fixed-effects methods if the data 
extracted from the included studies were deemed to be satisfactorily 
homogenous in terms of exposures, outcomes and modelling methods. 
However, after inclusion and extraction, it was clear that the studies and their 
data varied too greatly for meta-analysis. Narrative synthesis methods, along 
with tables and figures, were undertaken to describe and present the data 
from the individual studies. I chose to report on the most commonly reported 
RVTs, which included vessel widths (CRAE and CRVE), as well as tortuosity, 
which is separated into arteriolar and venular tortuosity, and finally on fractal 
dimension (FD), which includes a total FD measure and also separate FD 
measures for the arteriolar and venular vessels. A few of the studies reported 
on other vessel features, which are noted in the study descriptions, but not 
reported on in this review.  
 Results 
3.4.1 Results of the search 
A total of 872 citations were identified in the search plus an additional three 
from hand searching, for a total of 875 citations. Seven-hundred and 
nineteen of which were non-duplicates. After reviewing titles and abstracts, 
644 were deemed not relevant. Seventy-five full articles were retrieved. 
Thirty-eight were excluded after full text screening and a further six were 
excluded during data extraction. A total of 31 references from 15 studies 




3.4.2 Included Studies 
See Table 7, Table 8, and Table 9 (pages 100, 101 and 102, respectively) 
for general information about the included studies. Studies are arranged by 
study type (case-control, longitudinal and cross-sectional) and by ascending 
order of participants included. As with Chapter 2, all tables and figures are at 
the end of the chapter. 
Fifteen studies were included in this review. They include, in alphabetical 
order, the Australian Imaging, Biomarkers and Lifestyle Flagship Study 
of Aging (AIBL) (Frost et al., 2013), The Blue Mountains Eye Study (Liew 
et al., 2009), Cheung 2014 (Cheung et al., 2014a), Chronic Renal 
Insufficiency Cohort (CRIC) (Yaffe et al., 2013), Dunedin 
Multidisciplinary Health and Development Study (Dunedin Study) 
(Shalev et al., 2013), Epidemiology of Dementia in Singapore (EDIS) (Ong 
et al., 2014), Edinburgh Type 2 Diabetes Study (ET2DS) (Ding et al., 
2011), Los Angeles Latino Eye Study (LALES) (Gatto et al., 2012), 
Lothian Birth Cohort 1936 (LBC1936) (McGrory et al., 2016), Pittsburgh 
Epidemiology of Diabetes Complications Study (EDC) (Nunley et al., 
2018), the Rotterdam Study (de Jong et al., 2011), Singapore Malay Eye 
Study (SiMES) (Cheung et al., 2014b), South London Diabetes Study 
(SOUL-D) (Naidu et al., 2016), Wisconsin Epidemiologic Study of 
Diabetic Retinopathy (WESDR) (Ryan et al., 2016), and Williams 2015 
(Williams et al., 2015).  
Four studies used case-control methods (AIBL, Cheung 2014, SOUL-D and 
Williams 2015), nine were cross-sectional studies (Blue Mountains Eye 
Study, CRIC, Dunedin Study, EDIS, ET2DS, LALES, LBC1936, SiMES and 
WESDR) and two studies provided longitudinal data (EDC and the Rotterdam 
Study). 
The number of participants included in each study ranged from 119 to 5553. 
For the longitudinal analyses the mean follow-up times were 11.6 years in the 
Blue Mountains Eye Study and 17.8 years for EDC. The majority of studies 







As the measurement of cognition can be difficult and often subjective, it is not 
surprising that there were many different methods used to measure and 
report cognitive status or cognitive decline. Three of the four case-control 
studies utilised a diagnosis of Alzheimer’s disease (AD) as their case 
definition of cognitive decline. Four studies utilised a single scoring system to 
identify cognitive impairment or function: one study utilised the modified 
Telephone Interview of Cognitive Status (TICSM) tool, another used the 
Cognitive Abilities Screening Instrument-Short form (CASI-S) and/or Spanish 
English Neuropsychological Assessment Scales (SENAS) tools. A third study 
considered a lower score of the Abbreviated Mental Test (AMT), to indicate 
lower cognitive function and a fourth used the Mini-Mental State Exam 
(MMSE) to generate their cognitive outcome. Eight studies used a 
combination of tests and criteria to either determine a single measure of 
cognition or to investigate different cognitive domains separately.  
3.4.3 Findings of included studies on selected RVTs 
See Appendix 9 for a description of the statistical models used and 
covariates included and see Table 11 and Table 12 (page 105 and 108, 
respectively) for full results from each included study.  
Vessel widths 
I identified 14 studies that reported on CRAE and CRVE. Four studies used a 
case-control design, eight studies were cross-sectional and two studies were 
longitudinal.  
Central Retinal Arteriolar Equivalent (CRAE) 
Only three of the 14 studies identified an association between CRAE at 
baseline and cognitive decline and all three found that a narrower CRAE was 
associated with increased risk of cognitive decline. The three studies 
included one case-control study that evaluated AD (AIBL) and two cross-
sectional studies that evaluated cognitive ability by different tests (WESDR 
and LALES). AIBL estimated a mean and standard deviation (SD) of 
129.1µm (SD 10.3) in the control group and 122.9µm (SD 12.4) in the group 
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with AD and p value of 0.027 after adjusting using a false discovery rate 
method. It is assumed they were reporting units in µm, but that was not 
specified. WESDR reported a beta-coefficient (95% confidence interval (CI)) 
for CRAE per 10µm change of 0.140 (95% CI 0.062 to 0.219), p < 0.001 for 
mental efficiency, but there was no difference in verbal memory. The LALES 
study used the lowest decile scores of the Cognitive Abilities Screening 
Instrument-Short form (CASI-S) to indicate cognitive dysfunction and 
determined that decreased CRAE was associated with cognitive dysfunction 
(odds ratio (OR) 2.17, 95% CI 1.19 to 3.97). Of the studies that reported 
findings that were not statistically significant, one had a point estimate 
favouring narrower CRAE and two wider CRAE. Overall, there was little 
consensus between the 14 studies regarding the relationship between 
baseline CRAE and cognitive decline. See Figure 9 (page 110). 
One of the longitudinal studies, EDC, also evaluated change in CRAE over 
time and found evidence that all participants showed a decrease in CRAE but 
there was faster narrowing of CRAE (slope) in participants that had clinically 
relevant cognitive decline, compared with no cognitive decline or mild 
cognitive decline. These results are not included in Figure 9 because none of 
the other studies evaluated change in CRAE, and would therefore be 
inappropriate to compare.  
Central Retinal Venular Equivalent (CRVE) 
Of the 14 studies, two found an association between narrower CRVE and 
cognitive decline (AIBL and Cheung 2014) and four found an association 
between wider CRVE and cognitive decline (WESDR, Dunedin Study, Blue 
Mountain Eye Study and the Rotterdam Study). Two of these studies were 
case-control, three cross-sectional and one longitudinal. AIBL reported CRVE 
of 182.7µm (SD 15.8) in the control group and 169.7µm (SD 15.3) in the 
group with AD and a p = 0.0049, again, I assumed the unit is in µm. Cheung 
2014 reported an OR of 2.01 (95% CI 1.27 to 3.19) when comparing AD 
cases and controls for CRVE, and the report stated that the association was 
of narrower CRVE and AD. WESDR again reported on mental efficiency and 
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reported a beta of -0.127 (95% CI -0.207 to -0.047), p = 0.002, indicating that 
wider CRVE was associated with reduced mental efficiency. The Dunedin 
Study used 16 different cognitive assessment tests looking at multiple 
domains and found associations between wider CRVE and many of the tests 
and domains. Please see Table 11 (page 105) for the full list of results from 
the Dunedin Study. The Blue Mountain Eye Study used a cut-off point of ≤23 
on the Mini-Mental State Exam (MMSE) to determine cognitive impairment 
and found the widest CRVE quartile to be associated (OR 1.8, 95% CI 1.0 to 
3.2), p = 0.03. The only longitudinal study, the Rotterdam Study, used 
multiple screening exams and examination by multiple medical professionals 
trained at identifying dementia, to determine dementia status and when 
comparing this status with CRVE (per SD increase) they found a hazard ratio 
(HR) of 1.11 (95% CI 1.00 to 1.22), which indicates a possible association. Of 
the studies who’s findings were not statistically significant but reported their 
numeric findings, three reported a point estimate favouring narrower CRVE 
and one reported favouring wider CRVE. See Figure 10 (page 111). 
The EDC study also evaluated change in CRVE over the study period and 
found that on average all participants demonstrated a decrease in CRVE 
over time, but there was no difference between participants with cognitive 
impairment or not.  
Tortuosity 
A total of seven studies reported tortuosity as an outcome. Four were case-
control studies and three cross-sectional. No longitudinal studies evaluated 
tortuosity.  
Tortuosity-arterial 
One study found an association between increased arterial tortuosity and 
cognitive decline (Cheung 2014), and one study found an association 
between decreased arterial tortuosity and cognitive decline (Williams 2015), 
both of which were case-control studies. Cheung 2014 reported an OR of 
1.80 (95% CI 1.40 to 2.31) per SD increase in tortuosity. Also reporting per 
SD increase, Williams 2015 reported an OR of 0.78 (95% CI 0.63 to 0.97) p = 
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0.027. Of the non-significant findings, one study favoured decreased arterial 
tortuosity and one favoured increased, both of which were cross-sectional. 
See Figure 11 (page 112).  
Tortuosity-venular 
Two case-control studies reported an association between increased venular 
tortuosity and cognitive decline (SOUL-D and Cheung 2014) and a single 
case-control study found an association between decreased venular 
tortuosity and cognitive decline (AIBL). SOUL-D reported the difference in 
venular tortuosity as a beta coefficient of 0.13 (95% CI 0.002 to 0.250) with 
higher venular tortuosity in the cases, as determined by the lowest 10% of 
scorers using the Modified Telephone Interview for Cognitive Status 
(TICSM). AIBL reported a venular tortuosity of 7.660 (SD 1.554) in the 
controls group and 6.952 (SD 2.601) in the cases, p = 0.042. There are 
generally no units assigned to tortuosity. Cheung 2014 reported an OR of 
1.94 (95% CI 1.48 to 2.53) associating increased venular tortuosity with AD. 
See Figure 12 (page 112). 
Fractal Dimension (FD) 
Seven studies evaluated FD. Four studies evaluated total FD and five studies 
evaluated FD in arterial and venular vessels separately. Two studies 
evaluated total FD as well as FD split by vessel type.  
FD-total 
In the four studies that evaluated total FD, two found an association between 
decreased FD and cognitive decline (Cheung 2014 and SiMES) and two 
studies found no association, but one demonstrated a point estimate also 
favouring decreased FD. One study that found an association was a case-
control and one a cross-sectional study. Cheung 2014 reported an OR of 
1.54 (95% CI 1.23 to 1.93), supporting an association between decreased FD 
and AD. As with tortuosity, FD has no associated unit. SiMES compared the 
1st quintile to the 5th of FD measurements and reported an OR of 1.71 (95% 
CI 1.03 to 2.82), p = 0.036, with lower FD being associated with cognitive 
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impairment as determined by a low score on the Abbreviated Mental Test 
(AMT). See Figure 13 (page 113). 
FD-arterial (FD-a) 
Three of the five studies that evaluated FD-a found an association between 
decreased FD and cognitive decline, two case-control studies (AIBL and 
Cheung 2014) and one cross-sectional (EDIS). AIBL reported arterial FD to 
be 1.235 (SD 0.052) in the controls and 1.201 (SD 0.061) in the AD cases, p 
= 0.021. Cheung 2014 reported decreased arterial FD in those with AD with 
an OR of 1.35 (95% CI 1.08 to 1.68). EDIS, which evaluated people with 
cognitive impairment with no dementia (CIND) as determined by clinical 
criteria, found decreased arterial FD to be associated with CIND with an OR 
of 1.86 (95% CI 1.20 to 2.88). Both studies that did not find a statistically 
significant result also reported point estimates that favoured decreased FD. 
See Figure 14 (page 113). 
FD-venular (FD-v) 
Four of the five studies that reported on FD-v found an association between 
decreased FD and cognitive decline, four of which were case-control studies 
and one cross-sectional (AIBL, Cheung 2014, Williams 2015 and EDIS), and 
the fifth study, while not statistically significant, also found a point estimate 
favouring decreased FD. AIBL reported venular FD of 1.21 (SD 0.05) in the 
controls and 1.17 (SD 0.048) in the AD cases, p = 0.003. Cheung 2014 
reported an OR of 1.47 (95% CI 1.17 to 1.84) indicating decreased venular 
FD in the AD cases. Williams 2015 also reported decreased venular FD 
associated with AD cases with an OR of 0.77 (95% CI 0.062 to 0.97) p = 
0.025. EDIS, using per SD change, found an OR of 2.09 (95% CI 1.35 to 
3.22) indicating decreased venular FD to be associated with moderate 
cognitive impairment. See Figure 15 (page 114). 
The findings from the studies reporting on fractal dimension, total, arterial 
and venular, demonstrate evidence of an association between decreased 
fractal dimension and cognitive decline.  
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3.4.4 Quality assessment of included studies 
Please see Table 13 (page 115) for full descriptions of study quality on the 
predefined categories using the modified CASP tool. Note, I have not 
included columns for domains 1, 7 and 8 because the criteria was met for 
each study and there were few concerns regarding these domains.  
Did the study address a clearly focused issue? 
All included studies appropriately stated their research questions and used 
appropriate methods to answer the question. The EDIS study did not state in 
their methods which specific vessel measurements they would be evaluating, 
which increases the risk of bias as they may have chosen the measurements 
after analysis. The three studies that evaluated Alzheimer’s disease as their 
outcome utilised case-control methods as Alzheimer’s is relatively rare in a 
general population of elderly people. 
Was the study recruited in an acceptable way? 
Of the four case-control studies, there was concern in three with how their 
cases and controls were identified. For the SOUL-D study, the authors used 
the lowest 10% of the cognitive test as the cases, but the n = 69 is far less 
than 10% of n = 1084, the size of the total cohort. The AIBL study does not 
explain how their cases of AD were chosen from the larger cohort study. 
Williams 2015 used an opportunistic recruitment strategy that included non-
systematically identifying participants from clinical records using NINCDS-
ADRDA criteria. The way they identified controls was also subject to bias, 
asking carers, friends and family of the cases, who were not matched on any 
important criteria to the cases.  
For the cross-sectional studies, one study out of nine had recruitment that 
appeared to be at risk of introducing bias. The EDIS study included 
participants from the larger Singapore Chinese Eye Study (SCES) but only 
about 9% of those from SCES were enrolled in EDIS and it was not clear why 
such a small number was used. EDC, one of the two longitudinal studies did 
not include sufficient information to determine adequate participant selection 
or if the study was representative of the wider population. The other 
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longitudinal study, Rotterdam Study, used appropriate methods for identifying 
participants. 
Was the exposure and outcome accurately measured to minimise bias? 
Nearly all of the included studies were missing some criteria for accurate 
exposure and outcome measurement. Most commonly, for evaluation of the 
retinal vessel traits, there was no report of intra- or intergrader reliability, or in 
two cases, there was evidence of high variation between graders. In several 
studies there was no mention of blinding or masking of those that were 
measuring the retinal traits, and less commonly there was no indication of the 
use of a protocol or training of the assessors. There were also several 
studies that, when describing how cognition was measured, failed to indicate 
who would be performing the cognitive tests and if they received training. 
Have the authors identified all important confounding factors and included 
them in the analysis? 
Seven of the included studies did include all important confounding variables 
in their analyses. For the remaining studies that only had minor concerns, 
most commonly lipids were not controlled for in the statistical models used. 
Three studies did not include prevalent cardiovascular markers and two 
studies did not control for CRAE or CRVE in the respective analyses. It is 
important to control for these variables as CRAE and CRVE are highly 
correlated. One study did not control for blood pressure and a further study 
did not control for stroke, which is an important variable when evaluating 
cognition. The Dunedin Study was noted in red, indicating high risk of 
concern as they only controlled for gender and CRAE/CRVE in their 
analyses. The EDC study was also noted in red, as in the methods they 
describe controlling for several variables in their models, but most of the 
presented data was uncontrolled or was unclear how the variables were 
controlled for.  
Was the follow-up of subjects complete enough and long enough? 
There were only two longitudinal studies included in this review, EDC and the 
Rotterdam Study, and it was determined they both had enough participants 
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at follow-up and 17.6 years 11.6 years, respectively, was sufficient follow-up 
time.  
How precise are the results? Do you believe the results? 
Four of the studies provided credible, precise results. For the CRIC study, I 
have indicated this study as high concern as the authors did not provide any 
numeric data and only described the results. For the remaining studies, the 
most common concerns were low numbers and/or imprecise estimates, 
which are often linked. Another major concern was risk of chance findings as 
many of the studies included many outcomes and subgroups, but did not 
control for, or even discuss, the possibility of type I error. It is commonly 
accepted that out of 20 analyses, one association will be statistically 
significant due to chance, so studies that provide more than 20 analyses 
without controlling for multiple testing could be at risk of spurious findings.  
Do the results fit with other available evidence? 
This question can still be quite subjective as there has not been extensive 
research in this field to establish an answer. However, the AIBL study 
reported decreased tortuosity associated with AD, which is inconsistent with 
other studies. This difference could be suggestive of misinterpretation of the 
results and not necessarily opposing findings. Also, this could also be a sign 
of publication bias, and more studies that had evidence of an opposing 
association may have chosen not to publish their findings.  
Are sources of funding reported? 
All studies reported where the funding for the study came from. However, the 
LALES study only reported the specific grant numbers for the funding, and 
not the funding bodies themselves.  
 Discussion 
3.5.1 Summary of main results 
Overall, there appears to be a relationship between decreased fractal 
dimension and increased risk of cognitive decline, which was especially 
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apparent when arterial and venular FD were evaluated separately. However, 
there were still only a few studies that evaluated this vessel trait. Venular 
width, as described by CRVE appeared to have some evidence to be wider in 
those more at risk of cognitive decline. There is currently little or no evidence 
supporting an association between retinal vessel tortuosity and cognitive 
decline. The findings from this systematic literature review will be further 
discussed in the general discussion chapter of this thesis, in context of the 
findings from the primary analysis (Chapter 8) 
3.5.2 Quality completeness of data 
Overall quality of the included studies was good. There were only a few 
cases of major concern, which included two studies that used either inferior 
recruitment methods or did not explain their recruitment methods, one study 
that did not adequately describe or control for other risk factors in their 
model, one study that did not provide any results data, only briefly described 
the results, and a final study that used improper statistical analysis methods. 
There were other, concerns with recruitment, as well as exposure and 
outcome measurement and not controlling for all appropriate covariates, but 
these were minor and more likely a product of a lack of reporting rather than 
study design. 
3.5.3 Agreements and disagreements with similar 
reviews 
It is important to compare the findings of this systematic review to other 
similar reviews in order to understand the relevance and accuracy of the 
findings. As there is currently a great amount of interest in understanding if 
RVTs can help to understand the pathogenesis and possibly predict cognitive 
decline there have been several other systematic reviews investigating a 
similar research question as this one. In this section I present the findings of 
four such systematic reviews and compare their methodology and findings to 




The structure of this systematic review was partly based on a previous review 
conducted by Ding et al. (Ding et al., 2008). This review used a similar 
definition of cognitive decline, however the retinal signs included in the Ding 
review were more inclusive and included signs of retinopathy and other 
markers such as arteriovenous nicking. Ding included in the search all 
studies up until July 2007, when the search was conducted, and included a 
total of six studies, three of which evaluated the kinds of RVTs also included 
in this review. Meta-analysis was not conducted due to heterogeneity. In 
these three studies there was no evidence of an association between CRAE 
or CRVE and cognitive decline, which is in agreement with this review.  
A review published in 2013 by Heringa et al. included studies with a any 
measure or retinal vasculature, like Ding et al., 2008 (Heringa et al., 2013). 
Their outcome included dementia and cogntivie functioning, similar to this 
review, but also included brain imaging measures. There was more inclusion 
and exclusion criteria applied within the Heringa et al. review, which included 
excluding studies in people with type 1 diabetes, studies in people <50 years, 
studies that did not control for age and population based studies with ≤250 
people or patient-based studies with ≤50 people. The search was conducted 
between 1990 and 2013 and 16 studies were included, five of which were 
also included in this review. Meta-analysis was not conducted due to 
heterogeneity. This review concluded that in cross-sectional studies, while 
there was some association between both narrower CRAE and wider CRVE 
in those with dementia or decrease cognitive functioning the associations 
were inconsistent in direction and general not significant. In the longitudinal 
studies there was no association with CRAE and the associations with CRVE 
were mixed. Overall, these findings fit with the findings of this systematic 
review.  
A recent review by McGrory et al., included any retinal vascular sign, 
including retinopathy and age-related macular degeneration, as well as the 
RVTs included in this review, and focused on studies with participants with a 
diagnosis of dementia (Mcgrory et al., 2017). The review by McGrory et al. 
included 10 studies, five of which were included in this review. Because this 
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review focused solely on dementia as an outcome, they had more 
homogenous data and were able to conduct meta-analyses. For cross-
sectional studies, there were mixed results regarding both CRAE and CRVE, 
but two of the three studies in the meta-analyses showed evidence of lower 
CRAE and CRVE in people with Alzheimer’s dementia, but the third study 
showed no difference to controls, so overall there was no statistically 
significant difference. There was evidence of serious heterogeneity in each 
meta-analyses. The same three cross-sectional studies were included in a 
meta-analysis of fractal dimension, and there was evidence of reduced fractal 
dimension, or a sparser vascular network, in the cases with Alzheimer’s 
compared to those without. In the single longitudinal study that reported on 
CRAE and CRVE there was no association dementia and CRAE, but there 
was evidence of wider CRVE in those with dementia, which was mostly 
driven by those with vascular dementia. The findings of the McGrory et al. 
review were similar this those of this review, including possible evidence of 
reduced fractal dimension in those with cognitive decline. Also, there is 
currently very little longitudinal evidence to support the association between 
RVTs and cognitive decline.  
3.5.4 Conclusions 
There is evidence to support an association between retinal vessel 
characteristics, specifically venular width and fractal dimension, and cognitive 
decline. These associations should be explored further, specifically with high 
powered longitudinal studies. Further discussion will be conducted in 























Figure 11. Arterial tortuosity and risk of cognitive decline 
 





Figure 13. Total fractal dimension and risk of cognitive decline 
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The purpose of the methods chapter is to lay out the research questions I 
intend to answer in this thesis, provide details on the data and analysis 
methods used in this thesis. I will describe the design of the Edinburgh Type 
2 Diabetes Study (ET2DS), which is the cohort of people used in the 
analysis. Data collection methods for the cohort at baseline and year-10 
follow-up will be clarified, and analysis techniques for each research question 
described. I was actively involved in the primary data collection for the year-
10 follow-up of ET2DS, which included interviews in a clinical or home 
setting, as well as linkage with routinely collected data. Previously collected 
data on general health and demographics, as well as retinopathy and 
cognitive data from the baseline of ET2DS have been reproduced and 
modified for the specific needs of this thesis. The protocol for the baseline 
phase of the ET2DS has been previously published as well as information on 
baseline retinopathy and cognition (Price et al., 2008; Ding et al., 2010; 
Marioni et al., 2010). I used the checklist set out in the Strengthening the 
Reporting of Observational studies in Epidemiology (STROBE) statement for 
reporting methods and findings throughout this thesis (Elm et al., 2008).  
 Research questions 
For this thesis, I aim to evaluate and answer the following research 
questions: 
1. Is there an association between baseline retinal vessel traits and 
incident diabetic retinopathy after 10 years of follow-up? 
2. Is there an association between baseline retinal vessel traits and 
incident cognitive decline after 10 years of follow-up? 
3. Is there a change in retinal vessel traits over 10 years and are these 
changes associated with cognitive decline?
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 Edinburgh Type 2 Diabetes Study 
To answer these research questions, I used data from ET2DS, which is a 
population-based prospective cohort established in 2006-2007. The 
participants are made up of 1066 men and women aged between 60 and 75 
years at baseline, all with established type 2 diabetes and living in the 
Lothian region of central Scotland. The study was established in order to 
investigate cognitive and vascular complications of type 2 diabetes and the 
potential risk factors and pathways that are associated.  
4.2.1 Study population recruitment and follow-up 
Participants of ET2DS were chosen from the Lothian Diabetes Register 
(LDR), now a part of the Scottish Care Information-Diabetes Collaboration 
(SCI-DC), which contains clinical information on nearly all people with 
diabetes living in Lothian. At the time of the study baseline, all people within 
the LDR had a diagnosis of diabetes according to the World Health 
Organisation (WHO) criteria, described in Section 1.1, but in order to be 
enrolled in ET2DS participants had to meet certain criteria to ensure a robust 
diagnosis of type 2 diabetes. These criteria included: 
• participants had to be taking oral anti-diabetic medications and/or 
insulin; 
• or, if participants managed their diabetes through diet control methods 
alone, had to have a glycated haemoglobin (HbA1c) measure of 
>6.5% at the baseline clinic. 
If a person was only using dietary methods to control their diabetes and had 
an HbA1c measurement below 6.5%, their clinical records were reviewed 
and the diabetes diagnosis confirmed by a consultant diabetologist. In order 
to make sure enrolled participants did not have type 1 diabetes, records were 
carefully evaluated and potential participants excluded if the person started 
insulin within one year of diagnosis, or if there was evidence of pancreatic 
disease at the baseline clinic, or if they were treated with insulin and under 
35 years of age at diagnosis. Other reasons for exclusion were: 
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• a potential participant’s diagnosis could not be confirmed and their 
clinical and/or GP records could not be reviewed; 
• they were non-English speakers; 
• had poor eyesight (corrected visual acuity was worse than 6.36 for 
distance vision or unable to read large print text); 
• they were unable or unwilling to provide consent for their participation; 
• those who were physically unable to complete all elements of the 
assessment. 
The exclusions based on English language and eyesight were made because 
they prohibited participants from adequately undertaking certain cognitive 
tests. 
ET2DS Sample size 
A sample size of 1000 participants was calculated as the number needed to 
achieve 90% power (at the 5%, two-tailed significance level) to detect the 
difference between a continuous outcome measure and predictor variable 
with a Pearson correlation coefficient of ≥0.10. This sample size was 
calculated to be sufficient to detect, at the same power and significance level, 
any risk factor that contributed 1% or more to the variance in the outcome. 
Considering this study was designed as a prospective cohort, it was 
determined that retention of 800 participants at follow-up would be enough to 
achieve 90% power at the same significance level with a Pearson correlation 
coefficient ≥0.12. 
ET2DS Baseline Recruitment 
Recruitment of participants to the ET2DS commenced August 1, 2006, at 
which time a randomly selected sample of men and women by five-year age 
bands were selected from the eligible people in the LDR. A total of 5454 
eligible participants were invited and 1252 agreed to participate. From the 
1252, 1077 attended the baseline clinic. Eleven participants were excluded 
after or during attendance: four participants were not able to complete all the 
examinations for physical or emotional reasons, and seven did not meet the 
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ET2DS criteria for type 2 diabetes after full review of their clinical records. A 
total of 1066 participants were enrolled (Marioni et al., 2010).  
In order to obtain retinal fundus images that were used to evaluate 
retinopathy and retinal vessel traits, participants were asked to return for an 
appointment with a trained ophthalmologist. Fundus imaging took place 
within 2-3 weeks after the baseline clinic. Of the 1066 enrolled participants, 
1044 returned for fundus imaging (Ding et al., 2010). More information on the 
study retinal images can be found below in section 4.3.2. See Figure 16 for a 
full description of the baseline participant flow.  
Data collection clinics took place at one year and four years after the initial 
baseline clinic. These time points are not discussed within this thesis as data 
were not used from these time points for any of the analyses. 





Throughout the first year of my PhD programme I became actively involved in 
the primary data collection for the year-10 follow-up for ET2DS. This included 
data collection with participants in both the clinical and home setting, as well 
as arranging appointments and transportation for participants and liaising 
with the research staff where the clinical appointments took place and 
samples processed. Prior to sending appointment invitations for this phase of 
ET2DS, a newsletter was sent out to all participants that were still enrolled 
within the study and not known to be deceased. The newsletter, created by 
another ET2DS team member/PhD student (Anniek Sluiman, AS) with 
contributions from the study team, included information on findings from 
ET2DS as well as other diabetes related information. This was done in order 
to remind participants of their continuing enrolment in the study prior to 
receiving the clinic attendance letter, as it had been several years since their 
last invitation. If newsletters were returned by mail, the participant’s 
information was looked up within the NHS Lothian electronic health records 
system, known as TRAK, for any changes to the participant’s contact details 
or if they were deceased.  
Clinic invitations were sent out two weeks prior to the intended date, with a 
proposed date and time of an appointment and included a return envelope 
and tear-off page where the participant could indicate if they could make the 
appointment. Participants that returned the slip stating that they could not 
attend or participants that we did not hear back from were contacted by 
phone to arrange a suitable time. If a participant could not be contacted, they 
were added to a list to check if their contact details had changed or if they 
were deceased. Participants that could still not be reached were added to a 
list to be contacted at a later date. Participants that did not want to, or could 
not, attend a clinic visit were offered a home visit appointment. If this was 
unacceptable, we requested the reason they did not want to attend for the 
purposes of evaluating non-attendance. 
Clinic appointments for the year-10 follow-up began on August 1, 2016. One 
researcher, AS, began undertaking appointments at the Western General 
130 
 
Hospital’s Wellcome Trust Clinical Research Facility (WTCRF) and I joined 
on October 1, 2016. Primary data collection was completed for this phase in 
the end October 2017.  
Ethical approval 
At all data collection time points full consent was obtained from all 
participants at the onset of the appointment. At baseline, the study received 
full ethical permission from the Lothian Medical Research Ethics committee 
to carry out data collection. All data linkage that took place throughout the 
study period was also done under full ethical permission.  
New and updated requisite research and development (R&D) and ethical 
approvals from the NHS were obtained for the year-10 follow-up prior to 
initiation of data collection. The application for R&D and ethical approval was 
submitted using the Integrated Research Application System (IRAS), NHS 
R&D Form Version 5.3.0, by AS, along with the study’s principle investigator, 
Jackie Price. The Lothian NHS Board gave a favourable ethical opinion for 
the application on May 23, 2016 and R&D approval was granted on June 17, 
2016. The favourable response letters can be found in Appendix 10 and 
Appendix 11. Most of the data collection took place at the WTCRF, which 
provides specialist support for undertaking clinical research, including clinical 
facilities, research nursing staff support and medical laboratory for sample 
processing. Along with the R&D approval, I was granted a three-year NHS 
Honorary Research Contract after lodging a Research Passport application, 
Version 3, which allowed me to carry out research activities detailed in the 
R&D approved application for the study.  
4.2.2 Data collection 
Baseline clinic examinations 
At the baseline clinic, a wide number of physiological and cognitive 
assessments were undertaken by members of the ET2DS team working on 
the study at that time. Also, medical and other health related questionnaires 
were collected in order to get a full medical profile for each participant. All 
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assessments were performed by trained researchers who adhered to 
standard protocols and used a specifically designed data collection form. 
Inter- and intra-observer variability was evaluated for quality control (Price et 
al., 2008).  
Fasting venous blood samples were obtained and used to measure factors 
such as total serum cholesterol, HbA1c and inflammatory markers. Early 
morning urine samples were collected to measure creatinine and albumin 
output. Height was measured, without shoes, using a wall mounted 
measuring tape and estimated to the nearest 0.1 cm. Weight was measured 
without shoes or bulky clothing and recorded to the nearest 0.1 kg. Hip and 
waist measurements were taken to the nearest 0.1 cm. Systolic and diastolic 
blood pressure measurements were taken in the right arm using a standard 
stethoscope and aneroid dial sphygmomanometer after 10 minutes of rest. 
Systolic pressures were measured in the right and left brachial, posterior 
tibial and dorsalis pedis, using a Doppler probe and aneroid 
sphygmomanometer. A 12-lead electrocardiogram (ECG) was taken using a 
GE Marquette MAC 1200 ECG machine while the participant was lying still 
and relaxed.  Self-administered questionnaires were provided that covered 
demographics, diabetes history and treatment, educational attainment, 
smoking and alcohol habits, current medications, occupation and 
employment, stress, satisfaction with life, subjective social status, 
personality, and history of cardiovascular and cerebrovascular disease 
including the WHO chest pain and Edinburgh Claudication questionnaires. 
Digital retinal photography was taken at a separate appointment roughly 2-3 
weeks after the initial appointment (sections 4.3.1 and 4.4.4 give further 
details on retinal imaging and grading).  
Cognitive testing assessed major domains of cognitive ability, including 
delayed non-verbal memory, verbal declarative memory, logical memory, 
non-verbal reasoning, working memory, information processing speed, 
executive functioning, mental flexibility and crystallised intelligence. The 
cognitive tests that were administered, only if the participant presented with a 
blood glucose of ≥4.0 mmol/l and demonstrated adequate visual acuity, 
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included the combined Junior and Senior Mill Hill Vocabulary Scale (MHVS) 
(Raven, Raven and Court, 1998) and Wechsler memory Scale-III UK Faces 
and Family Pictures subtest (Faces) and Logical Memory subtest (LM) 
(Wechsler, 1987). From the WAIS, 3rd Edition (WAIS-III UK) participants 
undertook the Matrix Reasoning test (MR), the Letter-Number Sequencing 
test (LNS) and Digit Symbol Test (DST) (Wechsler, 1998). Trail Making Test 
Part B (TMTB) (Spreen & Strauss 1991) and Borkowski Verbal Fluency Test 
(VFT) (Lezak, 1995) were also administered. Other tests undertaken to 
screen for possible dementia and depressive mood tendencies were the 
Mini-mental State Exam (MMSE) (Folstein and Folstein, 1975), and Hospital 
Anxiety and Depression score (HAD) (Zigmond and Snaith, 1983), 
respectively. Baseline cognitive testing methods for the ET2DS have been 
published (Ding et al., 2011).  
Year-10 follow-up examinations 
Physiological examinations undertaken at year-10 were nearly the same as 
baseline and the same standard operating procedures (SOPs) were followed, 
including instrumentation, in order to ensure continuity between data 
collection points. Examinations that were undertaken by myself and one 
other ET2DS team member (AS) included height and weight, hip and waist 
measurements, systolic and diastolic blood pressure, as well as systolic 
blood pressures taken in the right and left brachial, posterior tibial and 
dorsalis pedis using a Doppler probe. Early morning urine was collected as 
well as a non-fasting blood sample.  
A questionnaire was administered to provide updated information regarding 
diabetes treatment and progression, any cardiovascular, cerebrovascular, 
liver disease or any other reasons for seeking medical attention since the 
previous data collection, including the WHO chest pain and Edinburgh 
Claudication questionnaires. The questionnaire also covered smoking and 
alcohol habits. We interviewed participants to fill out a validated standardized 
physical activity questionnaire called the International Physical Activity 
Questionnaire (IPAQ) (Craig et al., 2003), which was not performed at any 
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previous data collection point, but included several questions to help 
understand how much a participant’s physical activity would have changed 
over the course of the study.  
Cognitive testing was also undertaken at the 10-year follow-up and included 
all previously mentioned tests from baseline. In addition, the Diery-Liewald 
reaction time test (DLRT) (Deary, Liewald and Nissan, 2011) test was 
administered, which was not previously undertaken by the participants. 
Cognitive testing was administered by two researchers, myself and AS. We 
received training in cognitive test administration from the Human Testing 
Development Officer at the Centre for Cognitive Ageing and Cognitive 
Epidemiology (CCACE) at the University of Edinburgh. Throughout the data 
collection, we regularly performed quality control, which included sitting in on 
each other’s appointments to make sure we were following the same protocol 
and confident we were conducting the interviews and tasks in the same 
manner. Scoring of the tests was undertaken by the tester, but to check for 
errors, 10% of the participants’ cognitive tests were re-graded by the other 
tester. Any concerns with grading were discussed and consensus reached.  
As our cohort is made of elderly participants, it was common that they were 
unable or unwilling to travel to the research centre but were still interested in 
participating in the study. For these participants we conducted home visits. If 
a participant required a home visit, a suitable date and time was arranged 
over the phone and a new confirmation letter was sent out. All physiological 
and cognitive tests and measures that were carried out in the clinic setting 
were also able to be performed in a participant’s home. At all times, two 
researchers were present for each home visit for safety, continuity and time 
efficiency reasons.  
For home visits, we used the same type and brand of stethoscope, 
sphygmomanometer and Doppler probe to measure blood pressure. The 
scale used to measure weight was regularly checked against the scale used 
in the clinic setting and found to be consistently providing equivalent 
readings. Urine and blood samples were also obtained in the same manner 
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as in the clinic, and samples were kept in a cool box and brought to the 
medical laboratory at the end of the day. Time between draw, delivery to the 
laboratory and processing were noted. All cognitive testing materials and 
protocols were identical between the clinic and home setting. 
Data linkage and secondary data collection 
At baseline, routinely collected data were obtained from the Information and 
Services Division (ISD) of the NHS Health Services Scotland on all medical 
and surgical discharges from Scottish hospitals since 1981 (Scottish 
Morbidity Record [SMR01] scheme) and any International Statistical 
Classification of Diseases and Related Health Problems, 10th revision (ICD-
10) codes which indicated cardiovascular or cerebrovascular disease. This 
data linkage was also carried out in 2010 and 2015 to cover the periods after 
the initial linkage. At the 10-year follow-up, data for all 1066 participants were 
gathered from SCI-DC, which included HbA1c, systolic and diastolic blood 
pressure, total and high density lipoprotein (HDL) cholesterol, triglycerides 
and laser photocoagulation treatment. Retinopathy and maculopathy 
gradings, along with the retinal fundus images used to evaluate retinal vessel 
traits at the year-10 follow-up, were linked from the Scottish Diabetic 
Retinopathy Screening Collaborative (Scottish DRS), which are further 
described in section 4.4.4. 
In addition, at the year-10 follow-up, TRAK records were evaluated for all 
participants by one member of the research team who is a Specialist 
Registrar in Endocrinology and Diabetes, Dr Sheila Grecian (SG), to identify 
cases of liver disease, cardiovascular and cerebrovascular disease and 
dementia. Death records were identified for cause of death for participants 
that had died since the previous data collection. Death records were 
gathered from the National Records of Scotland, Birth, Death and Marriage 
Records. Questionnaires that resembled the medical questionnaire provided 
in clinic were sent to the GPs of the invited participants that did not come to 
the year-10 follow-up and were not known to be deceased.  
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 Retinal images and vessel traits 
4.3.1 Retinal images 
Baseline 
Data on baseline RVTs were generated by a software operator using images 
taken at an appointment approximately two to three weeks after the 
participant’s ET2DS baseline appointment. A total of 1066 participants 
attended their baseline appointment, and 1046 returned for the eye clinic and 
retinal imaging and 1044 had successful imaging for retinopathy grading (20 
individuals did not attend eye clinic, and 2 had ungradable images from poor 
quality). Fundus photography was undertaken within the NHS Princess 
Alexandria Eye Pavilion in Edinburgh. Pupillary dilation, mydriasis, was 
achieved using 1% tropocamide drops in both eyes and inspected after 20 
minutes for dilation. Dilation was not undertaken if the participant had ocular 
opacities, such as cataracts, or the participant had a false eye. Standard 7-
field non-stereoscopic colour photographs were taken of both eyes at 35° 
using a TOPCON TRC-50FX system (Topcon Optical Company, Tokyo, 
Japan). The images were taken by a single, specially trained medical 
photographer. All images were saved in non-compressed JPEG or TIFF 
format.  
Year-10 follow-up used to measure change in retinal vessel traits 
I requested retinal images from the Scottish DRS programme in order to 
evaluate change in RVTs over the 10 years of the study. Within the DRS 
programme, annual retinal images were taken after pupil dilation, using 1% 
tropicamide, with a TOPCON NW8 fundus system with Nikon D700 digital 
backs at a 45°-50° angle. Photography was performed by specially trained 
and accredited medical photographers. I was provided with all images within 
the Scottish DRS database from 2005 through 2017 of ET2DS participants 
who had consented. 
I performed follow-up analysis as a 1:1 matched nested case-control study to 
evaluate the association between changes in RVTs and cognitive decline. 
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This method was employed to avoid concerns of survival bias that would 
enter the data due to the age of the cohort and the fact that assessing 
change in RVTs requires a follow-up image, which would only be available 
for participants that were alive and well enough to have attended an imaging 
appointment. Using a nested case-control design, as opposed to a traditional 
case-control study, reduces concerns of bias as the control population is 
drawn from the same cohort as the cases. To reduce possible bias relating to 
the use of different imaging methods and software versions at baseline 
compared with follow-up, an image from the DRS taken close in time to 
baseline ET2DS attendance was analysed as well as a follow-up image 
(instead of using the previously analysed baseline ET2DS image).  
Cases of overt cognitive decline were chosen as participants with dementia 
and/or in the lowest decile of g at year 10. Age, within 5-year bands, and sex 
matched controls were chosen from those in the top 50% of year-10 g. The 
participants chosen for the cases and controls had to have attended the year-
10 clinic and had at least two retinal images that were a minimum five years 
apart, but the longest duration between images was chosen. Reasons that 
participants did not have a full 10 years of follow-up were generally that the 
latest available images were of poor quality and would not yield 
measurements for a reliable comparison or that participants did not return 
annually for their intended screening appointments. Poor image quality in 
older people is not uncommon due to other existing eye conditions, drooping 
eyelids, inability to hold their head still and eye-lashes obstructing the image.  
4.3.2 Retinal vessel traits measurement 
The values used for baseline retinal vessel traits (RVTs) were produced by a 
previous ET2DS team member, Emmanuel Sandoval Garcia (ESG). I 
prepared the baseline RVT data from ESG for use in my analyses evaluating 
baseline traits and follow-up outcomes. Separately, I produced data for the 
change in RVTs, evaluating changes in the traits from retinal images near 
baseline through the follow-up of the study. Along with the next two sections, 
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Figure 17 and Table 14 provide a description of the different retinal images 
used in the analyses and various relevant features. 
Baseline retinal vessel traits 
Retinal vessel data at baseline were measured using VAMPIRE software 
version 3.1.0 by ESG. The right eye was used unless it was not suitable for 
analysis, in which case the left eye was chosen, if appropriate. For this 
thesis, baseline vessel traits that were evaluated were width measures, 
central retinal arterial equivalent (CRAE) and central retinal venular 
equivalent (CRVE), as well as median arterial and venular tortuosity, and 
fractal dimension of the vascular network detected in an image. 
Year-10 follow-up – change in retinal vessel traits 
I performed the measurement of RVTs on the follow-up images using 
VAMPIRE WEB. This version is very similar to version 3.1.0 but not exactly 
the same in terms of the measurement processes. It would therefore be 
inappropriate to directly compare from images analysed using version 3.1.0 
to VAMPIRE WEB. As with the baseline traits, the right eye was used unless 
it was not suitable for analysis, in which case the left eye was chosen if 
appropriate. The software provides data on the optic disc location and size, 
fovea position, CRAE, CRVE and arteriovenous ratio (a ratio of the CRAE 
and CRVE width measurements) the number of straight vessels, tortuosity 
(separated by venular and arterial vessels, separately) as median and max 
raw figures, as well as a mean of the log transformed measurements. Data 
were also provided on the density of vessels as both pixels and percentage 
for Zone B and Zone C, separately. Finally, fractal dimension is reported, 
separately for venular and arteriolar vessels, for the whole field of view, Zone 
C or Zone C main vessels. Visual description of the different zones is 
provided in section 4.3.3. 
For this thesis, I evaluated CRAE and CRVE (both reported in units of 
pixels), the mean log transformed arterial and venular tortuosity, Zone B 
density in pixels and whole field of view fractal dimension. Zone B and whole 
field of view were chosen for density and fractal dimension, respectively, 
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because it was determined, from visual assessment, that many of the images 
taken from the Scottish DRS did not fully incorporate Zone C. Zone B was 
nearly always completely intact in the images, so this zone offers more 
standardised information. It did not seem appropriate to use a measure that 
focused primarily on Zone C when other options were available, as the 
values might vary depending on how much of Zone C was available in the 
image. When evaluating the change in RVTs, I used a simple difference 
between baseline and follow-up.  
For both baseline and follow-up RVT measurements, graders followed a pre-
specified protocol and were blinded to outcome status of the participant. 




Table 14. Comparison of images used for retinal vessel trait analysis 
Description Baseline retinal vessel 
traits  
Change in retinal vessel traits 




Used for research questions 
1 and 2 
Used for research question 3 
Image 
source 
ET2DS study Scottish DRS 
Image 
timeline 
Two to three weeks after 
baseline ET2DS 
appointment 
Baseline images were closest to 
original ET2DS baseline 
appointment and follow-up images 
were closest to 10-year follow-up 





colour digitial fundus images 
at 35° using a TOPCON 
TRC-50FX system (OD 
centred image used for 
analysis) 
Single-field, non-stereoscopic, 
fovea centred, colour digital 
fundus images at a 45°-50° angle 
using a TOPCON NW8 fundus 




Emmanuel Sandoval Garcia Rachel Bedenis Forster 
Traits 
evaluated 
CRAE, CRVE, medial 
arterial and venular 
tortuosity, fractal dimension 
CRAE, CRVE, mean log arterial 
and venular tortuosity, arterial, 
venular and total density (zone B 
pixels), and arterial, venular and 




3.1.0 VAMPIRE WEB 
All analysis was done on the right eye, unless the quality was unsuitable for the software, 
in which case the left was used if available; CRAE = central retinal arterial equivalent, 
CRVE = central retinal venular equivalent; ET2DS = Edinburgh Type 2 Diabetes Study; 
Scottish DRS = Scottish Diabetic Retinopathy Screening Collaborative; VAMPIRE = 
Vascular Assessment and Measurement Platform for Images of the Retina 
 
4.3.3 VAMPIRE Software 
Figure 18 shows the features and zones detected and labelled in the 
VAMPIRE software. For measuring vessel widths a summary index variable 
is used to approximate vessel widths of the central artery and venule and are 
called CRAE and CRVE. The software calculates these parameters from the 
six widest arteriole and venule vessels that cross the inner doughnut of zone 
B (Knudtson et al., 2003). Tortuosity, which is a measure of how vessels twist 
and turn, with a smaller value indicating a straighter vessel, is calculated 
using a curvature-based algorithm using the six widest arteriole and venule 
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vessels crossing between the optic disc boundary to the outer circle of zone 
C (Annunziata et al., 2014; Lisowska et al., 2014). Fractal dimension 
describes the complexity or density of the retinal vascular network and is 
measured by VAMPIRE using a method known as multifractal analysis using 
the generalised sand box method which calculates fractal dimension over 
several “scales” (Stosic and Stosic, 2006).  
 
 
Figure 18. VAMPIRE measurement zones 
For context, Figure 19, below, provides a visual comparison for the different 
types of vessel traits and what one-unit change looks like. As a note, arteries 
in a fundus camera image are lighter in colour than veins which tend to be a 
darker red/orange colour. For vessel widths and tortuosity there is little 
obvious difference detectable by visual inspection of the images, but a 
difference can be detected using software analysis. One standard deviation 




4.3.4 RVT measurement reliability and agreement 
It is important for RVT data generated using VAMPIRE to be reliable between 
graders and within graders, meaning no matter who graded the images, the 
values produced would be similar, and that values are independent of the 
grader and time of analysis.  
Interclass correlation coefficient (ICC) measures of inter and intra-rater 
reliability represent the proportion of total variability in the outcome 
attributable to the difference in graders or time and are commonly used for 
continuous data. I used the average, fixed rater ICC method to evaluate the 
reliability between and within graders for the various RVTs reported in this 
thesis using a two-way mixed effects design to evaluate the mean of two 
graders or two measurements for consistency (Koo and Li, 2016). For 
baseline measurements, 3%, 30 participants, were used for the analysis of 
inter- and 3%, 31 participants, for intra-grader reliability. For the follow-up 
change in RVT analysis, 10%, 35 participants, were randomly selected for 
analysis of intra-grader agreement. Interclass correlation coefficients are a 
relative measure and therefore dependent on the variability in the sample.  
In addition to calculating ICCs, I created Bland-Altman plots for baseline 
inter- and intra-rater and change analysis intra-rater RVTs reported in the 
thesis which offered a graphical representation of the agreement of 
measures within and between graders (Bland & Altman 1986). This method 
helps to visualise by how much a measure varies and applies 95% 
confidence interval limits to evaluate agreement.  
 Variable measurements and definitions 
This section describes the measurement of individual variables that were 
used in the description of the study population and the multivariable statistical 
analyses relating to my research questions. This includes baseline data 
variables on demography, cardiovascular disease/risk factors, and variables 
relating to the main outcomes of cognition and diabetic retinopathy. 
Measurement of retinal vessel traits (my main predictor variables) have 




 Demographic data were used to describe the full ET2DS at baseline, the 
population that returned for follow-up and as covariates within several 
statistical models. Variables included age (in years), sex, body mass index 
(BMI) in kg/m2, systolic blood pressure in mmHg, total and HDL cholesterol, 
both in mmol/l. Data on alcohol habits and smoking were also reported. For 
alcohol, participants indicated how many units per week they generally 
consumed. To evaluate the effects of alcohol, participants were categorised 
as consuming no alcohol, consuming between 1 and 13 units per week and 
consuming above 14 units per week, as 14 units is the current NHS 
recommended weekly consumption upper limit based on recent research 
findings (Gillum et al., 2018). For smoking, participants were categorised as 
an ex-smoker, never smoker or current smoker and within models, current 
and ex-smokers were combined as ‘ever-smokers’.  
To better understand the study population in the context of wider Scotland in 
terms of deprivation, the Scottish Index of Multiple Deprivation (SIMD) was 
identified for each participant based on their post code at baseline. The SIMD 
incorporates data from seven domains (current income, employment, health, 
education, housing, geographic access and crime) in order to describe the 
deprivation level of residents. At the time of the baseline phase of the 
ET2DS, the 2009 SIMD methodology was being used. This categorised 
people with a code of 1 through 5, with 1 indicating the most deprived areas 
and 5 as the least deprived areas (Scottish Government, 2009). 
4.4.2 Diabetes related variables 
Variables relating to diabetes included glycated haemoglobin, also known as 
HbA1c, reported as a percent (%). Duration of diabetes was reported in years 
and treatment of diabetes at baseline included options for ‘diet controlled’, 
oral anti-diabetic ‘tablets’ or ‘insulin’. Participants could be included in both 
the tablets and insulin categories if they received both and for the purposes 
of this thesis, these participants were classed solely in the insulin category in 
order to avoid double counting. During the follow-up time, non-insulin 
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injectable medications have become more common, so for the 10-year 
follow-up, medication lists were carefully evaluated for presence of these 
medications and a separate category was made, but this information was not 
evaluated within this thesis. In the medical questionnaire, participants were 
asked if they ever experienced a hypoglycaemic episode where they needed 
assistance. If a participant answered ‘yes’ to this question they were 
considered to have experienced a severe hypoglycaemic episode.  
4.4.3 Macrovascular events 
Macrovascular events comprise cases of myocardial infarction (MI), angina, 
coronary intervention, stroke and transient ischaemic attack (TIA). At 
baseline and follow-up, macrovascular events were identified by a 
combination of patient reporting and medical records. Strict criteria with a 
defined protocol were used in order to ensure events truly reflected the 
medical history of the participant. For all events, participants had to have 
indication of the event in their medical records as well as patient reporting of 
the event. Patient reporting could be direct reporting of the event with date 
and hospital they were seen in, medications indicating the condition 
(specifically for angina), or a positive WHO chest pain questionnaire for MI or 
angina. If the participant did not report the event, their case and the medical 
evidence were discussed between the research team and a consensus 
agreed upon. If the patient reported an event, but there was no medical 
records confirming it, the case was reviewed by the research team and in 
most cases it was decided the participant did not meet the minimum 
threshold. However, on occasion, specifically if the condition occurred and 
was treated overseas, the event was accepted.  
For the purposes of this thesis, baseline macrovascular events were used as 
a descriptive variable as well as a covariate in several of the statistical 
models. For the retinopathy outcome analyses, I included a combined ‘history 
of macrovascular disease’ variable that included MI, angina, stroke, TIA and 
coronary intervention. For the cognition outcome analyses, nearly the same 
145 
 
combined variable was used, but stroke was removed and was evaluated 
separately as it is strongly related to cognitive decline.  
4.4.4 Retinopathy  
Baseline retinopathy 
Using the digital retinal images from baseline of ET2DS (see section 4.3.4) 
retinopathy grading was undertaken by two trained optometrists, working 
independently, using all 7-fields. A predefined protocol was developed prior 
to grading using Early Treatment Diabetic Retinopathy Study (ETDRS) 
criteria (Early Treatment Diabetic Retinopathy Study Research Group, 1991). 
Diabetic retinopathy was considered to be present if microaneurysms alone, 
or in combination with other characteristic lesions, which include 
haemorrhages, cotton wool spots, intraretinal microvascular abnormalities, 
hard exudates, venous beading, venous loops and/or reduplication, fibrous 
proliferations, pre-retinal haemorrhage, vitreous haemorrhage and new 
vessels. A grade of 10 (diabetic retinopathy not present) up to 81 (advanced 
proliferative retinopathy) was given for each eye. See Table 15 for severity 
based on grade levels. To generate a binary retinopathy outcome for the 
purposes of this thesis, the grading of the worst eye of each participant was 
used and any grade 20 or above was considered as present diabetic 
retinopathy. 
Incident retinopathy at year-10 follow-up 
At the 10-year follow-up phase of the ET2DS, I requested diabetic 
retinopathy grading from the Scottish DRS programme at the time that I 
obtained digital retinal images. As for the retinal images, the grades provided 
were also from 2005 through 2017 for each consented participant within 
ET2DS. In the retinopathy screening programme, images are first processed 
through automatic software (Zachariah, Wykes and Yorston, 2015). This 
software is designed to detect any possible abnormalities, which will then be 
flagged and push the image to be reviewed by specially trained staff. Images 
that are not flagged are given a grading of R0. The Scottish DRS uses a 





where possible, specifically if the dementia diagnosis was Alzheimer’s 
dementia, vascular or mixed.  
General intelligence factor g 
Using results from the cognitive tests undertaken in the ET2DS, I generated 
a single factor, the general intelligence factor g, to discuss and evaluate 
cognitive decline. The general intelligence factor g was calculated using the 
data reduction technique known as principle components analysis (PCA), 
which generates a single factor that correlates with and explains a large 
portion of variance between the different cognitive tests and represents 
cognitive ability over a range of domains (Spearman, 1904). This technique is 
commonly used in social sciences to help analyse latent variables, which are 
variables that cannot be directly measured. Different aspects of cognition 
were measured using the various cognitive tests and then PCA used to 
generate a single measure to discuss cognition as a whole. Cognitive decline 
was used as an outcome in the analyses models by including the year-10 g 
as the outcome and baseline g’ as a covariate, which is a common method 
used in psychology research to evaluate cognitive change (Gow et al., 2008). 
Production of g for this thesis is further discussed in section 4.5.3. 
Factor analysis is a similar method to PCA used for variable reduction when 
evaluating latent variables in the social sciences. PCA is an arguably less 
complex technique that uses the original data to construct a single set of 
linear variates and can evaluate how the original variables contribute. Factor 
analysis creates a mathematical model from which the factors are estimated 
(Field, Miles and Field, 2012b). PCA was chosen at the baseline of the study 
as the data reduction method to generate a single intelligence factor, so it is 
what was continued for analysis. Also, PCA allows for the evaluation of the 
individual cognitive tests within statistical modelling means without increasing 
the risk of multiple testing. When using factor analysis, the factors generated 
are wholly separate from the underlying tests it is made up from and 
therefore to evaluate tests individually, one would be drastically increasing 
the analysis dimensions (Dunteman, 1989). 
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 Data preparation and analysis 
4.5.1 Data entry and cleaning 
At baseline and year-10 follow-up, members of the study team manually 
entered data into a Microsoft Access database. At baseline, double data-
entry was undertaken for all participants, and yielded an error rate of 0.02%. 
At the year-10 follow-up, 10% of entries were re-entered and an error rate of 
0.018% resulted. These errors were corrected by consulting the original 
paper data entry form and discussion between the research team, if needed. 
Impossible and outlier values 
In addition to correcting the identified errors, the range of values for all 
variables was evaluated for impossible and miscoded data. Individual 
participant files and data sources were inspected to determine if values in the 
database were correct. For continuous variables, outliers were evaluated 
using a cut-off of ±2.5 standard deviations from the mean. If the outlier value 
was physiological plausible it was left but noted for later model evaluation 
analysis. Also, individual tests were considered for impossible or implausible 
values and checked against the original data collection form and corrected if 
necessary.  
4.5.1 Missing data 
All data were evaluated for missing values. During the data cleaning process, 
variables that had contained zeros were inspected to make sure these were 
true zeros and not missing data, or if there were missing data, that they were 
not meant to be a true zero value. Any true missing data were coded as ‘NA’. 
Analysis with regression only uses complete-case analysis, so it is important 
to understand how the participants with missing data can alter the 
interpretation of the results. This was done by comparing important variables 
between the whole population and those with complete-cases only and no 
missing data. This helps to understand if the complete cases were similar to 




It is common in epidemiological research that authors do not report or fully 
consider the effect of missing data which can have a great impact on the 
findings (Eekhout et al., 2012). There are techniques that can be employed 
when data is missing that could alter the final analysis, and generally these 
techniques require the assumption of missing completely at random or 
missing at random (Baraldi and Enders, 2010). Multiple imputation was used 
to calculate the g variable when some test scores were missing for an 
individual, but such methods are unlikely to be necessary or appropriate for 
other variables used in this thesis. More is discussed on imputation regarding 
g in the following sections.  
Albumin to creatinine ratio (ACR) 
The baseline albumin to creatinine ratio (ACR) variable, as originally derived, 
had a large amount of missing data, n = 622 missing (58.3%). This is due to 
many participants having an albumin measurement below the threshold of 
detection. For the purposes of this thesis, I chose to take the upper limit of 
6.0 mg/l for the ratio. This allowed me to obtain an ACR for nearly all 
participants. Due to this method of imputation, individual ACR values may be 
uninformative. 
4.5.2 Variable distributions and transformations 
Continuous variables used for analysis were visually evaluated for normality 
using histogram plots. Variables that were found to be skewed, or non-
normal, were transformed for analyses. See Appendix 12 for variable 
histograms. 
Variables that were found to be non-normal were duration of diabetes, ACR, 
the TMTB cognitive test, and the retinal vessel traits of tortuosity, both arterial 
and venular, as well as fractal dimension. All variables, aside from fractal 
dimension, were log transformed using the natural log. Fractal dimension 
was only slightly skewed so rank transformation was used. This method was 
used for previous research of the same group, so methods were maintained 
for continuity.  
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4.5.3 Variable derivations 
Fractal dimension 
Fractal dimension is a unit-less value that lies between 1 and 2. Due to this 
feature, when used in logistic regression, the resulting odds ratio and 95% 
confidence interval can be difficult to interpret because they are usually in 
relation to a one point increase or decrease. For this reason, a standardised 
fractal dimension value was used in the logistic regression models. The 
standardised values were created by subtracting the mean and dividing by 
the standard deviation for each participant’s fractal dimension value. This 
produces a scaled variable with a mean of 0 and standard deviation of 1, but 
the values maintain the same relationship to one another as the unscaled 
variable. When used in logistic regression, the odds ratio can be interpreted 
as the odds given an increase of one standard deviation.  
General intelligence factor g 
Of the cognitive tests described in section 4.2.2, tests incorporated into the g 
calculation included the LM and Faces tests, MR, LNS, DST, TMTB and VFT. 
For both the LM and Faces tests, the immediate and delayed tests were 
highly correlated, so a sum was used. The TMTB variable, at both baseline 
and year-10, had a strong right-tail skew, so a natural log of this test outcome 
was always used.  
At baseline and follow-up, there were times when a participant physically 
could not or refused to complete all seven cognitive tasks. If a participant 
completed at least four of the seven cognitive tests, statistical imputation 
methods were used to incorporate these participants into the g calculation. A 
multiple imputation method was used, which is a method of imputation that 
generates several models of the imputed data using features of non-missing 
data and then combining the imputed models to account for the uncertainty of 
the missing data (Sterne et al., 2009). This method was chosen, as opposed 
to a simpler method of using the population mean, because multiple 
imputation better accounts for the variations in participants and missing data. 





4.5.4 Univariate statistical analysis 
Univariate analysis was carried out to evaluate the association between the 
different variables within the thesis. When comparing two groups, for 
continuous variables Welch’s two-sample t-test was used and categorical 
variables using Pearson’s chi-squared test with Yate’s continuity correction. 
Correlations between continuous variables within a single group was done 
using Pearson’s correlation coefficient. For univariate analysis within a single 
group between a continuous and categorical variable (of no more than two 
levels), the point-biserial correlation was used.  
4.5.5 Multivariable statistical analysis 
To answer the three research questions, multivariable regression models 
were used. For the regression analyses, I constructed the models by adding 
in related groups of covariates in a step-wise fashion to better understand the 
association between the predictor and outcome variables in relation to the 
covariates, building up to the fully inclusive models. If the variables were all 
added at once, it would be difficult to understand if certain categories of 
variables were more strongly associated than others. The blocks of 
covariates included in the regression were: 
1. the unadjusted model with just the RVT exposure variable and 
outcome; 
2. addition of age and sex;  
3. then cardio-metabolic risk factors (BMI, smoking status, systolic blood 
pressure, total cholesterol:HDL ratio); 
4.  diabetic risk factors (HbA1c, duration of diabetes and diabetic 
treatment type); 
5. finally, vascular disease risk factors were added (a composite history 
of macrovascular disease as well as ACR). 
If there was no evidence of an association at the unadjusted or age and sex 
adjusted stages, the analysis was halted in order to avoid the risk of findings 
through multiple testing. 
155 
 
Retinal vessel traits and incident diabetic retinopathy 
The provide an answer to the first research question, binomial logistic 
regression was employed to evaluate the relationship between baseline 
retinal vessel traits and incident diabetic retinopathy. Originally, cox 
proportional hazards regression was planned, but during the analysis, it was 
determined to not be an appropriate model due to outlier residuals creating 
high leverage within model, therefore producing an unreliable model that 
would not be likely be generalisable to other populations . More about model 
evaluation is described in section 4.5.6. The baseline RVTs were produced 
using the ET2DS study retinal images described in Section 4.3. The incident 
diabetic retinopathy outcome was derived using data from the Scottish DRS, 
as described in Section 4.4.4. 
Evaluating biomarker model improvement  
If any RVTs were found to be associated with incident retinopathy I planned 
to evaluate the addition of the RVT using Harrell’s concordance statistic, or c-
statistic, to see if the model was improved. The c-statistic is used to evaluate 
the discriminative ability of the logistic regression model and is a unit-less 
index denoting the probability that a randomly selected subject who 
experienced the outcome will have a higher predicted probability of having 
the outcome occur compared to a randomly selected subject who did not 
experience the event. This is equivalent to the area under the receiver 
operating curve and describes the goodness of fit of a logistic regression 
model. I also planned to compare the two models, with and without the RVT, 
using the likelihood ratio test, which compares the observed frequencies of 
the model to the predicted frequencies.  
Normally when evaluating the usefulness of a new biomarker, you would 
include the biomarker in an established risk prediction model and use the c-
statistic to determine the effect the new biomarker has. Unfortunately, there 
is currently no risk prediction model for diabetic retinopathy in general use 
(Sabanayagam et al., 2016). There have been several publications referring 
to the development of a prediction tool, but none have been reliably 
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replicated and implemented in clinical practice (Skevofilakas et al., 2010; 
Stratton et al., 2014). I used the findings of large cross-sectional and 
prospective studies that estimated the impact of common factors associated 
with diabetic retinopathy to inform which variables would be most important in 
a risk prediction model and then compare the RVT with this model. The risk 
factors to be used in the proposed model would have to be routinely collected 
and available. From the evidence from other studies, I chose to include 
HbA1c, systolic blood pressure and ACR as the ‘base prediction model’ 
(Stratton et al., 2001; Henricsson et al., 2003; Tam et al., 2009; Zhang et al., 
2010; Romero-Aroca et al., 2010, 2011; Pugliese et al., 2012; Bertelsen et 
al., 2013; Salinero-Fort et al., 2013; Xu et al., 2014; Y. Liu et al., 2017). 
Retinal vessel traits and cognitive decline 
To answer research question 2: ‘What is the association between baseline 
retinal vessel traits and incident cognitive decline?’, two different analyses 
were conducted, both using the same baseline RVTs used to answer 
research question 1, described in in Section 4.3. One analysis used a 
dementia diagnosis as an outcome, as described in Section 4.4.5 and 
logistic regression. For the second analysis, multiple linear regression was 
used to evaluate the relationship between the baseline RVTs and cognitive 
decline by the general intelligence factor g, also described in Section 4.4.5. If 
there was evidence of an association, linear regression was used to evaluate 
the RVTs and their association with the individual cognitive tests. 
Also, I evaluated the relationship between baseline retinopathy and dementia 
combined with the lowest decile g using age and sex adjusted logistic 
regression. For sensitivity analysis, incident dementia was combined with the 
lowest decile of g at year-10. 
Retinal vessel trait changes and cognitive decline 
Unadjusted logistic regression was used to evaluate the third research 
question regarding the association between change in retinal vessel traits 
and cognitive decline. The RVTs used in this analysis were derived from the 
retinal fundus images gathered from the Scottish DRS and described as 
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‘change in retinal vessel traits’, discussed further in Section 4.3.This analysis 
was done using a nested case-control design, further description of the cases 
and controls are described in Section 4.3.1. 
4.5.6 Model evaluation and diagnostics 
The purpose of model evaluation and diagnostics is to better understand if 
the model produced is robust and fits the observed data well and that the 
model is not overly influenced by a small number of cases. Evaluation may 
also help to better know if the model can be generalised to other samples.  
Firstly, model specific assumptions were evaluated to make sure they were 
not violated, which included the assumptions of linearity and multicollinearity. 
Next, I checked for evidence of interaction between predictor variables. Then, 
I evaluated how the predictor variables within the models improved the 
overall model by evaluating the change in the Akaike information criterion 
(AIC), the c-statistic, and also looking at the goodness of fit through the 
Hosmer-Lemeshow goodness of fit test. For the Hosmer-Lemeshow test, a 
non-significant p-value does not necessarily mean the model is a good fit, but 
rather that there is not any evidence of a poor fit. Finally, residuals were 
inspected for evidence of outliers and influential cases. An absolute value > 3 
was cause for further investigation, if more than 1% of sample cases had 
standardised residuals over 2.5, this indicated evidence of unacceptable 
error and was investigated. If more than 5% of cases had standardised 
residuals of above 2, then it was possible the model was a poor 
representation of the actual data and should be investigated.  
4.5.7 Sensitivity and subgroup analysis 
A strict definition of incident retinopathy was used in order to make sure only 
those truly with retinopathy were included in the analysis. This definition 
required that if a participant had a retinopathy grading of R1, they were only 
classed as having retinopathy if they had an R1 grading at a minimum of two 
consecutive screenings. Sensitivity analysis was undertaken to evaluate if 
there was a difference in findings if this definition was relaxed to include all 
participants that received an R1 grading.  
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Subgroup analysis was planned to evaluate the different severities of 
retinopathy gradings. Grading groups would include mild retinopathy (R1), 
moderate retinopathy (R2 and R3) and proliferative retinopathy (R4).  
Dementia diagnosis and lower g values are related and both indicate a level 
of cognitive decline. However, not all people with a lower g value have been 
diagnosed with dementia. Sensitivity analysis was planned to combine 
participants with a dementia diagnosis with those that were in the lowest 10% 
of follow-up g, as it can be argued these participants are all experiencing a 
level of cognitive decline.  
As described in the introduction chapter of the thesis, dementia is not a 
single pathology and the term is used to described various underlying 
aetiologies, which include Alzheimer’s disease and vascular dementia, 
among others. I planned to perform subgroup analysis looking at the different 
underlying pathologies of a dementia diagnosis, but unfortunately this level of 
detail was not available in a standardised way that would avoid bias, so no 
such subgroup analysis was performed.  
When evaluating cognition, there are several lifestyle and health factors that 
can be related to cognitive decline, which include alcohol consumption and 
the experience of hypoglycaemic episodes. Subgroup analysis was 
undertaken to see if there was differential association between RVTs and 
cognitive decline by differences in these characteristics. Participants were 
divided by alcohol consumption with a no alcohol group, low to moderate 
consumption group of 14 or less units of alcohol per week and a high 
consumption group over 14 units per week. At baseline, participants 
indicated if they ever experienced a hypoglycaemic episode that required 
assistance. Participants that responded ‘yes’ to this question were compared 
to participants that replied ‘no’. Age and sex adjusted models were used to 
evaluate these subgroups.  
A two-sided p value ≤ 0.05 was used to indicate evidence of statistical 
significance. Logistic regression results were presented as odds ratios (OR) 
and 95% confidence intervals (CI). Linear regression results were presented 
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as standardised beta coefficients (), R2 values. Aside from calculating g, all 
statistical analyses were performed using R version 3.5.1. The intelligence 
factor g was calculated using SPSS software version 21.  
 Chapter conclusion 
This chapter sought to lay out the research questions of the thesis, explain 
how the data used within this thesis were generated and analysed. Methods 
of the ET2DS were laid out including the recruitment and data collection 
procedures. Variable definitions were provided and clear explanation of 
analysis methods were reported based on the outcomes of incident 
retinopathy and cognitive decline. Logistic regression and linear regression 
methods were described to evaluate the relationships between the RVTs and 






5 Results I: ET2DS and descriptive statistics 
This chapter provides descriptive details of the Edinburgh Type 2 Diabetes 
Study (ET2DS) total population at baseline and presents relevant information 
regarding the participants that returned for the year-10 follow-up. The ET2DS 
participants are compared to those that did not attend at baseline, but were 
invited, to assess how representative participants are of people with type 2 
diabetes living in Lothian. Similarly, reasons for non-attendance at year-10 
are given and demographic details are provided to compare non-attenders to 
attenders at year 10, and a comparison of those that died during the follow-
up period with those that were still alive is presented. Description of the 
retinal vessel traits evaluated in this thesis and their association with 
covariates are provided. Finally, missing data is presented and summarised. 
For this chapter, and the following two results chapters, tables and figures 
are provided at the end of the chapter. 
 ET2DS baseline characteristics and 
representativeness 
At the baseline of ET2DS in 2006/2007, a total of 1066 participants attended 
the study clinic and were included in the cohort. The average age was 67.9 
(standard deviation (SD) 4.2) years and 51.3% of the population was male. 
Table 19 (page 171) describes the demographic characteristics of the 
baseline participants, as well as invited potential participants that did not 
participate in the study, for comparison. Overall, at recruitment the ET2DS 
cohort provided a good representation of older people in Lothian with type 2 
diabetes for important characteristics such as age, cholesterol, HbA1c and 
duration of diabetes and male and female were nearly perfectly 50% each. 
However, non-responders were more likely to be female, have higher systolic 
blood pressure and be from more deprived areas, compared with attenders, 
but these differences were small and unlikely to have a clinical impact. 
Figure 20 (page 172) depicts the participant flow of ET2DS from baseline 
through the 10 year follow-up. 
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 ET2DS 10-year follow-up 
5.2.1 Clinic and home visit attendance and reasons 
for non-attendance 
The 10-year follow-up data collection phase for the ET2DS began in 
2016/2017, after all ethical and institutional approval was granted. To include 
as many participants as possible, all ET2DS participants were contacted if 
they were not known to be dead and had not explicitly withdrawn from the 
study previously. A total of 845 participants (79% of original 1066) were 
contacted and 582 participants attended for a clinic or home visit.  However, 
one participant that attended the clinic was determined to be incapable of 
providing consent, so the appointment was aborted, and this person’s data 
was not included in the follow-up data. The final attendance was 581 for 
year-10 follow-up (69% of those contacted and 54% of total cohort). 
After data collection, there were 264 participants that were invited for this 
round of data collection but did not attend a clinic or home visit (31% of 
invited). The reasons for non-attendance are listed in Table 20 (page 172). 
The most common reason for non-attendance amongst invitees was death 
which was unknown to the research team at the time of sending invites (n = 
84). Chronic physical health conditions were the next most common reason 
(n = 49), which included conditions such as cancer, pulmonary conditions, 
diabetes related problems and long-term hospitalisation. Closely following 
were participants that were no longer interested in participating in the study 
but did not give a health or other related reason (n = 44).  
Mental health conditions, such as dementia, depression, anxiety and other 
cognitive problems, were the fourth most common reason given for non-
attendance (n = 30), followed by a total of 24 participants who the team were 
never able to make contact with. For these participants, multiple efforts were 
made to get in touch, including checking for new contact details, but no 
communication was established. 
Acute physical health conditions were the next main reason for non-
attendance (n = 15), including conditions such as myocardial infarction, 
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stroke and infection. If a participant missed their first appointment due to an 
acute condition, I or another team member would always ask if it would be 
possible to see them after some time had passed or offer a home visit. Often 
it was eventually possible to see participants that suffered an acute illness 
during the follow-up period, unless time did not allow, or mitigating 
complications made it inappropriate. A total of 10 participants had full-time 
carer roles for spouses or other family members and were not able to attend 
the clinic or receive a home visits. Eight participants had moved an 
unreasonable distance for a clinic or home visit.  
Total attrition through the 10-year study period was 485 (45.5%). The main 
reason for study attrition was death, n = 308 (63.5% of total attrition). A total 
of 53 participants declined attendance after baseline (10.9% of total attrition). 
At the latest data collection, 94 participants had a health concern preventing 
them from attending an appointment (19.4% of total attrition) and 30 
participants were lost to follow up at the latest data collection (6.2% of total 
attrition) (Table 21 (page 173)). 
5.2.2 Subgroup comparisons 
This section compares differences in baseline demographic and 
cardiometabolic risk factors in the study sub-populations to better understand 
how they may impact the data and conclusions drawn from it. Firstly, I looked 
at differences in study participants that attended the 10-year follow-up versus 
those that did not return. I also looked at those that were deceased after 10-
years versus those still alive. Finally, I looked at differences in baseline 
variables in returning participants that had a clinic visit versus a home visit. It 
would be expected that participants receiving a home visit would have poorer 
health at the follow-up, as this was a primary reason for not attending the 
clinic, but looking at the evidence of the baseline variable to determine the 
differences in these populations is important. Also, within this section I 




Comparison between year-10 attenders and non-attenders  
Evaluating baseline variables, those that attended the year-10 clinic or a 
home visit were of an overall healthier profile than those that did not attend. 
As presented in Table 22 (page 173), the year-10 attenders were younger 
(67.3 vs 68.6 years), had a lower body mass index (BMI) (31.1 vs 31.9) and 
systolic blood pressure (132.1 vs 134.8 mmHg), had a shorter median 
duration of diabetes (6 vs 7 years), were more likely to be treating their 
diabetes using diet compared with tablets or insulin, had less history of stroke 
(4.1% vs 7.8%) and cardiovascular disease (CVD) (27.5% vs 38.6%) and 
lower median albumin/creatinine ratio (ACR) (1.1 vs 1.3).  
Comparison between deceased at year-10 and those alive 
Comparing baseline variables of deceased participants to those still alive at 
the time of the 10-year follow-up, living participants were healthier at baseline 
than those who died. Table 23 (page 174) provides relevant baseline 
characteristics comparing those deceased and alive at the 10-year follow-up 
and shows those alive were younger (67.4 vs 69.1 years), had a lower 
systolic blood pressure (132.6 vs 134.9 mmHg), less duration of diabetes 
(7.5 vs 9.4 years), more likely to be controlling their diabetes through and 
tablets than insulin, less stroke (3.7% vs 10.7%) and CVD (27.0% vs 45.5%), 
and lower ACR (2.2 vs 6.2 mg/mmol).  
Comparison between participants that received clinic visits and home visits 
There were some minor, and probably not clinically relevant, differences at 
baseline between those that attended a clinic or home visit at year-10. This 
included more men, proportionally, having a home visit than clinic visit, a 
higher HbA1c in those that had a home visit, home visit participants were 
more likely to be on tablet medications and less likely to be diet controlled for 
diabetes treatment and home visit participants were more likely to have had a 
stroke at baseline. See Table 24 (page 175) for further data on these 
differences. Table 25 (page 175) shows that those that had a home visit had 
a far lower average general intelligence g and more likely to have had 
dementia, and not including these participants in the analysis would have 
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biased the data. There was no evidence to suggest a difference in incident 
diabetic retinopathy between clinic versus home participants.  
Prevalent and incident cardiovascular events  
To better understand the breakdown of the combined CVD events, Table 26 
(page 176) presents data on the number of participants that experienced a 
macrovascular event prior to baseline and then during the follow-up period. 
At baseline, 150 participants had experienced a myocardial infarction which 
was 14.1% of the total 1066 ET2DS population. Angina had been diagnosed 
in 298 participants (28.0%), 62 experienced a stroke (5.8%), 31 a transient 
ischemic attack (2.9%) and 110 had had a coronary intervention (10.3%). 
Through the 10-year follow-up 108 participants experienced an incident 
myocardial infarction (10.1%), an additional 67 were diagnosed with angina 
(8.7%), 88 participants experienced a stroke (8.3%), 41 experienced a 
transient ischaemic attack (3.8%) and 65 had a coronary intervention (6.1%). 
Proportions in Table 26 are determined for the entire ET2DS population (n = 
1066), except for angina, for which the proportion of incident angina is only 
for the 768 participants that did not have prevalent angina at baseline.  
 Retinopathy at baseline and year-10 follow-up  
At baseline, there were 340 cases of retinopathy, most of which (293) were 
background retinopathy (R1). There were 28 cases of R2 retinopathy, four of 
R3 and 15 participants had proliferative retinopathy (R4). At follow-up, of the 
718 participants that did not have evidence of retinopathy at baseline, a total 
of 82 had evidence of incident retinopathy, by the strict definition of any R2-
R4 grading, or if they only had an R1 grading and no higher, they had to have 
been given an R1 at a minimum of two consecutive screenings. Seventy-
seven cases were R1, one case of R2, R3 and R4 each had two cases. See 
Table 27 (page 176) for details of retinopathy grades at baseline and year-10 
follow-up. If the definition of incident retinopathy was relaxed to include any 
grade over R0 there would be 253 incident cases of retinopathy. This larger 




Missing retinopathy data at baseline was because a participant did not come 
to the ET2DS screening appointment and did not have a DRS screening 
around the time of ET2DS baseline. There were only eight participants at 
baseline with no retinopathy screening information. At follow-up there were a 
total of 20 participants with no follow-up retinopathy screening data. These 
cases were because a participant had not been to any DRS screening after 
the baseline of ET2DS (2005-2007). Of the 20 participants that had no follow-
up retinopathy screening 16 died during the study follow-up. Two died in 
2007, one in 2008, four in 2009, one in 2010, three in 2011, one in 2012 and 
2013, two in 2014 and one in 2017. 
 Dementia and cognition at baseline and year-10 
follow-up 
At baseline, none of the ET2DS participants had dementia, which was part of 
the exclusion criteria for the study. But during the 10 years of follow-up, we 
determined a total of 106 participants to have incident dementia. Evaluating 
cognitive decline over the 10 years of the study required participants to come 
back for in-depth cognitive testing, so it is important to understand how the 
data is impacted by those that did not attend and/or were deceased, at the 
time we undertook the follow-up appointments. See Table 28 (page 176) for 
baseline g and dementia status by attenders versus non-attenders and those 
deceased or alive at the year-10 follow-up of ET2DS. Participants that 
attended the year-10 clinics or home visits had a higher baseline g compared 
to those that did not re-attend (0.21 (SD 0.9) vs -0.26 (SD 1.0), respectively) 
and were less likely to be diagnosed with dementia (6.0% vs 14.6%, 
respectively). This same pattern was found comparing baseline g for those 
that died over the follow-up versus those that were alive (-0.3 (SD 1.0) vs 0.1 
(SD 1.0), respectively) and incident dementia was also higher in those that 
died over the follow-up period (13.5% vs 8.4%). These findings demonstrate 
that the population for whom we have follow-up cognitive scores for are also 
those that had higher cognitive ability at baseline and were less likely to be 
diagnosed with incident dementia. 
167 
 
 Retinal vessel traits 
5.5.1 Retinal vessel trait distributions and missing 
data 
1046 participants had baseline retinal images available for vessel trait 
analysis. The missing 20 participants did not attend the eye clinic 
appointment. Eighteen participants did not have images suitable for central 
retinal arteriolar equivalent (CRAE), central retinal venular equivalent (CRVE) 
and tortuosity measurements and 31 participants did not have images 
suitable for fractal dimension measurements. Images that were unsuitable 
were either due to them being too out of focus for the software to accurately 
capture the vessels, or there were too few suitable vessels to generate a 
robust analysis. In total, there were 1028 participants with CRAE, CRVE and 
tortuosity measures and 1015 with fractal dimension measurements, or 96% 
and 95% of the total population, respectively.  
Mean CRAE was 33.03 (SD 3.87) pixels and mean CRVE was 44.67 (SD 
5.01) pixels. Tortuosity is unit-less and reported as a mean value after log 
transformation of the measured values. The mean arterial tortuosity value 
was -10.07 (SD 1.15) and mean venular tortuosity was -9.95 (SD 0.89). The 
mean rank fractal dimension was 1.75 (SD 0.07) and is a unitless value that 
falls between 1 and 2. These values are presented in Table 29 page (177) 
and Appendix 12 presents histograms to demonstrate the distribution of the 
RVTs within the study population, along with other baseline characteristics.  
5.5.2 Repeatability of retinal vessel traits 
Retinal vessel traits that were interrogated at baseline and used in this thesis 
include CRAE, CRVE, log transformed median arterial tortuosity and venular 
tortuosity, and total fractal dimension. For the evaluation of change in RVTs, 
the same traits were evaluated, plus both arterial and venular fractal 
dimension, separately and the addition of a density measurement (total, 
arterial and venular, separately).  
Table 30 (page 177) presents the repeatability of the RVT measures using 
the average, fixed rater method. For baseline inter-and intra-grader 
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repeatability measures, evaluating the inter-class correlation (ICC) and 95% 
confidence intervals, values represent moderate to good reliability. Change 
analysis was only carried out by a single grader so only the intra-grader ICC 
values were measured, and from the ICC values and 95% CIs, there was 
moderate to good reliability. Bland-Altman plots were also created for the 
baseline inter-grader and change intra-grader repeatability measures to 
demonstrate level of agreement. Appendix 13 presents Bland-Altman plots 
for baseline inter-grader agreement and Appendix 14 for the follow-up intra-
grader agreement. 
5.5.3 Association between retinal vessel traits and 
baseline characteristics 
It is important to understand relationships between the RVTs and the other 
variables of interest that are associated with the outcomes, diabetic 
retinopathy and cognitive decline. Table 31 (page 178) shows the 
correlations between the five RVTs and the important demographic, 
cardiometabolic, diabetic and vascular variables.  
In the ET2DS population, decreased CRVE and decreased arterial tortuosity, 
were associated with increased age (r -0.08 (p = 0.015) and -0.07 (p = 
0.020), respectively). Increased CRAE and CRVE were associated with 
being female (correlation coefficient (r) 0.14 (p < 0.001) and 0.07 (p = 0.017), 
respectively) and increased arterial tortuosity was associated with being male 
(r -0.017 (p <0.001). Increased CRVE and increased venular tortuosity were 
both associated with increased BMI (r 0.08 (p = 0.012) and 0.10 (p <0.001), 
respectively).  Increased arterial tortuosity was associated with increased 
total cholesterol to high density lipoprotein (HDL) ratio (r 0.08 (p = 0.016)), 
while increased fractal dimension was associated with a decreased total 
cholesterol to HDL ratio (r -0.07 (p = 0.022). Increased venular tortuosity was 
associated with increased systolic blood pressure (r 0.08 (p = 0.009) while 
history of stroke and cardiovascular disease were both associated with a 
decreased venular tortuosity (r -0.08 (p = 0.011) and -0.06 (p = 0.048). 
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 Missing data 
Describing missing data and understanding the role it may play is a crucial 
part of any epidemiological analysis. Table 32 (page 179) presents the 
populations of participants used in the analyses undertaken in this thesis, 
based on the entire population and the population for which no data is 
missing. For the types of regression analyses that will be used, only 
participants with no missing data are included, so it is important to see how 
this population may or may not be different from the whole population. From 
visual inspection of Table 32, there do not appear to be any differences of 
concern between the total population and the populations with no missing 
data for the variables that will be used in the regression analyses. A total of 
1008 cases of 1066 had no missing data (n = 58 (5.4%) with missing data) in 
regard to the models that would be used for evaluating dementia. For the 
evaluation of incident retinopathy, of the 718 eligible participants, 689 had no 
missing data (n = 29 (4.0%) had missing data). Year-10 data, which was 
used to evaluate cognitive decline using change g in, had full case data for 
558 of the 581 attending participants (n = 23 (4.0%) with missing data). See 
Appendix 15 and Appendix 16 for graphical representations of the 
individual descriptive variables based on whole cases and cases with missing 
data for the whole ET2DS population. Throughout the following results 
chapters, n values for the variables are presented when describing the data 
in order to demonstrate where missing data are present. 
 Chapter summary 
This chapter summarised the data from the ET2DS collected at baseline and 
at the year-10 follow-up, which are relevant for this thesis. At baseline, the 
1066 participants in the ET2DS were shown to be largely representative of 
older people with type 2 diabetes living in the Lothian region of Scotland. A 
total of 581 participants returned for the year-10 follow-up, and these 
participants were found to have a healthier profile based on baseline 
cardiometabolic variables, compared with non-attenders. After 10 years, 
participants were found to have less cumulative diabetic retinopathy than 
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those diagnosed at baseline and poorer cognition. Also, participants that had 
died by year-10 were found to be unhealthier at baseline, when compared to 
those that had survived to the year-10 follow-up.  
Outcome variables used in subsequent chapters of this thesis include 82 
cases of incident retinopathy, 106 cases of incident dementia and the general 
intelligence factor g.   
Description of RVT measurements and their repeatability was evaluated and 
there was moderate to good repeatability for the different graders and time 
points, which helps to validate the use of the RVTs in analysis. There was 
very little missing data within the dataset and it was demonstrated that there 
was little difference between the total population and whole case datasets, 
















6 Results II: Retinal vascular traits and incident 
retinopathy 
This chapter presents the results of analyses on incident retinopathy as an 
outcome. The purpose of these analyses were to determine the association 
between retinal vessel traits (RVTs) measured at the baseline of the 
Edinburgh Type 2 Diabetes Study (ET2DS) and incident retinopathy over the 
10 years of the study. This chapter presents baseline characteristics of the 
study population (including RVTs) by incident retinopathy status. The results 
of logistic regression used to evaluate the association between RVTs and 
incident retinopathy are then presented.  The aim was to help determine if 
RVT measures might be useful as a novel biomarker for the development of 
diabetic retinopathy. Information regarding model evaluation is presented to 
help understand the fit and generalisability of the models.  
 Baseline characteristics by retinopathy status 
At the baseline of the ET2DS, of the 1066 participants, 340 were determined 
to have prevalent diabetic retinopathy and eight did not have sufficient data 
to determine their retinopathy status (they did not attend the baseline ET2DS 
eye screening and did not attend a DRS screening around the time of ET2DS 
baseline). These 348 people were excluded from the following analysis as I 
was interested in understanding the temporal relationship between measured 
RVTs and retinopathy, so those that already have evidence of the disease do 
not provide appropriate evidence. Therefore, I have evaluated the remaining 
population of 718 study participants for this analysis.  
Table 33 (page 189) presents baseline demographics information based on 
incident retinopathy status. Overall, those that went on to develop incident 
retinopathy were similar to those that did not for the variables evaluated, 
aside from those with retinopathy having increased HbA1c (7.6 vs 7.2 %Hb, 
standard deviation (SD) for both 1.0). Continuous variables are displayed 
using box plots based on incident retinopathy status in Figure 21 (page 190). 
Although there was evidence of increased HbA1c in those with incident 
retinopathy, the box plots show the differences were not large and most likely 
182 
 
not clinically relevant. Figure 22 (page 191) provides a visual representation 
using bar graphs of the differences in the categorical variables based on 
retinopathy status. There was little difference between those with diabetic 
retinopathy and those without. Although there were no statistically significant 
differences there was a trend towards more diet controlled diabetes at 
baseline in those that did not go on to develop incident retinopathy, which 
can be visualised in Figure 22.  
 Retinal vascular traits and incident retinopathy 
status 
6.2.1 Univariate analysis of retinal vascular traits by 
retinopathy status 
When evaluated by retinopathy status, there was evidence that those that 
went on to develop retinopathy had a narrower central retinal arteriolar 
equivalent (CRAE) (32.03 (SD 3.71) vs 33.03 (SD 3.78) pixels, p = 0.018), 
which represents narrower arterioles. This pattern was also observed with 
venules, where those with incident retinopathy had narrower central retinal 
venular equivalent (CRVE) compared with those with no retinopathy (43.54 
(SD 4.36) vs 44.53 (SD 5.04) pixels, p = 0.044). There was no evidence of a 
difference in arterial tortuosity based on retinopathy status with the mean 
population arterial tortuosity of -10.11 for both groups (SD 1.26 with 
retinopathy and 1.11 without retinopathy). However, there was evidence of 
increased venular tortuosity in those with incident retinopathy (-9.71 (SD 
1.06) vs – 10.01 (SD 0.87), respectively, p = 0.016. There was also reduced 
fractal dimension, or vascular complexity, in those with incident retinopathy. 
Those without retinopathy had a fractal dimension of 1.75 (SD 0.08) and 
those with retinopathy, 1.74 (SD 0.07), p = 0.048. The values can be found in 
Table 34 (page 191).  
6.2.2 Linearity of retinal vascular traits and 
retinopathy 
To assess linearity of the relationship between baseline RVTs and incident 
retinopathy, I created quartiles of each RVT and evaluated the risk of 
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retinopathy in each quartile. This method was chosen to provide reasonably 
sized groups in order to create meaningful crude incidence values to 
evaluate linearity. This was done in order to understand the direction of any 
associations that may have been found between the independent and 
dependent variables. Formal linearity testing for model evaluation is 
discussed later in the chapter after the logistic regression is described. 
Table 35 (page 192) gives the risk of incident retinopathy for each RVT by 
quartile and Figure 23 (page 193) presents these findings graphically. There 
was a reduced risk of retinopathy with decreasing CRAE. CRVE was similar, 
but with slightly lower risk in the first quartile, compared with the second, and 
then a reduction of risk in the third and fourth quartiles. Arterial tortuosity 
displayed a possible J-shaped relationship, with an increased risk in the first 
and fourth quartiles, but a reduced risk in the second and third. This could be 
interpreted as very low or very high arterial tortuosity associated with incident 
retinopathy and may be a case for not using this RVT strictly as a continuous 
variable. Both venular tortuosity and fractal dimension show similar, but 
opposite patterns, with increased risk clearly in one quartile, the fourth for 
venular tortuosity and first for fractal dimension, and then reduced risk in the 
remaining three quartiles. These could both be cases for combining the three 
lower risk quartiles and comparing them to the high-risk quartile. 
There are different methods of analysis of RVTs other than using them as the 
continuous variables directly extracted from the software. One method is to 
evaluate them as categorical values. This can be done by creating 
subgroups, such as quartiles, and analysing them as such. Taking this 
further, if there appears to be higher risk of the outcome at the upper and 
lower tails, which might indicate a J-shaped risk association, one could 
combine the upper and lower tail as a high risk group and compare it with the 
middle, lower risk group. Since I currently have very little information on the 
true association and these cut-offs are still very arbitrary, I chose to continue 
using the RVTs as continuous variables within the models.  
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 Association between retinal vascular traits and 
incident retinopathy – Logistic regression 
See Table 36 for full logistic regression results. 
6.3.1 CRAE 
In the unadjusted model, decreased CRAE was associated with incident 
retinopathy with an odds ratio (OR) of 0.93 (95% confidence interval (CI) 0.87 
to 0.99) and a p value of 0.028. This relationship was maintained after 
multivariable adjustment for age and sex (OR 0.93, 95% CI 0.87 to 0.99, p = 
0.023), as well as after adding cardiometabolic (OR 0.93, 95% CI 0.87 to 
0.99, p = 0.030) and diabetes related risk factors (OR 0.93, 95% CI 0.87 to 
1.00, p = 0.038), with very little change in the point estimate at each step. 
However, the relationship lost statistical significance after vascular disease 
history and CRVE were incorporated into the model (OR 0.95, 95% CI 0.87 
to 1.03, p = 0.212). This indicates a relationship between decreased CRAE 
and incident retinopathy, but not beyond other vascular markers of pathology 
and venular width.  
6.3.2 CRVE 
In the unadjusted model there was no evidence of an association between 
CRVE and incident retinopathy (OR 0.95, 95% CI 0.91 to 1.00, p = 0.058). 
After adjusting for age and sex and then cardiometabolic risk factors, the 
point estimate and confidence interval did not change, but there was 
evidence of an association between decreased CRVE and incident 
retinopathy, although very small (OR 0.95, 95% CI 0.91 to 1.00, p = 0.048). 
The association was lost after adding in diabetes related risk factors, 
although again there was no change to the point estimate (p = 0.051). 
However, when vascular disease risk factors and arterial width were 
accounted for, there was no evidence of an association (OR 1.00, 95% CI 
0.58 to 1.75, p = 0.999). 
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6.3.3 Arterial tortuosity 
There was no evidence of an association between arterial tortuosity and 
incident retinopathy in the unadjusted model (OR 0.99, 95% CI 0.81 to 1.22; 
p = 0.946). Analysis was ended after the age and sex adjusted model did not 
show any indication of an association (OR 0.99, 95% CI 0.80 to 1.22, p = 
0.923). 
6.3.4 Venular tortuosity 
From the logistic regression, there was evidence of a strong association 
between increased venular tortuosity and incident retinopathy. This 
relationship was evident in the unadjusted stage, OR 1.43 (95% CI 1.11 to 
1.84; p = 0.005) and was maintained after each block of covariates was 
added. After all covariates were added the OR was 1.51 (95% CI 1.15 to 
1.98) with a p value of 0.003. Above all commonly cited risk factors and 
potential biomarkers for retinopathy, increased venular tortuosity was 
independently associated with increased incident retinopathy.  
6.3.5 Fractal dimension 
In the unadjusted logistic regression model there was no evidence of an 
association between fractal dimension and incident retinopathy, but after age 
and sex adjustment there was possible evidence of an association (OR 0.79, 
95% CI 0.62 to 1.00) with p = 0.05, so further analysis was carried out. After 
cardiometabolic and diabetes risk factors were added there was an 
association between fractal dimension and retinopathy (OR 0.76, CI 0.60 to 
0.98) and p = 0.033. And after all covariates were added the OR was 0.75 
(95% CI 0.58 to 0.96) and p value was 0.017. Because a standardised 
variable was used for fractal dimension, the findings can be interpreted that 
with each standard deviation increase in fractal dimension, the odds of 
incident retinopathy decreases by 0.25.  
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6.3.6 Model evaluation 
Model evaluation was performed on the most complete model analysed. So, 
for arterial tortuosity that would have been the age and sex adjusted model 
but for the remaining RVTs that would have been the fully inclusive Model 5. 
Model assumptions 
Linearity between continuous variables and the outcome is a necessary 
assumption to meet when conducting regression analysis. In section 6.2.2, a 
crude measure of linearity was explored with the retinopathy outcome in 
order to influence how the results of the logistic regression were interpreted. 
In order to satisfy the linearity assumption for model evaluation, formal plots 
were generated and visually inspected to evaluate linearity between the 
continuous predictor variables and the logit of the outcome. There was no 
visual evidence of non-linearity for CRAE, arterial tortuosity and fractal 
dimension. There was a possible increase in the mid-range CRVE values, 
but this may have been due to outliers. Venular tortuosity also showed 
possible increased risk at both the very high and very low-end measures. All 
continuous covariates were then inspected by adding an interaction term of 
the log of itself within the model. All covariates met the linearity assumption, 
except for the CRVE model. For this reason, the extreme outlier values within 
the CRVE model were removed. There were no differences in the findings of 
the model after these values were removed, but the linearity assumption was 
no longer violated. Values presented in Table 36 represent the re-fitted 
model. There was no evidence of multicollinearity within any of the models.  
Model Fit 
Model fit was evaluated by comparing the c-statistic and AIC between the 
unadjusted model (Model 1) and the fully adjusted model (Model 5). Also, the 
Hosmer-Lemeshow goodness of fit test was used to look for evidence of poor 
model fit. All models demonstrated good fit, by c-statistic and AIC, and did 
not show evidence of poor fit. See Appendix 17 for values. When evaluating 
residuals, there was no evidence of strong outliers or influential cases 
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6.3.7 Sensitivity analysis 
Incident retinopathy was defined using a very strict definition in order to only 
include those that had established diabetic retinopathy. This definition 
required that if a person only had a retinopathy grading of R1, they must 
have this grading on at least two consecutive screenings in order to eliminate 
those with an image artefact, or possibly with a true microaneurysm that 
healed without progression. If the definition of incident retinopathy was 
loosened to include all those that ever had an R1 grading after baseline, the 
number with incident retinopathy would be 239. When the full logistic 
regression models included these 239 participants as having the outcome, 
there was no association found between any of the RVTs and incident 
retinopathy. See Appendix 18. As there were very few cases of retinopathy 
at the R2, R3 or R4 level, sensitivity analysis was not undertaken by 
separating out the severity of retinopathy. 
 Evaluation of RVTs as biomarkers for incident 
retinopathy 
From the fully controlled logistic regression models, it was clear that there 
was an association between increased venular tortuosity and incident 
retinopathy, as well as decreased fractal dimension and retinopathy. From 
this evidence, the next step would be to add the trait to an existing risk model 
for retinopathy. A reliable and clinically validated risk prediction model does 
not currently exist for retinopathy. Therefore, I created a basic model, using 
evidence from many studies that looked at risk factors for retinopathy, and 
then added in the RVTs of interest to see if the model was improved. 
Comparing a basic model of HbA1c, ACR and systolic blood pressure, to the 
same model with venular tortuosity added, the c-statistic, or discriminative 
ability of the model, improved from 0.624 to 0.640 and was confirmed by the 
Likelihood ratio test, p = 0.013. Also the AIC measure improved from 487.65 
to 483.43, which decreases with improvement. However, when fractal 
dimension was added to the basic model the c-statistic decreased from 0.625 
to 0.621 and a p value of 0.048, indicating the model does not improve. 
These values can be found in Table 37 (page 194). While these values do 
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not necessarily indicate a good model, as general convention suggests a c-
statistic over 0.7 to be good, it is demonstrating the clinical relevance of 
venular tortuosity, which should be considered in future risk prediction model 
generation.  
 Chapter summary 
This chapter presented my results on the association of baseline retinal 
vessel traits with incident retinopathy over the 10 years of follow-up.  In the 
ET2DS, 82 participants went on to develop evidence of diabetic retinopathy, 
out of the 718 that had no retinopathy at baseline. These 82 participants 
were similar to those without retinopathy for many baseline characteristics, 
except that they had higher HbA1c. From univariate analysis, narrower 
arterioles and venules, as wells as increased venular tortuosity and 
decreased fractal dimension were found in participants that went on to 
develop retinopathy. After applying multivariable logistic regression, 
controlling for a large number of metabolic, diabetic and vascular risk factors, 
increased venular tortuosity and decreased fractal dimension were 
associated with incident retinopathy. Venular tortuosity, in particular, showed 
potential as a novel biomarker for diabetic retinopathy in an analysis 














7 Results III: Retinal vascular traits and 
cognitive decline 
This results chapter focuses on cognition as an outcome, specifically 
cognitive decline. For this thesis I have used two outcomes to describe 
cognitive decline: (1) dementia diagnosis at follow-up as a binary outcome 
and (2) change in the continuous variable, g (general intelligence factor), 
made from a composite of seven cognitive tests that seek to measure 
different cognitive domains. This chapter describes the Edinburgh Type 2 
Diabetes Study (ET2DS) population that went on to have dementia and 
describes how g relates to other variables of interest. To evaluate the 
relationship between retinal vessel traits and cognitive decline I used logistic 
regression when evaluating dementia as an outcome and linear regression 
when evaluating change in g as an outcome. The results of a novel case-
control analysis assessing whether change in retinal vessel traits (RVTs), 
and not just baseline values, were associated with cognitive decline, are also 
presented. As with the previous chapter, model evaluation is reported in 
order to better understand how the models fit the data and how generalizable 
these findings may be to other similar populations.  
 Incidence of dementia and relationship with g  
I used both dementia and change in the derived general intelligence factor g 
to describe cognitive decline. For analyses on dementia, I used the entire 
ET2DS cohort of 1066 as dementia was identified partly through medical 
records. Using medical records for dementia diagnosis allows us to evaluate 
all participants within the cohort and not just those living at follow-up and 
available for dementia screening. Medical records, or in some cases, death 
records, for all 1066 participants were reviewed for evidence of dementia 
diagnosis. Because the study has such records for all participants, there was 
essentially no missing data for dementia. However, participants that have 
dementia but have not received testing or a formal diagnosis of dementia 
would still not be included as having dementia.  
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At baseline, none of the ET2DS participants had dementia, while incidence of 
dementia over the 10-year follow-up period included 106 participants, or 
9.9%. For year-10 g, participants had to undergo follow-up clinical testing, so 
the number used in this analysis was 581. As expected, these two outcome 
variables were related to each other. Of the 106 participants in the whole 
study population diagnosed with dementia at year 10, 35 (33%) attended the 
year-10 follow-up clinic (6% of follow-up population) and of these, 17 (49%) 
were in the lowest decile of year-10 g. Of the 58 participants in the lowest 
10% of follow-up g, 17 (29%) also had dementia. Participants with dementia 
at follow-up had a statistically significant lower mean g score (-1.83 (SD 
0.90)), compared to those without dementia (-0.20 (SD 1.01), p < 0.001) 
(Table 38 (page 207)). Figure 24 (page 207) demonstrates the relationship 
between year 10 g and dementia diagnosis. 
 Longitudinal association between baseline RVTs 
and incident dementia  
7.2.1 Demographics by dementia status 
Table 39 (page 208) as well as Figures 25 and 26 (page 209 and 210, 
respectively) give baseline demographic information by dementia status. 
Participants that went on to develop dementia were older (69.4 years 
compared to 67.8 years, p < 0.001) had lower body mass index (BMI) (30.0 
vs 31.6, p = 0.005) and were more likely to have retinopathy at baseline 
(40.6% vs 30.9%, p = 0.045). People that went on to develop dementia were 
more likely to be men and have a self-reported history of ever smoking, 
however these differences were not statistically significant, and a larger study 
population would be required to more definitively draw these conclusions. At 
baseline, those who went on to develop dementia had, on average, diabetes 
for a year longer, more likely to have had a stroke or other macrovascular 
disease history, but again, these differences were not statistically significant. 
Systolic blood pressure, total cholesterol:high density lipoprotein (HDL) 
cholesterol ratio, HbA1c, diabetes treatment and albumin/creatinine ratio 
(ACR) were all similar between those with and without dementia at follow-up. 
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7.2.2 Retinal vessel traits and dementia 
Retinal vessel traits were compared by dementia status. Overall, there was 
no evidence of a difference between the two groups. Mean central retinal 
arteriolar equivalent (CRAE) did not differ based on dementia status (33.00 
(standard deviation (SD) 4.30) vs 33.03 (SD 3.82)). Similarly, mean central 
retinal venular equivalent (CRVE) was very similar between the groups 
(43.77 (SD 5.42) for those with dementia and 44.77 (4.96) in those without 
dementia). For both arterial tortuosity and venular tortuosity, the participants 
with no dementia had slightly lower tortuosity values compared to those with 
dementia: -10.08 (SD 1.14) vs -10.04 (SD 1.24) and -9.96 (SD 0.88) vs -9.89 
(SD 0.96), respectively, but no statistical differences were identified. Mean 
fractal dimension was 1.75 (SD 0.07) in both those with and without 
dementia. See Table 40 (page 211).  
Linearity of retinal vessel traits and dementia 
As with the retinopathy outcome, it is important to evaluate the relationship 
between the RVTs and cognition and whether there is a clear linear 
relationship. Quintiles were created for each RVT and the risk of dementia 
within each quintile was calculated (Table 41 (page 211)). These 
relationships are visualised in the bar charts in Figure 27 (page 212). CRAE 
demonstrated a possible J-shaped relationship with dementia, with increased 
risk in the first and fourth quintiles. CRVE demonstrated a more 
straightforward relationship, with increased risk in the first quintile and similar 
risk in the second through fifth quintiles. Both arterial and venular tortuosity 
had risk patterns that were difficult to interpret, with risk varying between the 
quintiles. This was also true of fractal dimension. The participant numbers 
with dementia per quintile were often quite low, so this basic analysis was not 
adequately powered to fully demonstrate any true association, only to view 
possible direction. In model evaluation, I used statistical methods to 




7.2.3 Association between retinal vessel traits and 
dementia- logistic regression 
See Table 42 (page 213) for full logistic regression results for all RVTs. None 
of the evaluated RVTs showed any evidence of an association with 
dementia, using logistic regression. There were no statistically significant 
results from the unadjusted or age and sex adjusted models, so model 
building was not continued. For CRAE, the age and sex adjusted odds ratio 
(OR) was 0.99 (95% confidence interval (CI) 0.94 to 1.05) and 1.03 (95% CI 
0.99 to 1.07) for CRVE. The confidence intervals were quite narrow, 
indicating a precise result using these data. Arterial and venular tortuosity 
measures had ORs of 0.91 (95% CI 0.80 to 1.16) and 0.92 (95% CI 0.73 to 
1.16), respectively. The standardised fractal dimension showed no evidence 
of an association with dementia (OR 1.05, 95% CI 0.85 to 1.29). 
7.2.4 Model evaluation 
Model assumptions 
When evaluating linearity between continuous independent variables and the 
logit function the assumption of linearity was upheld for all age and sex 
adjusted models presented that evaluated the association between the retinal 
vessel traits and dementia. There was also no evidence of non-linearity 
based on visual inspection. 
For the age and sex adjusted models evaluating the association between 
RVTs and dementia there was no evidence of multicollinearity between the 
variables included in the models. This was demonstrated by variance inflation 
factors (VIFs) that were well below 10 and an average VIF no greater than 
one.  
Model fit 
All age and sex adjusted models demonstrated good fit, by c-statistic and 
AIC and did not show evidence of poor fit. See Appendix 19 for values. 




7.2.5 Sensitivity and subgroup analysis 
For sensitivity analysis, I increased the dementia outcome definition to 
include participants that fell in the lowest 10% for g at year-10. These 
participants may not have been diagnosed with dementia formally, but they 
did display diminished cognitive capabilities when compared with the whole 
cohort. This increased the number of people with the outcome from 106 to 
147. There were no major changes to the findings. There was evidence of an 
association between increased CRVE and dementia and/or lowest decile g, 
OR 1.04 (95% CI 1.01 to 1.06, p = 0.020) in the unadjusted model, but this 
association was no longer evident after adjusting for age and sex. See 
Appendix 20 for full results of this sensitivity analysis.  
Subgroup analysis was undertaken to evaluate any variable effects based on 
important characteristics in an age and sex adjusted model with dementia 
and/or lowest decile g as the outcome. Specifically, I looked at if there were 
any differential associations in those that consumed no alcohol, moderate 
alcohol (1 to 14 units per week) or high alcohol (15 or more units per week). 
There was some evidence that in those that did not drink alcohol, increased 
venular tortuosity was associated with dementia and/or lowest decile g (OR 
1.45, 95% CI 1.07 to 1.98, p <0.05), but none of the other alcohol categories 
had a similar association. In participants that drank 15 or more units of 
alcohol per week, decreased standardised fractal dimension was associated 
with dementia and/or lowest decile g (0.59, 95% CI 0.36 to 0.95, p <0.05). 
I also evaluated if there was a difference between those that had 
experienced a hypoglycaemic episode at baseline or not. There was an 
association between increased arterial tortuosity and the outcome, dementia 
and/or lowest decile g, OR 1.74 (95% CI 1.06 to 3.00, p <0.05), but the 
confidence interval was wide. This finding would need to be investigated in a 
larger cohort with more documented episodes of hypoglycaemic events. 
There were no differences between the subgroups for any of the other RVTs. 
See Table 43 (page 214) for full results from the subgroup analysis.  
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 Longitudinal association between baseline retinal 
vessel traits and cognitive decline  
7.3.1 Cognitive decline and risk factor variables 
In the population that returned for the year-10 follow-up, the mean g was 
found to be -0.29 (SD 1.07). This unit-less variable can be compared to the 
baseline g variable that has a mean of 0 and standard deviation of 1. This 
value indicates that average cognition decreased from baseline to follow-up. 
In those that returned for year-10 data collection, their baseline g was 0.21 
(SD 0.95), so compared with the baseline mean of 0 for the whole population, 
those that returned had a higher cognition at baseline (see section 5.4).  
In an unadjusted, univariate analysis, the general intelligence factor g at 
year-10 was negatively associated with age, which can be interpreted that 
with increased age, g is found to be decreased. There was also evidence of 
decreased g values in men, compared with women. After controlling for age 
and sex there was a slight, but significant association between lower g 
scores and increased BMI (-0.104), increased HbA1c (-0.119) and increased 
ACR (-0.159). Participants taking oral tablets or insulin at baseline were more 
likely to have a lower g at year-10, compared to those with diabetes 
management through diet alone (-0.124). Having a history of stroke or other 
macrovascular disease at baseline was also associated with lower g (0.146 
and 0.128, respectively). Also, lower g at baseline was associated with lower 
g at follow-up. There was no correlation between follow-up g and smoking 
history, systolic blood pressure, total cholesterol:HLD ratio, duration of 
diabetes or retinopathy, at baseline. See Table 44 (page 215) for 
correlations between follow-up g and baseline risk factors as well as Figure 
28 and Figure 29 (page 216 and 217, respectively) for graphical 
representations.  
7.3.2 Cognition and retinal vessel traits 
In the participants that returned for the year-10 data collection, their baseline 
CRAE and CRVE means were 33.02 (SD 3.88) and 44.75 (SD 4.97) pixels, 
respectively. The log arterial tortuosity mean was -10.04 (SD 1.15) and log 
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venular tortuosity was -9.96 (SD 0.88). Mean fractal dimension was 1.75 (SD 
0.07). See Table 45 (page 217). 
Evaluating the age and sex adjusted univariate relationship between the 
baseline RVTs and cognition at year-10, there were no obvious correlations 
between cognition and CRAE, CRVE or fractal dimension. There was 
evidence of a correlation between increased arterial and venular tortuosity 
and lower g (correlation coefficients -0.117 and -0.103, respectively). See 
Table 46 (page 218) and Figure 30 (page 218) for full correlations and a 
visual representation of the associations between the RVTs and follow-up g.  
7.3.3 Association between retinal vessel traits and 
cognitive decline- linear regression 
Table 47 (page 219) presents the full linear regression results evaluating the 
relationship between baseline RVTs and cognitive decline. There was no 
evidence of an association between any of the measured RVTs and cognitive 
decline in the unadjusted or age and sex adjusted models. 
7.3.4 Sensitivity and Subgroup analysis 
For the models in Table 47, year-10 g was used as the outcome, controlling 
for baseline g in order to evaluate cognitive decline, and not just cognitive 
status. If baseline g was removed, there was an association between 
increased arterial and venular tortuosity at baseline and lower g at year-10, in 
an age and sex adjusted linear regression model (standardised betas -0.127, 
p = 0.002; -0.087, p = 0.033, respectively), but these associations were lost 
after further controlling for cardiometabolic risk factors. 
Subgroup analysis was evaluated by looking at participants by their alcohol 
consumption (no alcohol, moderate alcohol, high alcohol) and by separately 
looking at participants that experienced a hypoglycaemic event at baseline. 
For participants that drank moderate alcohol (1-14 units per week), there was 
a strong association between increased arterial tortuosity and lower year-10 
g. The standardised beta was -0.217 and the p value was less than 0.001. 
There was no evidence of any other associations between RVTs and 
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cognitive decline in any of the subgroups in an age and sex adjusted linear 
regression (Table 48 (page 219)).  
7.3.5 Model evaluation 
Model assumptions 
There were no concerns with multi-collinearity for any of the models when 
evaluating the variance inflation factor (VIF). There was also no evidence of 
heteroscedasticity when visually evaluating the standardised residual plots. 
The residuals vs fitted plots did not indicate any issues of non-linearity. The 
Durbin-Watson test was used to evaluate independent errors, which showed 
no concerns with autocorrelation. 
Model fit 
Using standardised residual plots, and Cook’s distance, there was no 
evidence of highly influential outliers in any of the age and sex adjusted 
models evaluating RVTs and cognitive decline. Q-Q plots showed general 
normality for all models.  
 Association between baseline retinopathy and 
cognitive decline 
In addition to understanding the association between RVTs at baseline and 
cognitive decline, it is also of interest to evaluate if there is a relationship 
between retinopathy at baseline and cognitive decline at follow-up. Using 
logistic regression, there was evidence of a possible association between 
retinopathy and dementia and/or lowest decile g (OR 1.44, 95% CI 1.00 to 
2.06, p = 0.047) but this association was no longer significant after 
adjustment for age and sex. There was also no association between baseline 




 Change in retinal vessel traits and cognitive 
decline, a nested case-control study 
7.5.1 Demographics based on cognitive decline case 
status 
A total of 170 participants were included in this nested case-control study, 85 
cases and 85 controls. Cases and controls had to have attended the year-10 
data collection for full cognitive testing and have a minimum of 5 years 
between their baseline and follow-up retinal imaging. Cases were participants 
that had diagnosed dementia and/or were in the lowest 10% for follow-up g. 
Controls were randomly selected, age and sex matched from the top 50% of 
follow-up g.  
When comparing the baseline demographic profiles of the cases and 
controls, controls were more likely to have smoked (41.1% cases vs 56.5% 
controls, p = 0.046), cases had a slightly higher HbA1C (7.5% cases vs 7.1% 
controls, p = 0.026) and cases were more likely to have had a stroke (4.7% 
cases vs 0.0% controls, p = 0.043). All other reported demographics were 
similar between the groups. See Table 49 (page 220) for the full comparison. 
At the year-10 follow-up, cases had a higher rate of stroke (12.9% cases vs 
0.0% controls, p < 0.001), as was the case with baseline stroke. HbA1c, CVD 
prevalence and diabetic retinopathy prevalence were all roughly the same 
between cases and controls. There was a longer follow-up time between 
retinal images for the controls, compared with cases (8.6 years cases vs 9.2 
years controls, p = 0.017) See Table 47 (page 220) for full details.  
7.5.2 Change in RVTs through study follow-up 
Before comparing cases and controls, it is of interest to know if there were 
detectable changes in RVTs over the period between the baseline visit and 
10-year follow-up. Cases and controls were evaluated separately as it is 
statistically inappropriate to treat them as one group. There was no evidence 
of any changes in CRAE, CRVE or arterial and venular tortuosity in either the 
cases or controls. There was, however, a decrease in fractal dimension 
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(total, arterial and venular) as well as a decrease in density (total, arterial and 
venular) for both the cases and controls (Table 51 (page 221)).  
When comparing cases and controls, there was a greater decrease in the 
controls for venular fractal dimension, total vessel density and arterial 
density. For venular fractal dimension, there was a decrease of 0.03 in the 
cases vs 0.07 in the controls (p = 0.049). For total density, there was a 
decrease of 722 pixels in the cases and 989 pixels in the controls (p = 0.033) 
and for arterial density, 327 pixels in the cases and 416 pixels in the controls 
(p = 0.027). See Table 52 (page 221) for full differences in RVTs between 
cases and controls. Appendix 21 provides a graphical representation of the 
change in RVTs using spaghetti plots.  
7.5.3 Association between change in retinal vessel 
traits and cognitive decline – logistic regression 
When the association between change in RVTs and cognitive decline was 
evaluated using univariate logistic regression, there were no differences 
between cases and controls for CRAE, CRVE, tortuosity (arterial and 
venular), fractal dimension (total, arterial and venular) or venular density. 
There was an association indicating that greater decreased total density and 
arterial density were associated with the control status (OR 0.96, 95% CI 
0.92 to 0.99, p = 0.036 for total density and OR 0.92, 95% CI 0.84 to 0.99, p 
= 0.029 for arterial density). See Table 53 (page 223) for full univariate 
logistic regression analyses. 
As noted previously, there was a longer follow-up time for the controls by 
about seven months, when compared with the cases, so it is possible the 
greater decrease in fractal dimension and density in the controls was merely 
due to longer progression of time. Logistic regression was repeated for total 
and arterial density, controlling for the length of follow-up time between the 
retinal images. There was no longer an association between the changes in 
the RVTs and cognitive decline (Table 54 (page 223)). This was not a pre-
planned analysis but was important to see if the difference, although small, in 
follow-up time variable was having an effect on the association.  
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7.5.4 Model evaluation 
Model assumptions 
Linearity was assessed visually and there was no evidence of non-linearity 
for the models for the RVTs CRAE, CRVE, tortuosity (arterial and venular), 
arterial fractal dimension, venular fractal dimension, total and venular density. 
There was possible non-linearity in the total fractal dimension so the highest 
outliers were removed (only three cases over two standard deviations), which 
improved the linearity but did not alter the logistic regression outcome. 
Arterial density also showed some visual evidence of non-linearity, and when 
extreme outliers were removed the plot appeared more normal and the 
logistic regression results were not altered. There was no evidence of non-
linearity for any of the models when tested for using interaction terms of the 
log of the continuous variable.  
Model fit 
Because the main models for this analysis were univariate, there was no 
need to evaluate the c-statistic or AIC values. Using Hosmer-Lemeshow 
goodness of fit test to evaluate if there was evidence of poor model fit, there 
was no evidence of poor model fit when evaluated CRAE, tortuosity (arterial 
and venular), fractal dimension (total, arterial and venular) or density (total, 
arterial and venular). The model evaluating change in CRVE did show 
evidence of a poorly fit model. A new model was created evaluating the log of 
the absolute change in CRVE. This model did not show any evidence of a 
poor fit. This model showed evidence of an association between increased 
log absolute change in CRVE and cognitive decline (OR 1.08, 95% CI 1.02 to 
1.16, p = 0.009). This can be interpreted as more extreme changes in CRVE, 
either direction, were associated with cognitive decline. This analysis was not 
pre-planned, but offers a possible alternative to the poorly fit model using a 
simple change in CRVE.  
There was no evidence of serious outliers or influential cases for any of the 
models when evaluating residuals.  
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 Chapter summary 
This chapter presented results from the evaluation of dementia and cognitive 
decline in the ET2DS population at follow-up. Dementia was diagnosed in 
106 of the 1066 (9.9%) participants, and the general intelligence factor g was 
evaluated in the 581 participants that returned for follow-up analysis.  There 
was no evidence of an association between RVTs and cognitive decline, 
using either outcome. When evaluating the relationship between change in 
RVTs during the study follow-up and cognitive decline, using a nested case-
control study design, there was evidence of an association between less of a 
decrease in total and atrial density in the cases, but this association was 
most likely due to the longer follow-up in the controls than differences in 








































 Summary of key findings 
The Edinburgh Type 2 Diabetes Study (ET2DS) is a prospective cohort made 
up of 1066 elderly men and women with type 2 diabetes from the Lothian 
region of Scotland. At baseline, the cohort was found to be generally 
representative of the wider Lothian population with diabetes. After 10 years, 
581 participants returned for data collection at either a clinic appointment or 
home visit. The participants that returned for data collection were generally 
healthier, with higher cognitive ability, at baseline.  
8.1.1 Association between retinal vessel traits and 
incident retinopathy 
There was a total of 82 participants with incident diabetic retinopathy after 10 
years. After adjusting for a wide range of demographic, cardiometabolic, 
diabetic and vascular risk factors, there was an association between 
increased venular tortuosity and incident retinopathy (odds ratio (OR) 1.51, 
95% confidence interval (CI) 1.15 to 1.98; p = 0.003). For every one-point 
increase in venular tortuosity, which is very close to one standard deviation 
(SD for total population is 0.89), the odds of incident retinopathy increased 
1.51 times. The confidence interval indicates a strong association, with 
relatively good precision, that is statistically significant. Venular tortuosity was 
found to improve the discriminative ability of the logistic regression model, 
when compared with a basic model of conventional risk factors for 
retinopathy. These findings require further validation in a similar population 
but venular tortuosity should potentially be considered in future risk prediction 
model generation for diabetic retinopathy. 
There was also an association between decreased total fractal dimension 
and incident retinopathy (OR 0.75, 95% CI 0.58 to 0.96; p = 0.025). Due to 
the nature of this variable, a standardised fractal dimension variable was 
used, so the logistic regression findings can be interpreted as every standard 
deviation increase in fractal dimension decreased the odds of incident 
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retinopathy by 0.25. There were no independent associations between the 
remaining retinal vessel traits (RVTs) and incident retinopathy. 
8.1.2 Association between retinal vessel traits and 
cognition 
Overall, there were no associations between any of the reported RVTs and 
cognitive decline, measured by incident dementia or using cognitive testing 
and derivation of the general intelligence factor g. When evaluating cognitive 
decline, the baseline g value was controlled for in the model, otherwise the 
outcome would have been cognitive status at follow-up. When this baseline 
value was removed, there was an association between increased tortuosity, 
both arterial and venular, and lower cognitive status at year-10, when 
adjusting for age and sex. This association was no longer present after 
further controlling for cardiometabolic risk factors.  
In the evaluation of change in the RVTs and cognitive decline, as reported in 
the nested case-control study, there was evidence of an overall reduction in 
fractal dimension and density measures over the study period in both the 
cases and controls. When evaluating these associations using simple logistic 
regression there initially appeared to be an association between reduced 
change in total and arterial density in the cases, compared with the controls, 
but when the duration of follow-up was controlled for, this association was no 
longer statistically significant. These novel findings suggest that fractal 
dimension and density show a general, age-related decrease in elderly 
people with type 2 diabetes, but this decrease was not associated with 
cognitive decline.  
8.1.3 Implications for future prediction models 
Diabetic retinopathy is highly prevalent in people with diabetes, especially as 
the duration of diabetes increases. There is a need to understand who will 
continue with underlying, asymptomatic disease and who will develop severe, 
sight-threatening proliferative disease. Installation of retinopathy screening 
programmes has provided the opportunity to image and grade for retinopathy 
on a regular basis as well as monitor for progression, but and there is yet to 
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be a reliable prediction model to assist in helping to determine who is most at 
risk of progression, prior to irreversible pathophysiology (Sabanayagam et 
al., 2016).  
The evidence from this thesis provides a piece to the puzzle to help 
determine the usefulness of retinal venular tortuosity for inclusion in a 
prediction model, along with other reliable risk factors, such as blood 
pressure, HbA1c and microalbuminuria. Findings from the systematic review 
in Chapter 2, regarding venular tortuosity, provide further evidence. Another 
longitudinal cohort also found increased venular tortuosity to be associated 
with incident retinopathy (C.Y. Cheung et al., 2015). This study similarly 
looked at any diabetic retinopathy as an outcome. The five other studies in 
the systematic review that evaluated venular tortuosity did not find a 
statistically significant association with diabetic retinopathy, but four of them 
were cross-sectional, so could not offer evidence of temporality. Interestingly, 
all had a direction of association that did supported an association between 
venular tortuosity and retinopathy, so it is possible they were under powered 
to find an association, and do not necessarily provide evidence against this 
association.  
More evidence is needed to definitively determine if venular tortuosity could 
be useful in a prediction model, in the form of replication of the findings from 
this thesis and also looking more specifically at prediction of severe forms of 
the disease. If venular tortuosity is able to help predict progression to vision-
threating retinopathy, it could easily be implemented as retinal imaging is 
already acquired annually in Scotland for people with diabetes and in many 
other countries. If at risk people could be identified, they could be targeted for 
more intensive risk factor reduction and increased monitoring. This could 
help reduce related health care costs as limiting retinopathy to non-
proliferative disease is far cheaper to treat, and people who are not at 
increased risk may not need as frequent of screening, freeing up related 




 Contextualising the findings 
8.2.1 Strengths of using ET2DS 
The ET2DS database contains a wide number of variables that have been 
collected using standard methods that ensure highly accurate data. Primary 
data collection was conducted at several time points (mainly at baseline, year 
1, year 4 and year 10) adhering to prespecified detailed standard operating 
procedures in order to ensure accuracy between participants and between 
time points. Physiological and cognitive testing was performed by trained 
researchers, who regularly underwent quality control measures in order to 
limit observer bias. The same instruments and measurement tools were used 
by all researchers and kept as similar as possible between data collection at 
different time points. In addition, Information Services Division (ISD) 
Scotland, which manages the national database of NHS records, provided a 
good portion of the linked health data. ISD Scotland is world renowned as 
one of the best sources for reliable, high quality data, which is due to the high 
level of quality assurance of the data (Ireland, 2017).  
The baseline sample size of ET2DS was calculated to be able to determine a 
statistically significant association at 90% power between a predictor variable 
and outcome that had a correlation coefficient ≥0.10, as well as detect risk 
factors. The sample size was also calculated to account for dropouts at 
follow-up and still maintain the same power and significance with a 
correlation coefficient ≥0.12.  
Concerns of misclassification bias were limited through rigorous diagnostic 
definitions and criteria for all outcomes and events. This includes, but not 
limited to, dementia, cardiovascular and cerebrovascular events and 
retinopathy. Data entry was performed manually and included backstop 
methods to ensure as few errors as possible, which included double data 
entry and evaluating the database for impossible values, outliers and missing 
data.  
ET2DS currently has a prospective data collection period of 10 years, which 
is exceedingly rare in an elderly population with diabetes. The main reason 
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for attrition through the data collection period was death. Other reasons for 
not returning to the 10-year research clinic were chronic or acute health 
concerns, full-time carer responsibilities and not being able to contact a 
participant. Attrition bias is always a concern in cohort studies, but every 
effort to limit non-death related attrition was made, which resulted in low 
numbers and less concerns for this type of bias affecting the 
representativeness of the population (Brilleman, Pachana and Dobson, 
2010). In addition, data were collected through data linkage and routine data 
sources for the entire study population, reducing the impact of non-
attendance.  
8.2.2 Limitations of ET2DS 
Limitations of low events and subgroups 
Although ET2DS is a large cohort, evaluating certain subgroups, which 
reduces the population size, or rare outcomes, may produce underpowered 
analyses. This could result in type II error: a negative finding may not 
necessarily be indicative of evidence of no association, but rather an 
absence of evidence to prove an association (Altman and Bland, 1995). The 
sample size calculation for the cohort recommended 1,000 participants at 
baseline and 800 at follow-up to adhere to the specified power and 
significance levels to limit type I and type II error.  
Unfortunately, the cognitive decline outcome as measured with g, could only 
be analysed in participants that returned for cognitive testing at follow-up. 
Thus, the analysis was only carried out in 581 participants, which was lower 
than the original power calculation covered (Price et al., 2008). However, 
there would still be 90% power to detect a difference in correlation ≥0.15 in 
the population size that returned for cognitive testing, as opposed to the 
originally calculated 0.12 for follow-up. Although the incident retinopathy 
logistic regression only included 82 cases out of 718 participants, there was 
still a statistically significant relationship, with a moderate effect size, with 
increased venular tortuosity and decreased fractal dimension, indicating that 
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the sample size was sufficient to minimise type I and type II error in this 
analysis.  
The lack of power to evaluate certain groups was especially noted regarding 
disease severity and subtypes related to my specific outcomes. For diabetic 
retinopathy, I could not look at the association of the RVTs by severity, most 
notably non-proliferative versus proliferative diabetic retinopathy because our 
incident cases of proliferative disease were so few. These disease stages are 
markedly very different, especially on a microvascular level, and evaluating 
the RVTs could differ between them. 
With the cognitive decline outcome, specifically dementia, I was not able to 
evaluate the association of RVTs with different dementia aetiology: 
Alzheimer’s, vascular or mixed dementia. In Chapter 1, I highlighted 
differences between these forms of dementia, and these differences, 
especially regarding neurodegenerative versus cerebrovascular disease 
could be reflected in different pathological associations between RVTs and 
dementia development. However, given the difficulties inherent in diagnosing 
the different forms of dementia, the likely substantial overlapping pathology 
and the likelihood of mis-diagnosis (at least until post-mortem) (Knopman et 
al., 2003), even had I had full medical records and diagnoses available for 
my analysis, this may not have helped address the underlying question. 
Misclassification bias 
As previously mentioned, misclassification bias was limited in ET2DS using 
multiple, rigorous data sources. However, there is still concern for this type of 
bias for certain outcomes, such as retinopathy and dementia.  
Dementia diagnosis within the NHS is not achieved with a single diagnostic 
test, but requires a multitude of factors and a progressive pathway to identify 
and diagnose the possible condition (National Institute for Health and Care 
Excellence (NICE), 2018). For this reason, and several others, dementia 
remains underdiagnosed by possibly as much as half of those who have it 
(Connolly et al., 2011). All people with underlying dementia-related cognitive 
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pathology will not be identified as having frank dementia, which introduces 
bias into epidemiological research.  
Within this thesis, using g to more directly measure cognition through 
specially designed cognitive tests, rather than only relying on a clinical 
dementia diagnosis, allowed me to evaluate cognitive decline more 
specifically. However, this method relies on participants attending a research 
clinic and completing the tasks, which often leads to reduced numbers for 
analysis when comparing to dementia diagnoses that can be ascertained 
from medical records. Also, evaluating cognition using these methods may 
be describing different phenotypes of cognitive decline. While this does not 
necessarily pose a problem for this thesis, because I am interested in a 
predictive marker and not aetiology of cerebral disease, this should still be 
kept in mind when interpreting the results. 
Retinopathy diagnosis requires a person to attend annual retinopathy 
screening and be physically able to undergo imaging. Physical limitations 
common within an elderly cohort with diabetes would limit both the 
attendance and ability to obtain a clear image for retinopathy. Therefore, 
there may be a number of participants within the cohort that have clinical 
diabetic retinopathy but have not been identified within the screening 
programme. However, the Scottish Diabetic Retinopathy Screening 
Collaborative (Scottish DRS), has a very high participation rate, with 84% of 
eligible participants having been to a screening appointment in the previous 
15 months (Scottish Diabetes Monitoring Group, 2016).  
Healthy returning volunteer bias 
It is a common phenomenon in longitudinal research that participants that 
return for later follow-up are generally healthier. There are some obvious 
reasons for such an occurrence, such as participants that died during the 
follow-up would most likely have had a less healthy profile at baseline than 
those that survived, and very unhealthy participants may not physically be 
able to attend an appointment. I tried to minimise the latter concern by 
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holding home visits, in order to incorporate as many participants that were 
willing but unable to attend the clinic.  
I acknowledge that testing in a home setting could provide variable results to 
those obtained in the clinic setting. As a study team, we chose to perform 
home visits as the risk of varying results was outweighed by the potential loss 
of data that would occur given the age and declining health of our study 
population. The same researchers were conducting the clinic visits and the 
home visits, which helped to ensure continuity between research settings. To 
better understand the extent of potential bias from using both clinical and 
home visit data, analysis was performed comparing these two populations of 
participants on important health and demographic variables. Home visit 
participants did have a more unhealthy profile at baseline, but this serves to 
strengthen their inclusion as without them, the study would be more biased 
towards healthier participants.  
Participants that attended the year-10 clinic, when comparing baseline 
characteristics with non-attenders, were younger, had a reduced body mass 
index (BMI) and systolic blood pressure, had diabetes for less time, were 
more likely to be controlling their diabetes with diet rather than with tablets or 
insulin, less likely to have had a stroke or other macrovascular event and had 
a reduced albumin-creatinine ratio (ACR). It was also clear that returning 
participants had higher cognitive function at baseline, compared to those that 
did not return. This type of survival bias is more likely to obscure any findings 
as the returning population will be less likely to suffer from negative health 
outcomes and have an overall healthier profile of covariates.  
Although concerns with survival bias leading to a healthier returning 
population should be considered when interpreting the results, it should be 
noted that death accounted for a large portion of the attrition, and these 
death rates would not differ by much in the target population, making the 
findings of the study more generalisable to the wider population. This was 
demonstrated in a previous longitudinal study, which evaluated 
representativeness of their cohort of elderly participants during the follow-up, 
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based on routinely collected data and compared with an external group of 
people not enrolled in a study. They found that there were no major concerns 
of attrition bias, indicating these concerns may not have a large impact on the 
outcomes and generalisability (Lacey, Jordan and Croft, 2013). 
Retinopathy and duration of diabetes 
In the analysis assessing incident diabetic retinopathy (DR) as an outcome, it 
was imperative to remove participants that already had established 
retinopathy in order to investigate the temporal relationship between RVTs 
and incidence of retinopathy. Other studies have shown that people with 
diabetes that do not develop signs of progressive retinopathy earlier in their 
disease trajectory are possibly less likely to develop any clinically meaningful 
retinopathy during further follow-up (Jones et al., 2012). This trend is also 
supported from an early analysis of the Wisconsin Epidemiology Study of 
Diabetic Retinopathy (WESDR) cohort, where those diagnosed with 
retinopathy earlier in the study were more likely to have progressive disease 
compared with participants that did not have retinopathy at baseline but 
developed it later on, who were more likely to have more mild retinopathy 
(Klein et al., 1989). When developing a risk prediction tool for DR that would 
evaluate venular tortuosity for inclusion, it is recommended that a cohort with 
very newly diagnosed diabetes be used, before retinopathy can be 
established, and therefore capturing more people that will go on to have 
moderate and severe DR, and not just mild forms of the disease. 
Representativeness and changing demographics 
Representation of the wider population in a study population is not static. 
Even if a study population is found to be generalisable on certain key matters 
at the start of the study, years later, this same study population may no 
longer represent the population they are meant to. For example, the vast 
majority of participants in ET2DS are ethnically white, which was 
representative of the elderly population in Lothian at baseline. However, this 
demographic has most likely changed over time. Ethnicity is a known 
contributing risk factor for cardiovascular multimorbidity so changes in this 
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demographic may reduce the generalisability of the findings of the study 
(Mathur et al., 2011).  
Changing patterns of deprivation profiles by the Scottish Index of Multiple 
Deprivation (SIMD) may also affect the representativeness of the study 
findings over time. SIMD has been updated twice since the 2009 version 
used for ET2DS baseline was implemented. The designations for the data 
zones have changed in some areas, which can be seen in the interactive 
maps available online (Scottish Government, 2019). These concerns will be 
common among longitudinal studies, as the target population will often 
change by certain demographics during the follow-up period, and good study 
design, with measurement of a wide number of variables, can help to combat 
these issues. There is also a more general concern with SIMD in that it may 
be poor at describing individuals as the data zones are a generalisation and 
often the populations within them are quite heterogenous in terms of 
resources (Fischbacher, 2014). For this reason, SIMD was not used as a 
covariate within the models, but only to describe the representativeness of 
the study population at baseline in comparison to the target population. 
8.2.3 Strengths and weaknesses of analysis 
VAMPIRE 
Utilising the Vascular Assessment and Measurement Platform for Images of 
the Retina (VAMPIRE) software allowed for efficient analysis of the fundus 
images from participants in the ET2DS. This software was developed through 
an international collaboration and is constantly being improved upon in order 
to keep up with the growing demand for retinal analysis. In the results of this 
thesis, using a validated tool limited the measurement bias of the RVTs 
which was reflected in the acceptable intra- and intergrader reliability 
assessments. VAMPIRE software has been used successfully for other 
similar applications, such as identifying an association between fractal 
dimension and small vessel disease in two separate groups of participants 
(McGrory et al. 2018). A recent study, the first to use this type of software in 
felines, found VAMPIRE software to be a consistent diagnostic tool for 
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systemic hypertension in cats (Cirla et al., 2019). Using the Genetics of 
Diabetes Audit and Research- Tayside Scotland (GoDARTS) cohort in 
Dundee, the results from VAMPIRE software were used in combination with 
genetic and routine clinical information to create a robust prediction model for 
major cardiovascular events (Fetit et al., 2019).  
Producing and reporting of RVTs requires many choices, such as variations 
of a trait (maximum, minimum or median tortuosity), measurement zones 
(zone B, C or whole field), and very importantly, the mathematical algorithms 
incorporated in the software, all of which add heterogeneity when comparing 
to other datasets or studies. There is a need for structured debates on areas 
of standardisation of RVTs, which has been demonstrated by Mookiah et al, 
when they performed a pilot analysis using VAMPIRE software to analyse 
retinal images that were centred in different locations, fovea centred versus 
macula centred, and found noticeable differences in the output (Mookiah et 
al., 2018). 
Other areas where more evaluation of standardisation is needed is with 
differing algorithms, which has been demonstrated regarding tortuosity 
measurements by Lisowska et al. They showed varying levels of correlation 
when using five different algorithms to measure tortuosity (Lisowska et al., 
2014). They compared types of algorithms that were relatively simplistic, but 
failed to incorporate local changes, as well as more complex measures, 
specifically the curvature integral measures. The curvature integral measures 
were found to perform the best but required the presence of vessel 
centrelines and also were most sensitive to sample variation, indicating that 
algorithm selection needs to be considered alongside the study sample it will 
be used with. The tortuosity algorithm used in the version of VAMPIRE 3.1.0 
software to measure the ET2DS baseline RVTs utilises a curvature based 
algorithm (Annunziata et al., 2014).  
There are also different theories and methods for fractal analysis that alter 
the way the fractal dimension of a retina is measured and analysed. Fractal 
analysis is often done using segmented vessels and a method known as box-
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counting, but one group of researchers, Azemin et al, chose to use a Fourier 
Fractal Dimension (FFD) method that did not rely on vessel segmentation, 
but rather greyscale images, which they claim reduces manual input 
(MacGillivray et al., 2007; Azemin et al., 2011). Another complex choice for 
fractal analysis of the retina is the use of a singular fractal dimension or 
multifractal analysis, which is used when a single fractal descriptor does not 
fully capture the pattern (Stosic and Stosic, 2006). Multifractal analysis, which 
is what is incorporated in VAMPIRE software, calculates fractal dimension 
over several scales. How the output is then used is subject to the users and 
can vary. 
Retinal vessel analysis is currently of great interest to many researchers who 
study vascular disease and there are several other popular platforms for 
analysis, which include Singapore “I” Vessel Assessment (SIVA; National 
University of Singapore, Singapore), Quantitative Analysis of Retinal Vessel 
Topology (QUARTZ), Interactive Vessel Analysis (IVAN; University of 
Wisconsin Madison, WI) and Retinal Analysis (RA; Department of 
Ophthalmology and Visual Science, University of Wisconsin), to name a few. 
Although similar methods are reported between the software packages in 
terms of calculation of vessel measures, there will of course be algorithm 
differences and other variations that can make comparison between the 
software findings difficult.  
There is some indication that measurements between software platforms are 
similar, despite the differences mentioned in previous paragraphs, such as 
the findings presented by Downie et al in their conference abstract showing 
good agreement between VAMPIRE and IVAN software (Downie et al., 
2015). However, a recent study carried out a direct comparison of a wide 
number of vessel measurements between VAMPIRE and SIVA and found 
poor agreement between the software platforms (McGrory et al. 2018). 
Another study, which compared results for CRAE and CRVE between SIVA, 
IVAN and RA platforms, also found poor agreement (Yip et al., 2016). 
However, associations with systemic factors, including age, blood pressure 
and cholesterol, were similar between applications. Yip et al indicated that 
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use of a conversion algorithm between the platforms could help overcome 
differences. Caution should be taken when comparing results between 
studies that use different software to analyse vessels and future work needs 
to go into standardisation if the use of vessel traits in risk prediction becomes 
established. 
Measurement and analysis of retinal vessel traits 
In this thesis, all RVTs were evaluated and analysed as continuous variables. 
Other studies have created categorical variables for the different RVTs, 
generally with quartiles and then compare the largest quartile to the lower 
three (Cheung et al., 2008; Sophie Louise Rogers et al., 2008; Roy, Klein 
and Janal, 2011; Sasongko et al., 2012; Yang et al., 2016). I chose to use the 
variables as continuous because transforming continuous variables into 
discrete variables generally loses power for the analyses (Altman and 
Royston, 2006). Also, there is still relatively little known about these traits 
regarding normal health. There are currently no accepted cut-points and the 
arbitrary cut-points generated in one study may be very different from 
another. Because of these concerns, using these measures as discrete 
variables can be quite subjective and uninformative as there is evidence 
lacking regarding useful comparison groups. Furthermore, there is evidence 
that creating a discrete variable from a continuous one can increase the risk 
of type I error (Austin and Brunner, 2004). However, there may be a case for 
handling data in this manner, for example to combine the highest and lowest 
quartiles of a variable, or remove the higher or lower end of the values, if 
there is evidence that there is a j-shaped association with a certain outcome 
and not a simple linear association. But further investigation is warranted into 
this in order to make an informed decision about analysis.  
Within this thesis, there were possibly non-linear results between arterial 
tortuosity and retinopathy, Figure 23, where there appeared to be an 
increased risk in the first and fourth quartiles. However, categorisation of 
arterial tortuosity was not undertaken as it was not a part of the a priori 
analysis plan, and after careful consideration, would possibly be more likely 
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to lead to spurious results through arbitrary cut-points and multiple testing. I 
feel this area of research deserves greater evaluation, not only within 
ET2DS, but in other similar studies as well, in order to make an informed 
decision of how best to categorise these variables. 
There is evidence that the microvasculature of the retina pulses slightly 
during different phases of the cardiac cycle, with a decrease in width in 
systole and minor increase at the start of diastole, equalling a 4.8% change 
in width (Chen et al., 1994). These findings indicate that fundus images 
should be taken synchronised with electrocardiogram (ECG) readings to limit 
bias due to the cardiac cycle. However, a study evaluating inter- and intra-
observer bias between different software packages did not find a difference 
when using ECG-synced versus non-synced images (Wei et al., 2016). It is 
also debatable whether the software packages are sensitive enough to even 
pick up these very slight changes in width as the resolution of a fundus 
camera is roughly 7 microns and pulsatile changes are likely to be sub 
micron in size (MacGillivray et al., 2014).  
Very few studies have evaluated quantitative changes in the retinal vessels 
over time, so this thesis represents a novel application for this type of 
analysis. For analysing change in retinal vessels, routinely collected fundus 
images were used from the national retinopathy screening programme in 
Scotland, the Scottish Diabetic Retinal Screening Collaborative (Scottish 
DRS). This allowed me access to many high-quality retinal photos to choose 
from for each participant during the follow-up period. I was able to utilise the 
expertise and resources of images already collected and significantly reduce 
the time participants would spend in the research clinic in order to gather 
retinal images specifically for research purposes. This reduced research 
costs and recycled resources that would have otherwise not been used after 
the retinopathy screening was performed. This is one of the first studies to 
use images from the Scottish DRS with VAMPIRE software and there is great 
potential for future collaboration with this vast resource of fundus images.   
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Negatives of using images from the Scottish DRS include the requirement 
that study participants attended their annual NHS retinopathy screening 
appointment. Other limitations of using images taken for Scottish DRS 
purposes, rather than specifically for research purposes, included potential 
difficulties meeting the requirements for accurate use of retinal analysis 
software. For example, the use of different cameras or camera systems may 
influence certain image components. VAMPIRE, nor other similar software, 
have the capacity to standardise measurements between images from 
different camera systems, which could affect the results. 
Specific to this thesis, having an older population may have resulted in 
poorer image quality, and this problem may have been accentuated as 
participants aged during follow-up. It is common for retinal images to be more 
difficult to take in elderly people for many reasons, but mainly due to difficulty 
keeping the head still and eyes open enough, eye lashes creating artefacts 
as well as cataracts or other eye pathologies. I found that the software was 
still able to analyse vessels in images that were slightly blurry, but it is 
possible that the decrease in density and fractal dimension over time, seen in 
both the cases and controls, was due to poorer quality of follow-up images. In 
depth study is needed to better understand the capacity of the software and 
the appropriateness of comparing images of different quality. A suggestion 
would be to create a grading system of image quality and only comparing 
images of similar quality, although this would most likely severely reduce the 
number of usable images per person. Such automated image quality grading 
has been implemented in other analysis software (Welikala et al., 2016).  
When measuring change in the RVTs, there were concerns with survival 
bias, as participants available for follow-up retinal imaging would most likely 
be of a healthier profile than those that did not attend retinal imaging at least 
five years after their baseline image. This would most likely introduce 
selection bias and to overcome these concerns, a nested case-control study 
was used in order to create a more balanced comparison. Using a nested 
case-control design reduces common bias concerns in choosing the controls 
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compared with standard case-control studies because the controls are 
chosen from the same population as the cases.   
Statistical analysis 
The statistical analyses completed throughout this thesis were prepared and 
conducted using a detailed statistical analysis plan. Covariates were carefully 
chosen based on evidence of their association, or potential association, with 
the predictor and/or outcome variables. As I was interested in possible future 
use of RVTs within prediction models, covariates were chosen as known risk 
factors that are commonly measured and available through routine health 
data.  
Although not all of the variables used as covariates in the regression models 
were statistically significantly associated with the vessel traits, their addition 
to the models were still important as not all confounding can be evaluated 
simply through hypothesis testing, and also, thinking ahead to future meta-
analysis, addition of clinically relevant variables is important. In the literature, 
these variables have been previously associated with retinal vessel traits and 
with the outcomes.  
It is a generally accepted rule of thumb that one would want to have 10 cases 
per predictor variable within a logistic regression model to avoid issues of 
separation that can arise from a small population with one or more strongly 
predictive covariates (Albert and Anderson, 1984). Within some of the logistic 
regression models presented in this thesis this suggested ratio was violated. 
However, the models did not encounter problems with convergence and 
there was no evidence of separation or of any highly predictive risk factors. If 
separation was a major issue, there are techniques to overcome the problem, 
including combining covariates into a single factor using principle 
components analysis (PCA). However, this would reduce any ability to 
understand which factors are most associated with the outcome. Another 
method of overcoming such problems would be to use Firth’s method of 
producing finite parameters through penalised maximum likelihood 
estimations (Firth, 1993; Heinze and Schemper, 2002).  
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Methods for controlling for multiple testing were considered, but not 
employed within this analysis. A p value of 0.05 was used to indicate 
statistical significance throughout, but it is common convention that with this 
alpha level, type I error (rejecting the null hypothesis incorrectly) can occur 
once in every 20 comparisons. Bonferroni adjustment is a commonly used 
method that seeks to reduce the p value threshold in relationship to the 
number of test comparisons undertaken. However, controlling for multiple 
testing is a widely debated topic, with some arguing that correction is 
arbitrary (do you correct for number of tests in a single paper, an entire study, 
the duration of a researcher’s career?), and that type I is understood to be 
part of epidemiological research and controlling for it will only introduce more 
type II error (Perneger, 1998; Feise, 2002; Morgan, 2007).  
To combat concerns of type I error, a specific statistical analysis plan was 
created prior to any analysis in this thesis and adhered to strictly. There were 
few times where non-a priori analyses were carried out, and these analyses 
were explicitly noted. Evaluation of the effect size of the analysis, the 
confidence interval or beta values, and number of participants in the analyses 
were all taken into account when assessing a result, rather than just 
evaluating if a specific p value fell below the 0.05 threshold.  
Replication of the findings of this thesis in an independent dataset are crucial 
to understand if venular tortuosity or fractal dimension could be a useful 
biomarker for retinopathy. It is not uncommon to find associations between 
potential risk factors and disease outcomes in a study, to later find out the 
risk factor does not aid in prediction (Wald and Morris, 2011). Unfortunately, 
the ET2DS was not considered large enough to split the cohort in to two 
populations to develop the models in one group and then a separate group to 
validate the findings. Finding a similar study group that have measured the 
necessary covariates would be ideal to validating the results of this thesis. 
When thinking about and describing model fit, it is useful to retain the words 
of George Box in mind and keep perspective: “All models are wrong, but 
some are useful” (Box and Draper, 1987). Developing well-fitting models (ie 
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no serious outliers or influential cases) allows you to draw sound conclusions 
using the evidence for the studied population, but if the assumptions of the 
model type are violated, then you are limited in the generalisation of the 
model to other data sets (Field, Miles and Field, 2012a).  
Overall, the models generated in this thesis did not violate the assumptions 
of the model type and did not have evidence of poor fit. In cases where there 
were concerns, the reasons for poor fit or assumption violation were explored 
and remedied where possible, often with little or no change to the overall 
findings. There were problems with a poorly fit model for the density 
measures in the change in RVT and cognitive decline analysis, specifically 
with regards to linearity. Because this measure is relatively new, there is no 
evidence around what would constitute normality. It is therefore difficult to 
determine what would be a physiological outlier. Although there are possible 
issues with linearity, evaluating the spaghetti plots in Appendix 21, it is clear 
to see the linear relationship of decreased density over time.  
8.2.4 Comparisons with other similar studies 
Overall, there was a significant amount of heterogeneity amongst other 
similar studies, which include ethnicity, age and diabetes type of the study 
population, measurement and reporting of the outcome, software and 
algorithms used to produce the RVTs and how the RVTs were used in the 
analysis, to name a few of the most important factors. I have touched upon 
all of these topics previously in this chapter but want to emphasize how these 
differences can accumulate to make it quite difficult to compare between 
studies that appear on the outside to be measuring the same things. 
However, it is still important to look for overall association similarities that can 
help lead us to make robust conclusions regarding the use of RVTs.  
Collaborative effort in the form of providing raw data for re-analysis or meta-
analysis and future study development is needed if these differences are to 
be overcome. In the following sections, I provide rudimentary comparisons 
between the results of this thesis and those of the studies included in the 
systematic review chapters (Chapters 2 and 3). It should be kept in mind 
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when reading these cursory descriptions, the possible sources of 
heterogeneity that limit a direct comparison. Details of the individual studies 
are provided in the tables within the systematic review chapters and 
appendices.  
Diabetic retinopathy 
In this section I compare the findings of this thesis to those of the systematic 
review in Chapter 2, which attempted to collate the most relevant studies for 
comparison. 
The findings of the logistic regression evaluating the relationship between 
CRAE and incident retinopathy identified a borderline statistically significant 
association between narrower CRAE and DR, but this association was lost 
after controlling for markers of macrovascular disease. These findings 
indicate there to be evidence of an association, but possibly not a good 
predictive marker since the association is not independent of other known 
risk factors. However, of the longitudinal studies in the systematic review in 
Chapter 2, the majority identified wider CRAE to be associated with diabetic 
retinopathy. Three of these studies (AusDiab, Sydney Paediatric Diabetes 
Study and New Jersey 725) compared the largest quartile of CRAE with the 
smallest three quartiles. A single study, DCPD1987, which was conducted in 
younger people with type 1 diabetes, found narrower CRAE to be associated 
with proliferative diabetic retinopathy (PDR).  
Regarding venular width, most of the studies, both cross-sectional and 
longitudinal, found an association between wider CRVE and retinopathy, 
using their various methods of evaluating the outcome. Contrary to this, the 
findings from my analysis found a very borderline statistically significant 
association between decreased CRVE and incident retinopathy when 
controlling for age and sex, cardiometabolic and diabetes risk factors, but 
was no longer associated when controlling for vascular risk factors. Only a 
single longitudinal study (SiMES) also found evidence of narrower CRVE 
being associated with incident retinopathy. The discrepancy between ET2DS, 
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SiMES and the wider literature may be an issue with statistical model 
differences or linearity and further investigation into this issue is warranted.  
When I evaluated the relationship between arterial tortuosity and incident 
retinopathy in the ET2DS population, I found no association after 10 years. 
Of the other similar studies, three out of four cross-sectional studies identified 
a relationship between increased arterial tortuosity and retinopathy and one 
of two longitudinal studies found the same relationship for incident 
retinopathy. The remaining two studies did not find any statistically significant 
associations, but their point estimates favoured the same relationship. As 
previously discussed, it may not be completely appropriate to treat all the 
RVTs as continuous variables and instead create a discrete variable using 
specific cut-points. My own basic analysis of risk of diabetic retinopathy by 
quartile of arterial tortuosity indicated a possibility that both the more extreme 
lower and higher values may be indicative of higher risk and combining these 
categories could be informative as a measure of deviation from normality. As 
with CRAE, the differences could also be due to different statistical modelling 
choices, especially regarding covariates.  
The results from this thesis identified increased venular tortuosity as being 
associated with incident retinopathy, even after controlling for a wide number 
of covariates. As previously referred to in section 8.1.3, the findings from the 
systematic literature review are in modest agreement, as only a single 
longitudinal study (SiMES) that followed-up with participants for six years, 
also found increased venular tortuosity to be associated with diabetic 
retinopathy. SiMES was a smaller study than ET2DS, with a total of 434 
participants, and 59 cases of incident retinopathy, most with type 2 diabetes, 
but they also had participants with type 1 diabetes. The remaining studies, 
four cross-sectional and one longitudinal, did not find a statistically significant 
association, but all presented point estimates that favoured this relationship. 
The ET2DS analysis was the largest study and followed-up participants 
longer than any of the other studies evaluating venular tortuosity. It is very 
possible that with further follow-up, larger sample sizes, or more similar 
covariates, these other studies would find similar results.  
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Fractal dimension is a dynamic variable, incorporating considerable 
information about the vascular geometric structure and there is great interest 
in understanding the relationship with retinal pathology. In my analysis, I 
found evidence that decreased fractal dimension, and therefore decreased 
vascular complexity, was associated with incident diabetic retinopathy. This 
association was only corroborated in one cross-sectional and one 
longitudinal study, out of seven analyses, both of which evaluated 
proliferative diabetic retinopathy (PDR) as the outcome. The remaining three 
longitudinal studies did not find a statistically significant association, although 
two did have point estimates favouring decreased fractal dimension. In 
studies that evaluated PDR as an outcome, it would not be surprising to find 
a higher fractal dimension due to the presence of neovascularisation 
(Orlando et al., 2017).  
This brings up an interesting aspect of studying diabetic retinopathy using 
fractal dimension, in that during the course of the disease, there are 
cumulative vascular changes that may create opposing findings in fractal 
dimension. During the early phase of the disease, when microaneurysm are 
the main pathology, it is unclear if there would be any effect on fractal 
dimension, but as the disease progresses to more moderate or severe 
NPDR, there may actually be a reduction in vessel complexity because 
cumulative vascular damage has resulted in reduced number of vessels. In 
contrast, when a person has PDR, characterised by newly formed vessels, 
you may expect to see an increase in fractal dimension as a result. It is still 
unclear at this stage how the disease course of DR alters fractal dimension, if 
at all, but as more studies such as the data presented in this thesis, suggest 
that there may be, disease stage and severity need to be incorporated and 
considered. Unfortunately, in this thesis there were not enough people with 
incident PDR to undertake robust analysis.  
The authors of another study, SiMES, also attempted to evaluate the use of 
RVTs as a potential predictive biomarker for retinopathy when compared with 
traditional risk factors (Cheung et al., 2017). In this study the authors used 
PCA to combine the 12 traits provided by SIVA software. They combined the 
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PCA results with a model including established risk factors (age, sex, blood 
pressure, BMI, duration of diabetes, HbA1c, total cholesterol, HDL and 
estimated glomerular filtration rate (eGFR)) and evaluated the concordance 
statistic (c-statistic) and used Hosmer-Lemeshow to evaluate goodness of fit. 
They found an improvement of the c-statistic from 0.733 to 0.793 (p = 0.031) 
with the addition of the components. This agrees with my finding of the 
addition of venular tortuosity to a basic model of known risk factors, although 
I only used HbA1c, systolic blood pressure and albumin-creatinine ratio as 
the base model.  
Cognitive decline 
In the findings from the literature review in Chapter 3, from 14 studies that 
evaluated the relationship between retinal vessel widths and cognitive 
decline, there was little evidence of an association with dementia or lower 
cognition. For both CRAE and CRVE there were a few studies that did find 
an association, but the directions were mixed and the majority of studies 
found no association. The results from the primary analysis in this thesis also 
found no association between vessel widths and dementia or cognitive 
decline after 10 years, after adjusting for age and sex.  
For tortuosity, the results from this thesis did not find an association between 
either arterial or venular tortuosity and dementia or cognitive decline. These 
findings are in congress with the findings of the literature review, which found 
most studies to show no association and those that did find an association 
had mixed results. In this thesis, it is worth noting that for the analysis of 
cognitive decline, when baseline g was removed and the analysis was then 
only describing year 10 cognitive status and not decline, there was an 
association with increases in both arterial and venular tortuosity after age and 
sex adjustment. This association was lost after further adjustment for 
cardiometabolic risk factors. This should be considered when comparing with 




Findings from the few previous studies that evaluated fractal dimension, 
indicate there may be an association between decreased fractal dimension 
and decreased cognitive ability. However, this conclusion was only drawn 
from case-control and cross-sectional data and not from any longitudinal 
studies. It is therefore difficult to compare the results from the analysis of 
ET2DS, which did not find an association between fractal dimension and 
cognitive decline, measured either by dementia as an outcome or by g, after 
age and sex adjustment. Also, most of the studies in the literature review that 
evaluated fractal dimension looked specifically at Alzheimer’s dementia as 
their outcome, whereas my study had a mixed aetiology of dementia. 
However, when looking at the unadjusted correlation between year 10 g and 
fractal dimension, there is a relationship supporting the conclusions of the 
literature review, but not statistically significant. This analysis was only able 
to be done in the 581 participants that returned for the follow-up of the study, 
and possibly with a larger cohort the analysis would have reached statistical 
significance. 
One study, the Lothian Birth Cohort 1936 (LBC1936), which was included in 
the literature review in Chapter 3, published a new report of the findings from 
their study after the literature review search, so was not specifically included 
(McGrory, Ballerini, Okely, et al., 2019). This newer analysis of the cohort 
used growth-curve analysis of cognitive testing from three data collection 
time points after the RVTs were collected. Their previous reports evaluated 
only one time point of cognitive testing and compared it with childhood IQ to 
evaluate cognitive decline. This paper did not find any meaningful 
associations between the RVTs and cognitive decline, which corroborate the 
findings of this thesis, although it should be noted that LBC1936 is conducted 
in a general cohort of elderly people, and not specific to people with diabetes.  
Very few studies have evaluated change in RVTs over time and the effect of 
age and other factors. This study is unique in the length of follow-up time and 
the findings showing a clear reduction in fractal dimension. In a study in 
adolescents with type 1 diabetes in Australia, there was an increase in 
arteriolar and venular width, as well as venular tortuosity during the 2.6 year 
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follow up (Liew et al., 2017). It is not surprising there was an increase in 
vessel widths due to the age of the participants as it is expected the vessels 
would increase in size in early adolescents. This study did not find an 
association in fractal dimension. In contrast to our study, the WESDR study 
provided evidence of narrowing of arterials (CRAE) and widening of the 
venules (CRVE) after 6 years (Klein et al., 2012). WESDR did not report 
evaluating fractal dimension or change in other vessel traits. 
 Mechanistic explanation of changes in the retinal 
microvasculature 
A study published in 1986 demonstrated in three participants that increased 
brachial artery blood pressure from exercise, after increasing over a certain 
threshold, also leads to an increase in retinal vessel blood pressure that rose 
incrementally with brachial artery blood pressure (Robinson et al., 1986). In 
this study, the authors did not find any statistically significant changes in the 
width of the larger retinal vessels and concluded any changes due to 
vascular resistance would likely have occurred in smaller vessels that could 
not be captured by the imaging techniques used. This study demonstrated 
that there is a normal process of blood pressure autoregulation in the retina 
and with even a short duration of increased systemic blood pressure there 
were effects on the retinal blood flow.  
A more recent study with 51 participants and similar methods did find that 
with exercise there was a natural narrowing of the retinal arteries attributed to 
autoregulation, but this response was not found in older participants (above 
40 years) (Jeppesen, Gregersen and Bek, 2004). Retinal blood flow 
alterations have also been shown to be associated with diabetes (Yoshida et 
al., 1983; Palkovits et al., 2013). It is therefore probable that with sustained 
blood flow changes not only from chronically increased blood pressure, but 
also age and damage caused by hyperglycaemia, it is likely the smaller 
vessels in the retina undergo cumulative alterations in response.  
These evident changes lead to the question of whether alterations in the 
retinal microvasculature are a normal response to the blood flow changes, 
249 
 
due to pathological processes or possibly a mixture? The exact mechanistic 
pathways are currently unknown for those with diabetes or in the wider 
population (Carol Yimlui Cheung et al., 2015). Other theories have centred 
around common pathophysiological changes associated with sustained 
hypertension, ageing, atherosclerosis, inflammation and endothelial 
dysfunction, as well as blood flow parameters, including oxygenation and 
shear stress (Sun et al., 2009). Changes in the microvasculature in diabetes 
include increased sheer stress and reduced blood flow efficiency that put the 
vasculature at greater risk of damage (Tooke, 1995).  
In depth in vitro studies are needed to fully elucidate mechanistic pathways 
for changes in the retinal vasculature. While imaging of the retina is readily 
available and relatively simple, direct measurement and manipulation of the 
retinal microvasculature’s functional aspects, such as blood flow, is extremely 
difficult and invasive and researchers often resort to surrogate measures. 
There are promising results using flickering light to induce a vasodilatory 
response and study the endothelial function, as well as Doppler technology to 
study retinal blood flow and retinal oximetry to study oxygen saturation (Carol 
Yimlui Cheung et al., 2015). Further research and development in technology 
is needed in this area. 
 Future role of retinal vessel traits as a biomarker 
for vascular disease and recommendations for 
future research 
There is great excitement around the development of RVTs as biomarkers for 
vascular disease as many researchers have consistently found associations 
with risk factors and other factors associated with vascular pathology as well 
as vascular disease itself. However, there are still many questions left 
unresolved regarding the predictive capacity of RVTs and the heterogeneity 
between studies and software tools used to produce RVTs. As described 
previously, there are concerns with comparability of research findings that 
use different software platforms for RVT analysis and retinal differences may 
be quite different across different populations, such as by age, ethnicity and 
250 
 
comorbidities. These concerns only become more apparent as the list of 
vessel traits grows, with little understanding which, if any, play an important 
role in disease progression.  
One way to incorporate information from multiple traits is using reductive 
statistical methods such as PCA, which was briefly touched on in Section 
8.3.4 in a study evaluating retinopathy (Cheung et al., 2017). A recently 
published study evaluating RVTs and cardiovascular risk chose, instead of 
evaluating each of the 54 vessel traits alone, to use PCA to combine traits 
into three ‘vascular patterns’ to describe the participants and look for 
associations between the patterns and cardiovascular risk (Arnould et al., 
2018). The pattern described as ‘sparse vascular network’, comprising lower 
vascular complexity and increased width variability, was found to be 
associated with greater cardiovascular risk. This type of analysis was briefly 
described in a paper on the WESDR study, where the authors used PCA to 
combined eleven RVTs, along with a wide number of covariates, to evaluate 
prediction of incident or progression DR, or incident proliferative diabetic 
retinopathy (Klein et al., 2018).This paper reported no significant 
improvements in the models with the addition of the PCA vessel trait variable. 
Using methods such a PCA may help to better understand which factors may 
be most relevant in risk prediction and help to best utilise studies that do not 
have the power to evaluate each trait separately.  
The findings from this thesis, regarding the predictive capabilities of certain 
RVTs for retinopathy are very exciting. However, they require further 
validation. This is likewise for the novel findings regarding age-related 
change in fractal dimension and density. This would include validation using 
very similar methods and software as well as using other software or 
algorithms to determine how such differences would affect the outcomes and 
conclusions. Unfortunately, there are very few other cohorts specific to type 2 
diabetes with the same power and follow-up time as ET2DS. Also, the high-
quality data collection regarding risk factors, phenotypes and data linkage is 
generally missing in other cohorts, especially regarding retinal imaging. One 
such study that could be a good candidate for validation would the Genetics 
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of Diabetes Audit and Research Tayside and Scotland (GoDARTS) study 
based at the University of Dundee. This study also involves a series of 
routine linkages of a population of people with type 2 diabetes in Scotland, 
focused mainly in the Tayside region (Hébert et al., 2018). This study has 
already obtained fundus retinal images, as well as diabetic retinopathy 
gradings and dementia diagnoses. Due to the nature of the study, there 
would not be cognitive testing available that would match what has been 
done in ET2DS.  
Use of the UK Biobank, which contains data on over half a million people, 
has been considered as a comparative option. Although over 80,000 people 
in UK Biobank have retinal images, some of the images are unsuitable for 
use with software such as VAMPIRE due to quality (MacGillivray et al., 
2015). However, another research group working with QUARTZ software has 
been working to create a support vector machine classification tool to 
automatically classify the quality of images in the UK Biobank (Welikala et al., 
2016). Determining image suitability in an automatic way reduces bias and 
allows for quick processing, as opposed to manual assessment. Such tools 
are necessary when evaluating large numbers of image, which would be a 
necessity to validate the findings of this thesis.  
It is necessary to determine if the vessel traits should be used in prediction 
models as continuous variables or if categorical variables, larger versus 
smaller or grouping the largest with the smallest, would be more appropriate 
and useful. These types of categorisations may be outcome specific. This 
may become easier to determine as more information is gathered on what 
makes up a ‘healthy’ retinal geometric structure.  
8.4.1 Future research recommendations 
• Increased collaborative effort to evaluate and surmount heterogeneity 
between RVT measurement software; 
• Determine if using reductive statistical methods, such as principle 
components analysis, are a suitable way to describe the retinal traits 
and their associations with vascular disease 
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• Replication of findings that venular tortuosity and fractal dimension are 
independently associated with incident diabetic retinopathy; 
• Further exploration of venular tortuosity as a suitable biomarker for 
diabetic retinopathy with increased focus on disease severity; 
• Further evaluation of changes in retinal vessel traits over time, and 
replication of age-related decreased fractal dimension and density 
• Research into normal value ranges for the RVTs in a healthy 
population, which will help to best understand if the traits should be 
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Appendix 2. CASP Quality appraisal domain criteria 
Domain Criteria 
1) Did the study address 
a clearly focused issue? 
Did the authors clearly explain methods that 
minimised bias? 
2) Was the study 
recruited in an acceptable 
way; in case-control 
studies, were cases and 
controls recruited 
appropriately? 
Did the authors clearly explain methods that 
minimised bias? 
3) Was the exposure and 
outcome accurately 
measured to minimise 
bias? 
Did the authors identify software used for vessel trait 
analysis, were graders trained and masked? Did 
graders use a protocol and did they report intra/inter-
grader reliability? How was retinopathy 
determined/cognition measured and were pre-
specified criteria identified? Were trained, blinded 
graders used to diagnose retinopathy/measure 
cognition? 
4) Have the authors 
identified all important 
confounding factors and 
included them in the 
analysis? 
Common covariates for retinopathy: age, sex, 
smoking, blood pressure, lipid measures, duration of 
diabetes, blood glucose. Additional for cognition: 
history of stroke. Were these variables controlled for 
or was there discussion around the variables 
controlled for were used or not used? Did authors 
control for CRAE and CRVE in the opposing width 
analyses? Inclusion of these covariates is just a 
guideline to assist the reader, but not necessary if the 
study authors are clear why they chose the covariates 
they used.   
5) Was the follow up of 
the subjects complete 
enough and long 
enough? 
Follow-up for at least six years was considered 
acceptable, three to five years was of possible 
concern and less than three years was considered 
insufficient follow-up time. Was there a large, 
unexplained proportion of the baseline participants 
missing from the follow-up? 
6) How precise are the 
results and do you 
believe the results? 
Evaluation of this domain was based on several 
features including population size, point estimates, 
confidence intervals, multiple testing and attrition.  
7) Do the results fit with 
other available evidence? 
Any gross deviations from similar studies? 
8) Are sources of funding 
and/or conflicts of interest 
reported? 












Appendix 6. Cognition literature review: OVID Platform 







6. 2 or 3 or 4 or 5 






13. 8 or 9 or 10 or 11 or 12 
14. 7 and 13 
15. limit 14 to yr="2007 -Current" 
16. limit 15 to human 































Appendix 12. Variable distributions 















































































Appendix 16. Continuous variable comparison between 








Appendix 21. Change in retinal vessel traits- spaghetti plots 
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